Antagonists

By developing antibodies or fragments of specific binding sites, using recombinant VH domain and CDRH3 sequences, the problem of insufficient specific binding of PCSK9 antagonists in the treatment of hyperlipidemia and hypercholesterolemia was solved, and the plasma reduction was significantly reduced The therapeutic effect of cholesterol levels.

CN118955722APending Publication Date: 2024-11-15KYMBA LIMITED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410921351.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-12-19
Filing Date
2019-12-18
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In the treatment of hyperlipidemia and hypercholesterolemia, existing PCSK9 antagonists have problems with specific binding sites and affinity, resulting in unsatisfactory treatment results.

Method used

An antibody or fragment was developed that contains binding sites specifically binding to PCSK9, using recombinant VH domains and CDRH3 sequences selected from specific gene segments such as IGHV4-59 and IGHV3-9, with improved affinity and Specificity.

Benefits of technology

The plasma total and non-HDL-cholesterol levels of individuals significantly lowered, providing a more effective treatment for hyperlipidemia and hypercholesterolemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955722A_ABST
    Figure CN118955722A_ABST
Patent Text Reader

Abstract

The present invention relates to a proprotein convertase subtilisin Kexin type 9 (Proprotein Convertase Kexin Kexin type 9; the proprotein convertase subtilisin Kexin Kexin type 9 is a proprotein convertase subtilisin Kexin Kexin type 9; pCSK9) antagonists, such as antibodies and fragments; and methods, uses, and combinations.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application with a filing date of December 18, 2019, Chinese application number 201980083914.X, and invention name “Antagonist”. Technical Field

[0002] The present invention relates to proprotein convertase subtilisin kexin type 9 (PCSK9) antagonists, such as antibodies and fragments; and methods, uses and combinations. Background Art

[0003] Proprotein convertase subtilisin / kexin type 9 (PCSK9) is a serine protease involved in regulating the levels of low density lipoprotein receptor (LDLR) protein (Horton et al., 2007; Seidah and Prat, 2007). In vitro experiments have shown that adding PCSK9 to HepG2 cells reduces the levels of cell surface LDLR (Benjannet et al., 2004; Lagace et al., 2006; Maxwell et al., 2005; Park et al., 2004). Mouse experiments have shown that increasing PCSK9 protein levels reduces the levels of LDLR protein in the liver (Benjannet et al., 2004; Lagace et al., 2006; Maxwell et al., 2005; Park et al., 2004), while PCSK9 knockout mice have increased LDLR levels in the liver (Rashid et al., 2005). In addition, various human PCSK9 mutations that result in increased or decreased plasma LDL levels have been identified (Kotowski et al., 2006; Zhao et al., 2006). PCSK9 has been shown to directly interact with the LDLR protein, be engulfed with the LDLR, and co-immunofluoresce with the LDLR in the endosomal pathway (Lagace et al., 2006).

[0004] PCSK9 is a prohormone-proprotein convertase in the subtilisin (S8) family of serine proteases (Seidah et al., 2003). Humans have nine prohormone-proprotein convertases that can be divided between S8A and S8B subfamilies (Rawlings et al., 2006). Furin, PC1 / PC3, PC2, PACE4, PC4, PC5 / PC6, and PC7 / PC8 / LPC / SPC7 are classified in the S8B subfamilies. Crystal and NMR structures of different domains from mouse furin and PC1 disclose a subtilisin-like pro-domain and a catalytic domain, with the P domain located directly at the C-terminus of the catalytic domain (Henrich et al., 2003; Tangrea et al., 2002). Based on the amino acid sequence similarity within this subfamilies, all seven members are predicted to have similar structures (Henrich et al., 2005). SKI-1 / S1P and PCSK9 are classified in the S8A subfamilies. Sequence comparisons with these proteins also suggest the presence of a subtilisin-like prodomain and catalytic domain (Sakai et al., 1998; Seidah et al., 2003; Seidah et al., 1999). In these proteins, the amino acid sequence at the C-terminus of the catalytic domain is more variable and does not suggest the presence of a P domain.

[0005] Prohormone-proprotein convertase is expressed in zymogen form, and it matures through a multi-step process. In this process, the function of the front domain is twice. The front domain first serves as a chaperone protein, and is required for the proper folding of the catalytic domain (Ikemura et al., 1987). Once the catalytic domain is folded, autocatalysis occurs between the front domain and the catalytic domain. After this initial cleavage reaction, the front domain is still combined with the catalytic domain, and it then serves as an inhibitor of catalytic activity (Fu et al., 2000). When conditions are appropriate, the site in the front domain is matured through the second autocatalytic event (Anderson et al., 1997). After this second cleavage event occurs, the front domain and the catalytic domain dissociate, thereby producing an active protease.

[0006] Autocatalysis of the PCSK9 zymogen occurs between Gln152 and Ser153 (VFAQ|SIP (SEQ ID NO:67)) (Naureckiene et al., 2003) and has been shown to be required for its secretion from cells (Seidah et al., 2003). A second autocatalytic event at a site within the prodomain of PCSK9 has not been observed. Purified PCSK9 is made of two species that can be separated by non-reducing SDS-PAGE; a prodomain of 17 Kd and a catalytic domain plus C-terminal domain of 65 Kd. PCSK9 has not been isolated without its inhibitory prodomain, and measurements of the catalytic activity of PCSK9 have been variable (Naureckiene et al., 2003; Seidah et al., 2003).

[0007] In certain embodiments, the PCSK9 polypeptide comprises terminal residues, such as, but not limited to, leader sequence residues, targeting residues, amino-terminal methionine residues, lysine residues, tag residues, and / or fusion protein residues. "PCSK9" has also been referred to as FH3, NARC1, HCHOLA3, proprotein convertase subtilisin / kexin type 9, and neural apoptosis-regulating convertase 1. The PCSK9 gene encodes a proprotein convertase protein belonging to the proteinase K subfamily of the secreted subtilase family. The term "PCSK9" refers to both the proprotein and the product generated after the proprotein is autocatalyzed. When only the autocatalytic product (e.g., an antigen binding protein or ligand bound to the cleaved PCSK9) is referred to, the protein may be referred to as "mature," "cleaved," "processed," or "active" PCSK9. When only the inactive form is referred to, the protein may be referred to as an "inactive," "proform," or "unprocessed" form of PCSK9. The term PCSK9 also encompasses PCSK9 molecules that incorporate post-translational modifications of the PCSK9 amino acid sequence, such as PCSK9 sequences that have been glycosylated, PCSK9 sequences from which the signal sequence has been cleaved, PCSK9 sequences from which the prodomain has been cleaved from the catalytic domain but not separated from the catalytic domain (see, e.g., US20120093818A1). Figure 1 A and 1B).

[0008] PCSK9 controls the expression of low-density lipoprotein (LDL) receptors in the liver by promoting lysosomal degradation of the receptors. Inhibition of PCSK9 results in increased expression of LDL receptors in hepatocytes and lowers plasma cholesterol levels by increasing the clearance of LDL particles by the liver. Treatment with monoclonal antibodies against PCSK9 is a clinically successful therapeutic intervention in patients diagnosed with hyperlipidemia or hypercholesterolemia that is unresponsive to statin therapy. The anti-PCSK9 antibody alirocumab is marketed by Regeneron Pharmaceuticals, Inc as Praluent TM The anti-PCSK9 antibody evolocumab is marketed by Amgen, Inc as Repatha TM Product name for sale. Summary of the invention

[0009] In the first configuration , the present invention provides:

[0010] An antibody or fragment comprising a binding site that specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9), wherein the binding site comprises a VH domain encoded by a nucleotide sequence derived from the recombination of a human VH gene segment, a DH gene segment, and a JH gene segment, wherein the VH gene segment is selected from IGHV4-31, IGHV4-59, IGHV4-4, and IGHV3-9.

[0011] In the second configuration , the present invention provides:

[0012] An antibody or fragment which specifically binds to PCSK9 and comprises the CDRH3 sequence of the anti-PCSK9 antibody according to the present invention, or the CDRH3 sequence comprising 3, 2 or 1 amino acid substitutions.

[0013] In the third configuration , the present invention provides:

[0014] An antibody or fragment (optionally according to any one of the preceding claims) that specifically binds to PCSK9 and comprises a VH domain comprising the CDRH3 sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); or said sequence comprising 3, 2 or 1 amino acid substitutions.

[0015] In the fourth configuration , the present invention provides:

[0016] An antibody or fragment comprising a binding site that specifically binds to PCSK9, wherein the binding site comprises a VH domain, and the VH domain comprises the amino acid sequence of the VH domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid that is at least 70% identical thereto.

[0017] In the fifth configuration , the present invention provides:

[0018] An antibody or fragment (optionally according to any one of the preceding claims), comprising a binding site that specifically binds to PCSK9, wherein the binding site comprises a VL domain, the VL domain is encoded by a nucleotide sequence derived from the recombination of a human VL gene segment and a JL gene segment, wherein the VL gene segment is selected from IGKV3-11, IGKV2-28 and IGKV2-29.

[0019] In the sixth configuration , the present invention provides:

[0020] An antibody or fragment that specifically binds to PCSK9 and comprises the CDRL3 sequence of the anti-PCSK9 antibody of the present invention, including the CDRL3 sequence with 3, 2 or 1 amino acid substitutions.

[0021] In the seventh configuration , the present invention provides:

[0022] An antibody or fragment that specifically binds to PCSK9 and comprises a VL domain comprising the CDRL3 (and optionally CDRH3) sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said sequences each comprising 3, 2 or 1 amino acid substitutions.

[0023] In the eighth configuration , the present invention provides:

[0024] An antibody or fragment comprising a binding site that specifically binds to PCSK9, wherein the binding site comprises a VL domain, and the VL domain comprises the amino acid sequence of the VL domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid that is at least 70% identical thereto.

[0025] In the ninth configuration , the present invention provides:

[0026] An antibody or fragment that specifically binds to PCSK9 and comprises the heavy chain amino acid sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); or an amino acid that is at least 70% identical thereto.

[0027] In the tenth configuration , the present invention provides:

[0028] An antibody or fragment that specifically binds to PCSK9 and comprises the light chain amino acid sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); or an amino acid that is at least 70% identical thereto.

[0029] In the eleventh configuration , the present invention provides:

[0030] An antibody or fragment that specifically binds to an epitope of human PCSK9 that is identical to the epitope bound by an antibody of the invention (eg, CL-274711 or CL-148219QLT).

[0031] In the twelfth configuration , the present invention provides:

[0032] An antibody or fragment that competes with the antibody of the invention for binding to human PCSK9.

[0033] In the thirteenth configuration , the present invention provides:

[0034] An anti-PCSK9 antibody or fragment of the invention for use in treating or preventing a PCSK9-mediated disease or condition (optionally hyperlipidemia or hypercholesterolemia) in a subject.

[0035] In the fourteenth configuration , the present invention provides:

[0036] A combination of an amount of an anti-PCSK9 antibody or fragment and an amount of a statin (optionally comprising multiple doses of said antibody and / or statin), wherein said antibody or fragment is according to the present invention.

[0037] A combination of an amount of an anti-PCSK9 antibody or fragment and an amount of an ANGPTL3 inhibitor (e.g., an anti-ANGPTL3 antibody, such as evinacumab) (optionally comprising multiple doses of said antibody and / or statin), wherein said antibody or fragment is according to the present invention. Optionally, said combination further comprises a statin.

[0038] In the fifteenth configuration , the present invention provides:

[0039] A use of an antibody, fragment or combination of the invention for the manufacture of a medicament for administration to an individual for the treatment or prevention of a PCSK9-mediated disease or condition, optionally hyperlipidemia or hypercholesterolemia.

[0040] In the sixteenth configuration , the present invention provides:

[0041] A method of treating or preventing a PCSK9-mediated disease or condition (optionally hyperlipidemia or hypercholesterolemia) in a subject, the method comprising administering to the subject a therapeutically effective amount of an antibody, fragment or combination of the invention, wherein the PCSK9-mediated disease or condition is thereby treated or prevented.

[0042] In the seventeenth configuration , the present invention provides:

[0043] A pharmaceutical composition comprising the antibody, fragment or combination of the present invention and a pharmaceutically acceptable excipient, diluent or carrier.

[0044] In the eighteenth configuration , the present invention provides:

[0045] A nucleic acid encoding the VH domain and / or VL domain of the antibody or fragment of the present invention

[0046] In the nineteenth configuration , the present invention provides:

[0047] A nucleic acid encoding a VH domain comprising the amino acid sequence of the VH domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); or an amino acid at least 70% identical thereto.

[0048] In the twentieth configuration , the present invention provides:

[0049] A nucleic acid encoding the heavy chain and / or light chain of an antibody or fragment of the invention.

[0050] In the twenty-first configuration , the present invention provides:

[0051] A vector comprising a nucleic acid; optionally wherein the vector is a CHO or HEK293 vector.

[0052] In the twenty-second configuration , the present invention provides:

[0053] A host cell comprising a nucleic acid or a vector.

[0054] In the twenty-third configuration , the present invention provides:

[0055] An antibody, fragment, combination, vector, host cell, use or method as described herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figure 1 : CL-148219hPCSK9 neutralization relative to benchmark test antibodies;

[0057] Figure 2 : CL-148219 restoration of LDL uptake relative to a benchmark test antibody;

[0058] Figure 3 : CL-148219 affinity relative to the benchmark test antibody;

[0059] Figure 4 : CL-148219 plasma non-HDL reduction relative to the benchmark test antibody;

[0060] Figure 5 : CL-148489hPCSK9 neutralization relative to benchmark test antibodies;

[0061] Figure 6 : CL-148489 restoration of LDL uptake relative to a benchmark test antibody;

[0062] Figure 7 : CL-148489 affinity relative to the benchmark test antibody;

[0063] Figure 8 : CL-148489 plasma non-HDL reduction relative to the benchmark test antibody;

[0064] Fig. 9 : Study design;

[0065] Fig.10 : Total cholesterol;

[0066] Fig.11 : Total non-HDL cholesterol;

[0067] Fig.12 : HDL cholesterol;

[0068] Fig.13 : triglycerides;

[0069] Figure 14: Phospholipid and cholesterol profiles;

[0070] Fig.15 : Shows the effect of a single 1 mg / kg subcutaneous dose of CL-148219QLT, benchmark test antibody F (commercially available antibody), or a single 10 mg / kg subcutaneous dose of isotype control on total cholesterol levels (± SEM) in APOE*3Leiden.CETP transgenic mice fed a Western-type diet containing 0.15% cholesterol and 15% saturated fat;

[0071] Fig.16 : Shows the effect of a single 3 mg / kg subcutaneous dose of CL-148219QLT, benchmark test antibody F, or a single 10 mg / kg subcutaneous dose of isotype control on total cholesterol levels (± SEM) in APOE*3Leiden.CETP transgenic mice fed a Western-type diet containing 0.15% cholesterol and 15% saturated fat;

[0072] Fig.17: Shows the effect of a single 10 mg / kg subcutaneous dose of CL-148219QLT, benchmark test antibody F, or isotype control on total cholesterol levels (± SEM) in APOE*3Leiden.CETP transgenic mice fed a Western-type diet containing 0.15% cholesterol and 15% saturated fat;

[0073] Fig.18 : Shows the effect of a single 1 mg / kg subcutaneous dose of CL-148219QLT compared to 1 and 3 mg / kg doses of benchmark test antibody F on total cholesterol levels (± SEM) in APOE*3Leiden.CETP transgenic mice fed a Western-type diet containing 0.15% cholesterol and 15% saturated fat;

[0074] Fig.19 : Shows the effect of a single 3 mg / kg subcutaneous dose of CL-148219QLT compared to 3 and 10 mg / kg doses of benchmark test antibody F on total cholesterol levels (± SEM) in APOE*3Leiden.CETP transgenic mice fed a Western-type diet containing 0.15% cholesterol and 15% saturated fat;

[0075] Figure 20: Shows the effect of a single 1 mg / kg (A), 3 mg / kg (B) or 10 mg / kg (C) subcutaneous dose of CL-148219QLT / benchmark antibody F, 1 and 3 mg / kg of CL-274711 (A, B) or 10 mg / kg isotype control on non-HDL cholesterol levels (± SEM) in APOE*3Leiden.CETP transgenic mice fed a Western-type diet containing 0.15% cholesterol and 15% saturated fat;

[0076] FIG21 : Comparison of the effect of a single 1 mg / kg (A) and 3 mg / kg (B) subcutaneous dose of CL-148219QLT, versus 1 and 3 (A) or 3 and 10 mg / kg (B) doses of benchmark test antibody F on non-HDL cholesterol levels (± SEM) in APOE*3Leiden.CETP transgenic mice fed a Western-type diet containing 0.15% cholesterol and 15% saturated fat;

[0077] Figure 22: shows the lipoprotein profiles in APOE*3Leiden.CETP transgenic mice (A: VLDL cholesterol; B: VLDL phospholipids; C: LDL cholesterol; D: LDL phospholipids) following a single subcutaneous 1, 3 or 10 mg / kg dose of benchmark test antibody F / CL-148219QLT, 3 or 10 mg / kg of CL-274711 or a 10 mg / kg dose of isotype control, the mice being fed a Western-type diet containing 0.15% cholesterol and 15% saturated fat; and

[0078] Fig.23 : Shown are antibody concentrations (± SEM) in male C57 / Bl6 mice over time following a single 3 mg / kg subcutaneous dose of benchmark test antibody F, CL-148219QLT, or CL-274711.

[0079] Figure 1 CL-148219 increased human PCSK9 internalization and neuralization over baseline in an in vitro cell-based assay. HepG2 cells were treated with AF647-labeled human PCSK9 gain-of-function mutants in the presence of isotype control, baseline, or CL-148219, followed by BODIPY LDL. Cells were then harvested and stained with CytoFlex TM The fluorescence signal of AF647 was detected by flow cytometry.

[0080] Fig.24 CL-148219 increased human PCSK9 internalization and neuralization over baseline in an in vitro cell-based assay. HepG2 cells were treated with AF647-labeled human PCSK9 gain-of-function mutants in the presence of isotype control, baseline, or CL-148219, followed by BODIPY LDL. Cells were then harvested and stained with CytoFlex TM The fluorescence signal of AF647 was detected by flow cytometry.

[0081] Fig.25 : In an in vitro cell-based assay, CL-148219 increased LDL uptake more favorably than the baseline. HepG2 cells were treated with AF647-labeled human PCSK9 gain-of-function mutants in the presence of isotype control, baseline, or CL-148219, followed by BODIPY LDL. Cells were then collected and the fluorescence signal of BODIPY was detected by a CytoFlex flow cytometer.

[0082] Fig.26 :Affinity of CL-148219. Affinity was determined by KD. TMSPR analysis system measuring the KD of CL-148219 against human and mouse PCSK9 at pH 7.6.

[0083] Fig. 27 : In a hyperlipidemia mouse model (E3L.CETP mice), CL-148219 showed excellent function in reducing non-HDL cholesterol compared to the baseline. E3L.CETP mice were treated with a Western diet for 4 weeks and then injected with antibodies. At different times after Ab injection, blood was collected and the amount of plasma HDL and total cholesterol was measured. Then, the amount of plasma non-HDL cholesterol was calculated by subtracting HDL from total cholesterol.

[0084] Fig.28 : In an in vitro cell-based assay, CL-148219QLT increases human PCSK9 internalization neuralization over baseline. HepG2 cells were treated with AF647-labeled human PCSK9 gain-of-function mutants in the presence of isotype control, baseline, or CL-148219QLT, followed by BODIPY LDL. Cells were then harvested and the fluorescent signal of AF647 was detected by a CytoFlex flow cytometer.

[0085] Fig.29 : In an in vitro cell-based assay, CL-148219QLT increased LDL uptake more favorably than the baseline. HepG2 cells were treated with AF647-labeled human PCSK9 gain-of-function mutants in the presence of isotype control, baseline, or CL-148219QLT, followed by BODIPY LDL. Cells were then collected and the fluorescence signal of BODIPY was detected by a CytoFlex flow cytometer.

[0086] Fig.30 : Affinity of CL-148219QLT. Affinity was determined by KD. The KD of CL-148219QLT against human and mouse PCSK9 at pH 7.6 was measured by the Proteon SPR analysis system.

[0087] Fig.31 : In a hyperlipidemia mouse model (E3L.CETP mice), CL-148219QLT showed excellent function in reducing non-HDL cholesterol compared to the baseline. E3L.CETP mice were treated with a Western diet for 4 weeks, followed by antibody injection. At different times after Ab injection, blood was collected and the amount of plasma HDL and total cholesterol was measured. Then, the amount of plasma non-HDL cholesterol was calculated by subtracting HDL from total cholesterol.

[0088] Fig.32: In an in vitro cell-based assay, CL-148489 moderately neuralizes human PCSK9 internalization. HepG2 cells were treated with AF647-labeled human PCSK9 gain-of-function mutants in the presence of isotype control, benchmark, or CL-148489, followed by BODIPY LDL. Cells were then collected and the fluorescent signal of AF647 was detected by a CytoFlex flow cytometer.

[0089] Fig.33 : In an in vitro cell-based assay, CL-148489 increased LDL uptake more favorably than the baseline. HepG2 cells were treated with AF647-labeled human PCSK9 gain-of-function mutants in the presence of isotype control, baseline, or CL-148489, followed by BODIPY LDL. Cells were then collected and the fluorescence signal of BODIPY was detected by a CytoFlex flow cytometer.

[0090] Fig.34 : Affinity of CL-148489. Affinity was determined by KD. The KD of CL-148489 against human and mouse PCSK9 at pH 7.6 was measured by the Proteon SPR analysis system.

[0091] Fig.35 : In a hyperlipidemia mouse model (E3L.CETP mice), CL-148489 showed excellent function in reducing non-HDL cholesterol compared to the baseline. E3L.CETP mice were treated with a Western diet for 4 weeks and then injected with antibodies. At different times after Ab injection, blood was collected and the amount of plasma HDL and total cholesterol was measured. Then, the amount of plasma non-HDL cholesterol was calculated by subtracting HDL from total cholesterol.

[0092] Fig.36 : In an in vitro cell-based assay, CL-274698 increases human PCSK9 internalization neuralization over baseline. HepG2 cells were treated with AF647-labeled human PCSK9 gain-of-function mutants in the presence of isotype control, baseline, or CL-274698, followed by BODIPY LDL. Cells were then collected and the fluorescent signal of AF647 was detected by a CytoFlex flow cytometer.

[0093] Fig.37: In an in vitro cell-based assay, CL-274698 increased LDL uptake more favorably than the baseline. HepG2 cells were treated with AF647-labeled human PCSK9 gain-of-function mutants in the presence of isotype control, baseline, or CL-274698, followed by BODIPY LDL. Cells were then collected and the fluorescence signal of BODIPY was detected by a CytoFlex flow cytometer.

[0094] Fig.38 : Affinity of CL-274698. Affinity was determined by KD. The KD of CL-274698 against human and mouse PCSK9 at pH 7.6 was measured by the Proteon SPR analysis system.

[0095] Fig.39 : In a hyperlipidemia mouse model (E3L.CETP mice), CL-274698 showed excellent function in reducing non-HDL cholesterol compared to the baseline. E3L.CETP mice were treated with a Western diet for 4 weeks, followed by antibody injection. At different times after Ab injection, blood was collected and the amount of plasma HDL and total cholesterol was measured. Then, the amount of plasma non-HDL cholesterol was calculated by subtracting HDL from total cholesterol.

[0096] Fig.40 : In an in vitro cell-based assay, CL-274711 increases human PCSK9 internalization neuralization over baseline. HepG2 cells were treated with AF647-labeled human PCSK9 gain-of-function mutants in the presence of isotype control, baseline, or CL-274711, followed by BODIPY LDL. Cells were then collected and the fluorescent signal of AF647 was detected by a CytoFlex flow cytometer.

[0097] Fig.41 : In an in vitro cell-based assay, CL-274711 increased LDL uptake more favorably than the baseline. HepG2 cells were treated with AF647-labeled human PCSK9 gain-of-function mutants in the presence of isotype control, baseline, or CL-274711, followed by BODIPY LDL. Cells were then collected and the fluorescence signal of BODIPY was detected by a CytoFlex flow cytometer.

[0098] Fig.42 : Affinity of CL-274711. Affinity was determined by KD. The KD of CL-274711 against human and mouse PCSK9 at pH 7.6 was measured by the Proteon SPR analysis system.

[0099] Fig.43: In a hyperlipidemia mouse model (E3L.CETP mice), CL-274711 showed excellent function in reducing non-HDL cholesterol compared to the baseline. E3L.CETP mice were treated with a Western diet for 4 weeks and then injected with antibodies. At different times after Ab injection, blood was collected and the amount of plasma HDL and total cholesterol was measured. Then, the amount of plasma non-HDL cholesterol was calculated by subtracting HDL from total cholesterol. DETAILED DESCRIPTION

[0100] definition

[0101] Unless otherwise defined herein, scientific and technical terms shall have the meaning commonly understood by those of ordinary skill in the art. In addition, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[0102] Unless the context clearly indicates otherwise, the singular terms "a", "an" and "the" include plural referents. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. The abbreviation "eg" is derived from the Latin exempli gratia and is used herein to indicate a non-limiting example. Therefore, the abbreviation "eg" is synonymous with the term "for example".

[0103] In the specification and claims, the term "about" is used to modify quantities such as: ingredients, concentrations, volumes, processing temperatures, processing times, yields, flow rates, pressures, and similar values ​​and ranges thereof in the composition, which are used to describe embodiments of the present invention. The term "about" refers to changes in numerical quantities, such as those that may occur through commonly measured and used operating procedures for preparing compounds, compositions, concentrates, or using formulations; through unintentional errors in these procedures; through differences in the manufacture, source, or purity of the starting materials or ingredients used to perform the method; and similar considerations. The term "about" also encompasses amounts that differ from a specific initial concentration or mixture due to aging of the formulation, and amounts that differ from a specific initial concentration or mixture due to mixing or processing the formulation. When modified by the term "about", the claims appended hereto include equivalents of these amounts.

[0104] As used herein, "administer" or "administration" refers to the act of physically delivering a substance (e.g., an anti-hPCSK9 antibody provided herein) as present in vitro to a patient by injection or otherwise, for example, by mucosal, intradermal, intravenous, intramuscular delivery, and / or any other physical delivery method described herein or known in the art. When treating a disease or its symptoms, administration of the substance generally occurs after the onset of the disease or its symptoms. When preventing a disease or its symptoms, administration of the substance generally occurs before the onset of the disease or its symptoms.

[0105] The terms "antibody", "immunoglobulin" or "Ig" are used interchangeably herein and mean an immunoglobulin molecule that recognizes a target (e.g., a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or a combination of the foregoing) through at least one antigen recognition site within the variable region of the immunoglobulin molecule and specifically binds to the target. As used herein, the term "antibody" encompasses complete polyclonal antibodies, complete monoclonal antibodies, antibody fragments (e.g., Fab, Fab', F(ab')2, and Fv fragments), single-chain Fv (scFv) mutants, multispecific antibodies (e.g., bispecific antibodies (including dual binding antibodies)), chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antigenic determinant portion of an antibody, and any other modified immunoglobulin molecule comprising an antigen recognition site, as long as the antibody exhibits the desired biological activity. The term "antibody" may also refer to a Y-shaped glycoprotein having a molecular weight of approximately 150 kDa, consisting of four polypeptide chains: two light (L) chains and two heavy (H) chains. There are five types of mammalian Ig heavy chain isotypes, represented by the Greek letters alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ). The type of heavy chain defines the class of the antibody, namely IgA, IgD, IgE, IgG, and IgM, respectively. Based on differences in constant domain sequence and function, the gamma and alpha classes are further divided into subclasses, such as IgG1, hIgG2, mIgG2A, mIgG2B, IgG3, IgG4, IgA1, and IgA2. In mammals, there are two types of immunoglobulin light chains, λ and κ. The "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of the heavy or light chain of an antibody. The variable domains of the heavy and light chains may be referred to as "V H ” and “V L ". These domains are generally the most variable part of the antibody (relative to other antibodies of the same class) and contain the antigen binding site. An example of an antibody is a heavy chain only (ie, H2) antibody, which includes a dimer of heavy chains (5'-VH-(optional hinge)-CH2-CH3-3') and no light chains.

[0106] The antibodies described herein may be oligoclonal, polyclonal, monoclonal (including full-length monoclonal antibodies), camelized, chimeric, CDR-grafted, multispecific, bispecific (including dual-binding antibodies), catalytic, chimeric, humanized, fully human, anti-idiotypic antibodies, including antibodies that may be labeled in soluble or conjugated form, alone or in combination with other amino acid sequences provided by known techniques, and fragments, variants or derivatives thereof. The antibodies may be from any species. The antibodies described herein may be naked antibodies or conjugated to other molecules such as toxins, radioisotopes, etc.

[0107] The terms "antigen binding site", "antigen binding domain", "antigen binding region", "antigen binding fragment" and similar terms refer to the portion of an antibody that includes the amino acid residues that interact with an antigen and imparts its specificity and affinity to the antigen (e.g., the complementarity determining region (CDR)). The antigen binding region may be derived from any animal species, such as rodents (e.g., rabbits, rats, or hamsters) and humans. Preferably, the antigen binding region will be of human origin.

[0108] The antigen-binding fragments described herein may include single-chain Fv (scFv), single-chain antibodies, single-domain antibodies, domain antibodies, Fv fragments, Fab fragments, F(ab') fragments, F(ab')2 fragments, antibody fragments exhibiting desired biological activity, disulfide-stabilized variable regions (dsFv), dimeric variable regions (bifunctional antibodies), anti-idiotype (anti-Id) antibodies (including, for example, anti-Id antibodies to antibodies), intrabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed by antibody fragments and epitope-binding fragments of any of the above. Specifically, the antibodies and antibody fragments described herein may include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e., molecules containing antigen binding sites. Antibodies are digested with enzymes (papain) to produce two identical antigen-binding fragments (also referred to as "Fab" fragments and "Fc" fragments), which have no antigen-binding activity but have the ability to crystallize. When used herein, "Fab" refers to an antibody fragment comprising one constant domain and one variable domain of each of the heavy and light chains. The term "Fc region" is used herein to define the C-terminal region of the immunoglobulin heavy chain, including native sequence Fc regions and variant Fc regions. "Fc fragment" refers to the carboxyl terminal portion of the two H chains bound together by disulfide bonds. The effector function of the antibody is determined by the sequence in the Fc region, which is also recognized by Fc receptors (FcR) found on certain types of cells. The antibody is digested by enzyme (pepsin) to produce a F(ab')2 fragment, in which the two arms of the antibody molecule remain linked and include two antigen binding sites. The F(ab')2 fragment has the ability to cross-link antigens.

[0109] With respect to gene segments, the term "derived from recombination of..." will be readily apparent to the skilled artisan, who will understand that B cells recombined their variable region gene segments to produce the coding sequences of the variable domains. For example, "derived from the recombination of human VH gene segments, DH gene segments, and JH gene segments" involves recombining a human VH gene segment with a DH gene segment and a JH gene segment to form a rearranged VDJ sequence encoding a heavy chain antibody variable domain. Joining and somatic hypermutation may also be features of the process, whereby the resulting recombinant VDJ sequence comprises one or more nucleotide additions, substitutions, or deletions (e.g., p additions and / or n additions) not included in the germline V, D, and J sequences. Equivalents will be expressed as Vκ and Jκ gene segments for the κ light chain variable domain, and Vλ and Jλ for the λ light chain variable domain. It is intended that any post-translational modifications may additionally be encompassed in the variable domain.

[0110] As used herein, "Fv" refers to the smallest fragment of an antibody that retains both the antigen recognition site and the antigen binding site. This region consists of a dimer of one heavy chain and one light chain variable domain in tight non-covalent or covalent association. In this configuration, the three CDRs of each variable domain interact to define the V H -V L The antigen binding site on the surface of the dimer. The six CDRs collectively confer antigen binding specificity to the antibody. However, even if a single variable domain (or half of an Fv that includes only three CDRs specific for an antigen) has the ability to recognize and bind to an antigen, the affinity is lower than that of the entire binding site.

[0111] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., except for possible naturally occurring mutations and / or possible post-translational modifications (e.g., isomerization, amidation) that may be present in small amounts, the individual antibodies comprising the population are consistent. Monoclonal antibodies are highly specific and directed against a single antigenic determinant or epitope. In contrast, polyclonal antibody preparations typically include different antibodies directed against different antigenic determinants (or epitopes). As used herein, the term "monoclonal antibody" encompasses complete and full-length monoclonal antibodies and antibody fragments (e.g., Fab, Fab', F(ab')2, Fv), single-chain (scFv) mutants, fusion proteins including antibody portions, and any other modified immunoglobulin molecules including antigen recognition sites. In addition, "monoclonal antibody" refers to such antibodies produced in a variety of ways, including, but not limited to, fusion tumors, phage selection, recombinant expression, and transgenic animals.

[0112] The monoclonal antibodies herein may include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and / or light chain is identical or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies that exhibit the desired biological activity.

[0113] The term "humanized antibody" refers to a subset of chimeric antibodies in which a "hypervariable region" from a non-human immunoglobulin (donor antibody) replaces residues from a hypervariable region in a human immunoglobulin (acceptor antibody). In general, a humanized antibody will comprise substantially all of at least one and usually two variable domains, wherein all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin sequence, and all or substantially all of the framework regions are those of a human immunoglobulin sequence, but the framework regions may contain one or more substitutions that improve antibody performance, such as binding affinity, isomerization, immunogenicity, etc.

[0114] The term "bispecific antibody" is meant to include specificities for two target molecules and includes, but is not limited to, antibodies such as DVD-Ig (see DiGiammarino et al., "DVD-Ig for Dual Specific Targeting"). TM Design and generation of DVD-Ig TM molecules for dual-specific targeting)”, Methods in Molecular Biology (Meth. Mo. Biol.) 2012, 889, 145-156); mAb 2 (See WO2008 / 003103, mAb 2Description of the forms is incorporated herein by reference); FIT-Ig (see WO2015 / 103072, the description of the FIT-Ig backbone is incorporated herein by reference); mAb-dAb; dock and lock; Fab-arm exchange; SEED body; trifunctional mAb; LUZ-Y; Fcab; κλ body; orthogonal Fab; sc diabody-Fc; diabody-Fc; tandem scFv-Fc; Fab-scFv-Fc; Fab-scFv; intrabody; BiTE; diabody; DART; TandAb; sc diabody; sc diabody-CH3; diabody-CH3; triple body; miniantibody; minibody; TriBi minibody; scFv-CH3 KIH; scFv-CH-CL-scFv, F(ab')2-scFv; scFv-KIH; Fab-scFv-Fc; tetravalent HCab; ImmTAC; knob-hole; knob-hole with common light chain; knob-hole with common light chain and charge pair, charge pair, charge pair and common light chain; DT-IgG; DutaMab; IgG(H)-scFv; scFv-(H)IgG; IgG(L)-scFv; scFv-(L)IgG; IgG(L,H)-Fv; IgG(H)-V; V(H)-IgG; IgG(L)-V; V(L)-IgG; KIH IgG-scFab; 2scFv-IgG; IgG-2scFv; scFv4-Ig; and zybody. For a review of bispecific formats, see Spiess, C. et al., Mol. Immunol. (2015). In another embodiment, the bispecific molecule comprises an antibody fused to another non-Ig format, such as: a T cell receptor binding domain; an immunoglobulin superfamily domain; an Agnathan variable lymphocyte receptor; a fibronectin domain (e.g., Adnectin TM ); antibody constant domain (eg, CH3 domain, such as Fcab TM CH2 and / or CH3), wherein the constant domain is not a functional CH1 domain; scFv; (scFv)2; sc-bifunctional antibody; scFab; derived from CTLA-4 (Evibody TM ) backbone of centyrin and epitope binding domains; lipocalin domains; protein A, such as the Z domain of protein A (eg, Affibody TM or SpA); A domain (e.g. Avimer TM or Maxibody TM); heat shock proteins (e.g., and epitope binding domains derived from GroEI and GroES); transferrin domains (e.g., trans-body); ankyrin repeat proteins (e.g., DARPin TM ); peptide aptamers; C-type lectin domains (e.g. Tetranectin TM ); human γ-crystallin or human ubiquitin (affilin); PDZ domains; scorpion toxins; and kunitz-type domains of human protease inhibitors. For non-limiting examples of knob-and-hole technology, see, e.g., US5,731,568 and WO98 / 50431 (both incorporated herein by reference).

[0115] The principle is to engineer the paired CH3 domains of the heterodimer heavy chain so that one CH3 domain contains a "knob" and the other CH3 domain contains a "hole" at the opposite position in space. The knob is generated by replacing small amino acid side chains at the interface between the CH3 domains, while the hole is generated by replacing larger side chains with smaller ones. The knob is designed to be inserted into the hole to favor the heterodimerization of different CH3 domains while destabilizing the formation of homodimers. In the mixture of antibody heavy and light chains assembled to form the bispecific antibody, the proportion of IgG molecules with paired heterodimer heavy chains is therefore increased, thereby improving the yield and recovery of active molecules.

[0116] Mutations Y349C and / or T366W may be included to form a "knob" in the IgG CH3 domain. Mutations E356C, T366S, L368A and / or Y407V may be included to form a "hole" in the IgG CH3 domain. Knobs and holes may be introduced into any human IgG CH3 domain, such as IgG1, IgG2, IgG3 or IgG4 CH3 domains. A preferred example is IgG4. As mentioned, IgG4 may comprise other modifications, such as "P" and / or "E" mutations. The a-type IgG4 ("ra") sequence contains the substitutions Y349C and T366W ("knob"), and the b-type IgG4 ("γb") sequence contains the substitutions E356C, T366S, L368A and Y407V ("hole"). Both ra and γb also contain a "P" substitution (S228P) at position 228 in the hinge to stabilize the hinge region of the heavy chain. Both ra and γb also contain an "E" substitution (L235S) in the CH2 region at position 235 to eliminate binding to FcγR. Therefore, the relevant sequence of the IgG4-PE heavy chain is ppcp P cpapef E ggps.

[0117] Other advances in bispecific IgG engineering are the idea of ​​using a common light chain, as described in WO98 / 50431. Describes bispecific antibodies comprising two heavy chain-light chain pairs, wherein the variable light chains of the two heavy chain-light chain pairs have a common sequence. WO98 / 50431 describes combining a common light chain approach with specific complementary interactions (e.g., knob-hole) in the heavy chain heterodimerization interface to promote heterodimer formation and hinder homodimer formation. Combined, these approaches enhance the formation of desired heterodimers relative to undesired heterodimers and homodimers.

[0118] While the knob-and-hole technique involves engineering amino acid side chains to create complementary molecular shapes at the interface of paired CH3 domains in a bispecific heterodimer, another way to promote heterodimer formation and hinder homodimer formation is to engineer amino acid side chains to have opposite charges. Binding of CH3 domains in heavy chain heterodimers favors the pairing of oppositely charged residues, whereas paired positive charges or paired negative charges will make homodimer formation less energetically favorable. WO2006 / 106905 describes a method for producing a heteromultimer composed of more than one type of polypeptide (e.g., a heterodimer of two different antibody heavy chains), the heteromultimer comprising substitutions in amino acid residues to form an interface between the polypeptides such that heteromultimer binding will be modulated, the method comprising:

[0119] (a) modifying a nucleic acid encoding amino acid residues that form an interface between polypeptides from an initial nucleic acid so that binding between polypeptides that form one or more multimers will be inhibited in a heteromultimer that can form two or more types of multimers;

[0120] (b) culturing the host cell so that the nucleic acid sequence modified by step (a) is expressed; and

[0121] (c) recovering the heteromultimer from the host cell culture,

[0122] The modification in step (a) is to modify the initial nucleic acid so that one or more amino acid residues at the interface are substituted, so that two or more amino acid residues (including mutant residues) forming the interface will carry the same type of positive or negative charge.

[0123] An example of this is inhibiting binding between heavy chains by introducing electrostatic repulsion at the interface of heavy chain homodimers, for example by modifying the amino acid residues that contact each other at the interface of the CH3 domains, the amino acid residues comprising:

[0124] Positions 356 and 439

[0125] Positions 357 and 370

[0126] Positions 399 and 409,

[0127] Residue numbering is according to the EU numbering system.

[0128] By modifying one or more of these residue pairs to have similar charges (both positive or both negative) in the CH3 domain of the first heavy chain, pairing of heavy chain homodimers is inhibited by electrostatic repulsion. By engineering the same residue pair or residue pairs in the CH3 domain of the second (different) heavy chain to have opposite charges compared to the corresponding residues in the first heavy chain, pairing of heterodimers of the first and second heavy chains is promoted by electrostatic attraction.

[0129] The amino acids at the CH3 interface of the heavy chain constant region are modified to introduce charge pairs, and the mutations are listed in Table 1 of WO2006 / 106905. It is reported that the amino acids at heavy chain positions 356, 357, 370, 399, 409 and 439 are modified to introduce charge-induced molecular repulsion at the CH3 interface, which has the effect of increasing the efficacy of the expected bispecific antibody. For example, one heavy chain constant region may be an IgG4 constant region containing the mutation K439E (positively charged Lys is replaced by negatively charged Glu), and the other heavy chain constant region may be an IgG4 constant region containing the mutation E356K (negatively charged Glu is replaced by positively charged Lys), using EU numbering. "Charge pairing" is generated by the spatial proximity of residues 439 and 356 in the Fc region assembled by heterodimerization of these two constant regions.

[0130] When two different heavy chain constant regions are used, these can be linked in either orientation to the two different VH domains of the antibody.

[0131] WO2006 / 106905 also exemplifies bispecific IgG antibodies in which the CH3 domain of IgG4 is engineered with a knob-hole mutation. Type a (IgG4γa) is an IgG4 substituted at Y349C and T366W, and type b (IgG4γb) is an IgG4 substituted at E356C, T366S, L368A and Y407V.

[0132] In another example, the introduction of charge pairs in the antibody VH and VL domains is used to suppress the formation of "incorrect" VH-VL pairs (VH from one antibody is paired with the VL of another antibody). In one example, the Q residues in VH and VL are changed to K or R (positive) or to E or D (negative) to suppress hydrogen bonding between Q side chains and introduce electrostatic repulsion.

[0133] Other examples of charge pairs are disclosed in WO2013 / 157954, which describes a method for producing a molecule comprising a heterodimeric CH3 domain from a single cell, the molecule comprising two CH3 domains capable of forming an interface. The method comprises providing in the cell

[0134] (a) a first nucleic acid molecule encoding a polypeptide chain comprising a first CH3 domain, the chain comprising a K residue at position 366 according to the EU numbering system, and

[0135] (b) a second nucleic acid molecule encoding a polypeptide chain comprising a second CH3 domain, this chain comprising a D residue at position 351 according to the EU numbering system,

[0136] The method further comprises the step of culturing the host cell, thereby allowing expression of the two nucleic acid molecules and harvesting the molecule comprising the heterodimeric CH3 domain from the culture.

[0137] Other approaches to engineering electrostatic interactions in polypeptide chains to promote heterodimer formation over homodimer formation are described in WO2011 / 143545.

[0138] Another example of engineering at the CH3-CH3 interface is the strand exchange engineered domain (SEED) CH3 heterodimer. The CH3 domain consists of alternating segments of human IgA and IgG CH3 sequences that form complementary SEED heterodimer pairs, called "SEEDbodies" [WO2007 / 110205].

[0139] Bispecific antibodies have also been generated with heterodimeric heavy chains that are variously modified in the CH3 domain to alter their affinity for binding to purification agents such as protein A. WO2010 / 151792 describes a heterodimeric bispecific antigen binding protein comprising

[0140] A first polypeptide, which includes, from N-terminus to C-terminus, a first epitope binding region that selectively binds to a first epitope, an immunoglobulin constant region including a first CH3 region of human IgG selected from IgG1, IgG2 and IgG4; and a second polypeptide, which includes, from N-terminus to C-terminus, a second epitope binding region that selectively binds to a second epitope, an immunoglobulin constant region including a second CH3 region of human IgG selected from IgG1, IgG2 and IgG4, wherein the second CH3 region includes a modification that reduces or eliminates binding of the second CH3 domain to protein A.

[0141] Therefore, the Fc region may include one or more mutations to facilitate the differential purification of active heterodimers from homodimer species. The CH3 of one heavy chain constant region may include mutations His435Arg and / or Tyr436Phe (EU numbering) [], while the CH3 of the other heavy chain constant region lacks the mutations. For example, Emicizumab includes an Fc region in which one CH3 includes His435 and the other CH3 includes His435Arg.

[0142] The bispecific antibodies of the present invention can adopt any of these bispecific technologies and molecular formats as desired.

[0143] In one embodiment, the bispecific antibody is a mAb 2 mAb 2 The constant regions of the intact antibodies are fused to the modified constant regions. H and V L The domain that has been engineered to form an antigen binding site is called an "Fcab". Fcab / mAb 2 The technology behind the format is described in more detail in WO2008 / 003103, and mAb 2 The description of the versions is incorporated herein by reference.

[0144] In another embodiment, the bispecific antibody is a "dual binding antibody". As used herein, the term "dual binding antibody" is a bispecific antibody in which two antigen binding domains are connected by V H / V L Pairing is formed, and includes the following: FIT-Ig (see WO2015 / 103072, incorporated herein by reference); mAb-dAb; lock-key structure; Fab-arm exchange; SEED body; trifunctional mAb; LUZ-Y; Fcab; κλ body; orthogonal Fab; sc bifunctional antibody-Fc; bifunctional antibody-Fc; tandem scFv-Fc; Fab-scFv-Fc; Fab-scFv; intracellular antibody; BiTE; bifunctional antibody; DART; TandAb; sc bifunctional antibody; sc bifunctional antibody-CH3; bifunctional antibody-CH3; triple body; miniantibody; miniantibody; scFv-CH3 KIH; scFv-CH-CL-scFv, F(ab')2-scFv; scFv-KIH; Fab-scFv-Fc; tetravalent HCab; ImmTAC; knob-hole; knob-hole with common light chain; knob-hole with common light chain and charge pair, charge pair, charge pair and common light chain; DT-IgG; DutaMab; IgG(H)-scFv; scFv-(H)IgG; IgG(L)-scFv; scFv-(L)IgG; IgG(L,H)-Fv; IgG(H)-V; V(H)-IgG; IgG(L)-V; V(L)-IgG; KIH IgG-scFab; 2scFv-IgG; IgG-2scFv and scFv4-Ig.

[0145] The term "hypervariable region", "CDR region" or "CDR" refers to the region of the variable domain of an antibody with a high degree of sequence variability and / or forming a structurally defined loop. In general, the antigen binding site of an antibody contains six hypervariable regions: three in the V H (CDRH1, CDRH2, CDRH3), and the three are at V L In (CDRL1, CDRL2, CDRL3). These regions of the antibody heavy and light chains confer antigen binding specificity to the antibody. CDRs can be defined according to the Kabat system (see Kabat, EA et al., 1991, "Sequences of Proteins of Immunological Interest", 5th edition, NIH Publication No. 91-3242, US Department of Health and Human Services). Other systems can be used to define CDRs, such as the following systems: the system designed by Chothia et al. (see Chothia, C. & Lesk, AM, 1987, "Canonical structures for the hypervariable regions of immunoglobulins", Journal of Molecular Biology (J. Mol. Biol.), 196, 901-917) and the IMGT system (see Lefranc, MP, 1997, "Unique database numbering system for immunogenetic analysis", Immunol. Today, 18, 50). Antibodies typically contain 3 heavy chain CDRs and 3 light chain CDRs. The term one or more CDRs is used here to indicate one or several of these regions. A skilled person in the art can easily compare different naming systems and determine whether a particular sequence can be defined as a CDR.

[0146] A "human antibody" is an antibody that has an amino acid sequence corresponding to that of an antibody produced by a human being and / or has been prepared using any of the techniques for preparing human antibodies, and specifically excludes humanized antibodies that include non-human antigen binding residues. The term "specifically binds to" refers to a measurable and reproducible interaction, such as binding between a target and an antibody, which is determined by the presence of the target in the presence of a heterogeneous group of molecules, including biomolecules. For example, an antibody that specifically binds to a target (which may be an epitope) is an antibody that binds to this target with a higher affinity, avidity, ease, and / or duration than it binds to other targets. In one embodiment, the extent of antibody binding to an unrelated target is less than about 10% of the binding of the antibody to the target, as measured, for example, by radioimmunoassay (RIA).

[0147] The antibody or fragment thereof that specifically binds to the hPCSK9 antigen may have cross-reactivity with related antigens. Preferably, the antibody or fragment thereof that specifically binds to the hPCSK9 antigen does not cross-react with other antigens (but may optionally cross-react with PCSK9 of different species (e.g., rhesus monkey or mouse)). It can be, for example, by immunoassay, BIAcore TM Or other techniques known to those skilled in the art to identify antibodies or fragments thereof that specifically bind to the hPCSK9 antigen. When the antibody or fragment thereof binds to the hPCSK9 antigen with a higher affinity than to any cross-reactive antigen, as determined using experimental techniques such as radioimmunoassay (RIA) and enzyme-linked immunosorbent assays (ELISA), the antibody or fragment thereof specifically binds to the PCSK9 antigen. Typically, a specific or selective reaction will be at least two times the background signal or noise, and more typically greater than 10 times the background (e.g., greater than 15 times, greater than 20 times, greater than 50 times, or greater than 100 times). For a discussion of antibody specificity, see, for example, Paul (ed.), 1989, Fundamental Immunology Second Edition, Raven Press, New York, pp. 332-336.

[0148] The term "aliphatic amino acid" means that the amino acid R group is non-polar and hydrophobic. The hydrophobicity increases with the number of C atoms in the hydrocarbon chain. Glycine, alanine, valine, leucine and isoleucine are aliphatic amino acids.

[0149] The term "aromatic amino acid" means that the amino acid R group contains an aromatic ring system. Phenylalanine, tyrosine and tryptophan are aromatic amino acids.

[0150] The term "hydroxyl-containing amino acid" means that the amino acid R group contains a hydroxyl group and is hydrophilic. Serine, cysteine, threonine and methionine are hydroxyl-containing amino acids.

[0151] The term "basic amino acid" means that the amino acid R group is nitrogen-containing and is basic at neutral pH. Histidine, lysine, and arginine are basic amino acids.

[0152] The term "cyclic amino acid" means that the amino acid R group has an aliphatic ring structure. Proline is the only cyclic aliphatic amino acid.

[0153] The term "acidic amino acid" means that the amino acid R group is polar and negatively charged at physiological pH. Aspartic acid and glutamic acid are acidic amino acids.

[0154] The term "amide amino acid" means that the amino acid R group contains an acyl group. Asparagine and glutamine are amide amino acids.

[0155] As used herein, "authorization number" or "sales authorization number" refers to the number awarded when the regulatory agency determines that a specific medical product and / or composition can be sold and / or provided for sale in an area under the jurisdiction of the agency. As used herein, "regulatory agency" refers to one of the agencies responsible for evaluating (e.g., the safety and efficacy of medical products and / or compositions) and controlling the sale / sale of such products and / or compositions in a given area. The Food and Drug Administration (FDA) of the United States and the European Medicines Agency (EPA) of Europe are only two examples of such regulatory agencies. Other non-limiting examples may include SDA, MPA, MHPRA, IMA, ANMAT, Drug Office of the Department of Health of the Hong Kong Special Administrative Region of the People's Republic of China, CDSCO, Medsafe and KFDA.

[0156] As used herein, "buffer" refers to a chemical agent that is able to absorb a certain amount of acid or base without undergoing a strong change in pH.

[0157] As used herein, the term "carrier" refers to a diluent, adjuvant (e.g., Freund's adjuvant (complete and incomplete)), excipient or vehicle with which the therapeutic agent is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, plant or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. When the pharmaceutical composition is administered intravenously, water is a preferred carrier. Saline solutions and aqueous solutions of dextrose and glycerol can also be used as liquid carriers, particularly for injectable solutions.

[0158] As used herein, the term "composition" is intended to encompass a product comprising specified ingredients (eg, an antibody of the invention), optionally in specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients, optionally in specified amounts.

[0159] As used herein, the terms "comprising" and "comprises" are used in reference to antibodies, fragments, uses, compositions, methods, and individual components thereof that are essential to the method or composition, while being open to inclusion of unspecified elements, whether essential or not.

[0160] The term "consisting of" refers to the antibodies, fragments, uses, compositions, methods and respective components thereof as described herein, excluding any elements not recited in said description of the embodiments.

[0161] As used herein, the term "consisting essentially of" refers to those elements required for a given embodiment. The term permits the presence of elements that do not significantly affect the basic and novel or functional characteristics of that embodiment.

[0162] In the case of polypeptides, as used herein, the term "derivative" includes polypeptides comprising the following amino acid sequences: hPCSK9 polypeptides, fragments of hPCSK9 polypeptides, or antibodies or fragments that specifically bind to hPCSK9 polypeptides, which derivative polypeptides have been altered by the introduction of amino acid residue substitutions, deletions, or additions. As used herein, the term "derivative" also includes hPCSK9 polypeptides, fragments of hPCSK9 polypeptides, or antibodies that specifically bind to hPCSK9 polypeptides that have been chemically modified, such as by covalently linking any type of molecule to the polypeptide. By way of example and without limitation, hPCSK9 polypeptides, fragments of hPCSK9 polypeptides, or hPCSK9 antibodies may be chemically modified, such as by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting / capping groups, protein cleavage, attachment to cellular ligands or other proteins, etc. Derivatives are modified in a manner that is different from the naturally occurring or starting peptide or polypeptide (in terms of the type or position of the molecule attached). Derivatives further include the absence of one or more chemical groups that are naturally present on the peptide or polypeptide. Derivatives of hPCSK9 polypeptides, fragments of hPCSK9 polypeptides, or hPCSK9 antibodies can be chemically modified using techniques known to those skilled in the art, including, but not limited to, specific chemical cleavage, acetylation, formulation, metabolic synthesis of tunicamycin, etc. In addition, derivatives of hPCSK9 polypeptides, fragments of hPCSK9 polypeptides, or hPCSK9 antibodies may contain one or more non-classical amino acids. The polypeptide derivatives possess similar or identical functions to the hPCSK9 polypeptides, fragments of hPCSK9 polypeptides, or hPCSK9 antibodies described herein.

[0163] As used herein, the term "effector function" (or "effector-enabled") refers to one or more of the following: antibody-dependent cell-mediated cytotoxic activity (ADCC), complement-dependent cytotoxic activity (CDC)-mediated responses, Fc-mediated phagocytosis or antibody-dependent cellular phagocytosis (ADCP), and recycling of antibodies through the FcRn receptor.

[0164] "Effective amount" refers to an amount that can effectively achieve the desired effect, including treatment or prevention results, at the desired dosage and time period. "Therapeutically effective amount" refers to the minimum concentration required to achieve a measurable improvement or prevention of a specific condition. The therapeutically effective amount herein may vary according to factors such as the patient's disease state, age, sex and weight, and the ability of the antibody to elicit the desired response in the individual. The therapeutically effective amount is also the amount in which the therapeutic beneficial effects of the antibody exceed its toxic or adverse effects. "Preventatively effective amount" refers to an amount that can effectively achieve the desired prevention results at the desired dosage and time period. In some embodiments, the effective amount of an antibody of the present invention is about 0.1 mg / kg (mg antibody / kg individual weight) to about 100 mg / kg. In certain embodiments, the effective amount of the antibody provided herein is about 0.1 mg / kg, about 0.5 mg / kg, about 1 mg / kg, 3 mg / kg, 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, about 50 mg / kg, about 60 mg / kg, about 70 mg / kg, about 80 mg / kg, about 90 mg / kg or about 100 mg / kg (or ranges therein). In some embodiments, as used herein, "effective amount" also refers to the amount of the antibody of the invention to achieve a specified result (e.g., inhibiting the hPCSK9 biological activity of a cell).

[0165] As used herein, the term "epitope" refers to a localized region on the surface of an antigen, such as an hPCSK9 polypeptide or hPCSK9 polypeptide fragment, which is capable of binding to one or more antigen binding regions of an antibody and has antigenic or immunogenic activity, i.e., is capable of eliciting an immune response, in an animal, preferably a mammal, and most preferably in a human. An epitope with immunogenic activity is a portion of a polypeptide that elicits an antibody response in an animal. An epitope with antigenic activity is a portion of a polypeptide to which an antibody specifically binds, as determined by any method known in the art, such as by an immunoassay described herein. An antigenic epitope need not necessarily be immunogenic. An epitope is typically composed of a group of chemically active surface molecules (e.g., amino acids or sugar side chains) and typically has specific three-dimensional structural characteristics and charge-to-mass ratio characteristics. The polypeptide region that contributes to the epitope may be contiguous amino acids of the polypeptide, or the epitope may be aggregated by two or more non-contiguous regions of the polypeptide. An epitope may or may not be a three-dimensional surface feature of an antigen. In certain embodiments, an hPCSK9 epitope is a three-dimensional surface feature of an hPCSK9 polypeptide (e.g., in a trimerized form of an hPCSK9 polypeptide). In other embodiments, the hPCSK9 epitope is a linear feature of the hPCSK9 polypeptide (e.g., in a trimerized or monomeric form of the hPCSK9 polypeptide). The antibodies provided herein can specifically bind to: an epitope in a monomeric (denatured) form of hPCSK9, an epitope in a trimerized (native) form of hPCSK9, or both a monomeric (denatured) form and a trimerized (native) form of hPCSK9. In specific embodiments, the antibodies provided herein specifically bind to an epitope in a trimerized form of hPCSK9, but do not specifically bind to a monomeric form of hPCSK9.

[0166] As used herein, the term "excipient" refers to an inert substance that is commonly used as a diluent, vehicle, preservative, binder or stabilizer for drugs, and includes, but is not limited to, proteins (e.g., serum albumin, etc.), amino acids (e.g., aspartic acid, glutamic acid, lysine, arginine, glycine, histidine, etc.), fatty acids and phospholipids (e.g., alkyl sulfonates, octanoate, etc.), surfactants (e.g., SDS, polysorbate, nonionic surfactants, etc.), sugars (e.g., sucrose, maltose, trehalose, etc.), and polyols (e.g., mannitol, sorbitol, etc.). See also Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, Pennsylvania, which is incorporated herein by reference in its entirety.

[0167] As used herein, "authorization number" or "sales authorization number" refers to the number awarded when the regulatory agency determines that a specific medical product and / or composition can be sold and / or provided for sale in the area under the jurisdiction of the agency. As used herein, "regulatory agency" refers to one of the agencies responsible for evaluating (e.g., the safety and efficacy of medical products and / or compositions) and controlling the sale / sale of such products and / or compositions in a given area. The Food and Drug Administration (FDA) of the U.S. and the European Medicines Agency (EPA) of Europe are only two examples of such regulatory agencies. Other non-limiting examples may include SDA, MPA, MHPRA, IMA, ANMAT, Drug Office of the Department of Health of the Hong Kong Special Administrative Region of the People's Republic of China, CDSCO, Medsafe and KFDA.

[0168] As used herein, "injection device" refers to a device designed to perform an injection, which includes the step of temporarily fluidly coupling the injection device to a person's tissue (usually subcutaneous tissue). Injection further includes administering a certain amount of liquid drug into the tissue and decoupling or removing the injection device from the tissue. In some embodiments, the injection device may be an intravenous device or IV device, which is a type of injection device used when the target tissue is blood in the circulatory system (e.g., blood in a vein). A common but non-limiting example of an injection device is a needle and a syringe.

[0169] As used herein, "buffer" refers to a chemical agent that is able to absorb a certain amount of acid or base without undergoing a strong change in pH.

[0170] As used herein, "packaging" refers to how the components are organized and / or confined into a unit suitable for distribution and / or use. The packaging may include, for example, boxes, bags, syringes, ampoules, vials, test tubes, flip-top packaging, barriers and / or containers to maintain sterility, labeling, etc.

[0171] As used herein, "instructions" refers to written, printed or graphic matter displayed on the actual container of an article of manufacture, such as written material displayed on a vial containing a pharmaceutically active agent or details about the composition and use of the product contained in a kit containing the composition of interest. The instructions set forth the method of administering or carrying out the intended treatment.

[0172] In the case of a peptide or polypeptide, as used herein, the term "fragment" refers to a peptide or polypeptide that includes less than the full-length amino acid sequence. Such fragments may, for example, result from truncations at the amino terminus, truncations at the carboxyl terminus, and / or internal deletions of residues from the amino acid sequence. Fragments may, for example, result from alternative RNA splicing or in vivo protease activity. In certain embodiments, a PCSK9 fragment comprises a polypeptide comprising an amino acid sequence having at least 5 consecutive amino acid residues, at least 10 consecutive amino acid residues, at least 15 consecutive amino acid residues, at least 20 consecutive amino acid residues, at least 25 consecutive amino acid residues, at least 40 consecutive amino acid residues, at least 50 consecutive amino acid residues, at least 60 consecutive amino acid residues, at least 70 consecutive amino acid residues, at least 80 consecutive amino acid residues, at least 90 consecutive amino acid residues, at least 100 consecutive amino acid residues, at least 125 consecutive amino acid residues, at least 150 consecutive amino acid residues, at least 175 consecutive amino acid residues, at least 200 consecutive amino acid residues, or at least 250 consecutive amino acid residues of an amino acid sequence of an hPCSK9 polypeptide or an antibody that specifically binds to an hPCSK9 antigen. In a specific embodiment, a fragment of an hPCSK9 polypeptide or an antibody that specifically binds to an hPCSK9 antigen retains at least one, at least two, or at least three functions of the polypeptide or antibody.

[0173] The term "free" can refer to a polypeptide, such as PCSK9 or a fragment and variant thereof, combined with a buffer, wherein the polypeptide is not bound to a cell surface or cell membrane. Therefore, the term "free" can refer to a polypeptide that is capable of surface expression (i.e., comprising one or more transmembrane domains or membrane binding domains) but is not expressed on the cell surface or bound to a protein expressed on the cell surface in its present state. Free polypeptides can also refer to free recombinant or native or unbound polypeptides. In the case of phage presentation, free antigens can be selected in solution (referred to herein as "soluble selection") or adsorbed to a surface, such as to the surface of a 96-well plate (referred to herein as "bio-panning selection").

[0174] As used herein, the term "fusion protein" refers to a polypeptide comprising the amino acid sequence of an antibody and the amino acid sequence of a heterologous polypeptide or protein (i.e., a polypeptide or protein that is not normally a part of an antibody (e.g., a non-anti-PCSK9 antigen antibody)). When used with respect to PCSK9 or anti-PCSK9 antibodies, the term "fusion" refers to joining a peptide or polypeptide or a fragment, variant and / or derivative thereof to a heterologous peptide or polypeptide. Preferably, the fusion protein retains the biological activity of PCSK9 or the anti-PCSK9 antibody. In certain embodiments, the fusion protein comprises a PCSK9 antibody VH domain, a VL domain, a VH CDR (one, two or three VH CDRs) and / or a VL CDR (one, two or three VL CDRs), wherein the fusion protein specifically binds to a PCSK9 epitope.

[0175] When referring to antibody use, the term "heavy chain" refers to five different types, called alpha (α), delta (δ), epsilon (ε), gamma (γ) and mu (μ), based on the amino acid sequence of the heavy chain constant domain. These different types of heavy chains are well known and produce five categories of antibodies, namely IgA, IgD, IgE, IgG and IgM, including four subclasses of IgG, i.e. IgG1, IgG2, IgG3 and IgG4. Preferably, the heavy chain is a human heavy chain. In the human population, there are multiple heavy chain constant region alleles of each immunoglobulin or immunoglobulin subclass. The nucleotide and amino acid sequences of these allelic variants can be obtained in publicly available databases, such as IMGT, ENSEMBL Swiss-Prot and Uniprot. Allelic variants can also be identified in various genome sequencing projects. In one embodiment, the antibodies and antibody fragments disclosed herein include heavy chains encoded by IgG1 constant region alleles, including but not limited to human IGHG1*01 (SEQ ID Nos: 340, 341, and 537), IGHG1*02 (SEQ ID Nos: 340, 341, and 537), IGHG1*03 (SEQ ID Nos: 523 and 524), IGHG1*04 (SEQ ID Nos: 525 and 526), ​​and IGHG1*05 (SEQ ID Nos: 340, 341, and 537). In one embodiment, the antibodies and antibody fragments disclosed herein include proteins encoded by IgG2 constant region alleles, including but not limited to human IGHG2*01 (SEQ ID Nos: 527 and 528), IGHG2*02 (SEQ ID Nos: 529 and 530), IGHG2*03 (SEQ ID Nos: 527 and 528), IGHG2*04 (SEQ ID Nos: 531 and 532), IGHG2*05 (SEQ ID Nos: 527 and 528) and IGHG2*06 (SEQID Nos: 533 and 534). In one embodiment, the antibodies or antibody fragments disclosed herein include proteins encoded by IgG3 constant region alleles, including but not limited to human IGHG3*01, IGHG3*02, IGHG3*03, IGHG3*04, IGHG3*05, IGHG3*06, IGHG3*07, IGHG3*08, IGHG3*09, IGHG3*10, IGHG3*11, IGHG3*12, IGHG3*13, IGHG3*14, IGHG3*15, IGHG3*16, IGHG3*17, IGHG3*18 and IGHG3*19.In one embodiment, the antibodies or antibody fragments disclosed herein include proteins encoded by IgG4 constant region alleles, including, but not limited to, human IGHG4*01 (see, e.g., the sequence listing herein), IGHG4*02 (see, e.g., the sequence listing herein), IGHG4*03 (see, e.g., the sequence listing herein), and IGHG4*04 (see, e.g., the sequence listing herein). In another example, the heavy chain is a disabled IgG isotype, such as disabled IgG4. In certain embodiments, the antibodies of the present invention include a human γ4 constant region. In another embodiment, the heavy chain constant region does not bind to the Fc-γ receptor, and, for example, includes a Leu235Glu mutation. In another embodiment, the heavy chain constant region includes a Ser228Pro mutation to increase stability. In another embodiment, the heavy chain constant region is IgG4-PE (see, e.g., the sequence listing herein). In another embodiment, the antibodies and antibody fragments disclosed herein include a heavy chain constant region encoded by a murine IgG1 constant region allele, including, but not limited to, mouse IGHG1*01 or IGHG1*02. In one embodiment, the antibodies and antibody fragments disclosed herein include a heavy chain constant region encoded by a murine IgG2 constant region allele, including but not limited to mouse IGHG2A*01, IGHG2A*02, IGHG2B*01, IGHG2B*02, IGHG2C*01, IGHG2C*02, or IGHG2C*03. In one embodiment, the antibodies or antibody fragments disclosed herein include a protein encoded by a murine IgG3 constant region allele, including but not limited to mouse IGHG3*01.

[0176] As used herein, the term "host" refers to an animal, preferably a mammal, and most preferably a human.

[0177] As used herein, the term "host cell" refers to a specific individual cell transfected with a nucleic acid molecule and the offspring or potential offspring of such a cell. Due to the possible presence of mutations or environmental influences in succession or the integration of the nucleic acid molecule into the host cell genome, the offspring of such a cell may not be identical to the parent cell transfected with the nucleic acid molecule.

[0178] The term "in combination" refers to the use of more than one therapy in the context of administering other therapies. The use of the term "combination" does not limit the order in which the therapy is administered to an individual suffering from a disease. The first therapy may be administered before (e.g., 1 minute, 45 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks) administering the second therapy to an individual suffering from, suffering from, or susceptible to a PCSK9-mediated disease, at the same time or after (e.g., 1 minute, 45 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks). Any additional therapy can be administered in any order with other additional therapies. In certain embodiments, the antibodies of the invention may be administered in combination with one or more therapies currently administered for the prevention, treatment, control and / or amelioration of PCSK9-mediated diseases (e.g., therapies that are not antibodies of the invention). Non-limiting examples of therapies that may be administered in combination with the antibodies of the invention include analgesics, anesthetics, antibiotics or immunomodulators or any other agent listed in the US Pharmacopoeia and / or the Physician's Desk Reference.

[0179] As used herein, "injection device" refers to a device designed to perform an injection, which includes the step of temporarily fluidly coupling the injection device to a person's tissue (usually subcutaneous tissue). Injection further includes administering a certain amount of liquid drug into the tissue and decoupling or removing the injection device from the tissue. In some embodiments, the injection device may be an intravenous device or IV device, which is a type of injection device used when the target tissue is blood in the circulatory system (e.g., blood in a vein). A common but non-limiting example of an injection device is a needle and a syringe.

[0180] As used herein, "instructions" refers to written, printed or graphic matter displayed on the actual container of an article of manufacture, such as written material displayed on a vial containing a pharmaceutically active agent or details about the composition and use of the product contained in a kit containing the composition of interest. The instructions set forth the method of administering or carrying out the intended treatment.

[0181] An "isolated" or "purified" antibody or protein is an antibody (e.g., natural or recombinant) that has been identified, separated, and / or recovered from a component of the environment in which it was produced. For example, an antibody or protein is substantially free of cellular material or other impurity proteins from the cell or tissue source from which the antibody is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes antibody preparations in which the antibody is separated from cellular components of the cells from which the antibody is isolated or recombinantly produced. Thus, antibodies that are substantially free of cellular material include antibody preparations having less than about 30%, 20%, 10%, or 5% (dry weight) of heterologous proteins (also referred to herein as "impurity proteins"). When the antibody is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium accounts for less than about 20%, 10%, or 5% of the volume of the protein preparation. When the antibody is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals involved in the synthesis of the protein. Thus, such antibody preparations have less than about 30%, 20%, 10% or 5% (by dry weight) of chemical precursors or compounds other than the antibody of interest. In a preferred embodiment, the antibodies of the invention are isolated or purified.

[0182] The term "Kabat numbering" and similar terms are recognized in the art and refer to a system for numbering amino acid residues that are more variable (i.e., hypervariable) than other amino acid residues in an antibody heavy chain variable region or antigen binding portion thereof (Kabat et al., (1971) Ann. NY Acad. Sci., 190:382-391 and Kabat et al. (1991) Sequences of Proteins of Immunological Interest, 5th ed., U.S. Department of Health and Human Services, NIH Publication No. 91-3242). For the heavy chain variable region, the hypervariable region is generally within the range of amino acid positions 31 to 35 of CDR1, amino acid positions 50 to 65 of CDR2, and amino acid positions 95 to 102 of CDR3.

[0183] As used herein, "label" or "labeled" refers to the addition of a detectable moiety to a polypeptide, such as a radioactive tag, a fluorescent tag, an enzyme tag, a chemiluminescent tag, or a biotinyl or gold. Radioisotopes or radionuclides may include 3 H. 14 C. 15 N. 35 S. 90 Y. 99 Tc, 115 In,125 I. 131 I, fluorescent labels may include rhodamine, lanthanide phosphors or FITC, and enzyme labels may include horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase. By way of illustration and not limitation, additional labels include: enzymes such as glucose-6-phosphate dehydrogenase ("G6PDH"), α-D-galactosidase, glucose oxidase, glucoamylase, carbonic anhydrase, acetylcholinesterase, lysozyme, malate dehydrogenase, and peroxidase; dyes (e.g., cyanine dyes such as Cy5 TM 、Cy5.5 TM . or Cy7 TM ); additional fluorescent labels or fluorescent agents include, for example, fluorescein and its derivatives, fluorescent dyes, GFP (GFP stands for "green fluorescent protein"), other fluorescent proteins (e.g., mCherry, mTomato), dansyl, umbelliferone, phycoerythrin, phycocyanin, allophycocyanin, o-phthalaldehyde and fluorescamine; fluorophores, such as lanthanide cryptates and chelates, such as europium, etc. (PerkinElmer and Cisbio analysis); silent change labels or silent change agents (c hemiluminescer, such as isoluminol, luminol and dioxetane; sensitizers; coenzymes; enzyme substrates; particles, such as latex or carbon particles; metal sols; microcrystals; liposomes; cells, etc., which may be further labeled with dyes, catalysts or other detectable groups; molecules, such as biotin, digoxygenin or 5-bromodeoxyuridine; toxin moieties, such as toxin moieties selected from the group consisting of Pseudomonas exotoxin (PE, or cytotoxic fragments or mutants thereof), diphtheria toxin or cytotoxic fragments or mutants thereof, botulinum toxin A, B, C, D, E or F, ricin or cytotoxic fragments thereof (e.g. ricin A), abrin or cytotoxic fragments thereof, saponin or cytotoxic fragments thereof, pokeweed antiviral toxin or cytotoxic fragments thereof and bryodin 1 or cytotoxic fragments thereof.

[0184] When used in referring to antibodies, the term "light chain" refers to an immunoglobulin light chain, which has two types lambda (λ) and kappa (κ) in mammals. Preferably, the light chain is a human light chain. Preferably, the light chain constant region is a human constant region. In the human population, there are multiple light chain constant region alleles. The nucleotide and amino acid sequences of these allele variants can be obtained in publicly available databases, such as IMGT, ENSEMBL, Swiss-Prot and Uniprot. In one embodiment, the antibodies or antibody fragments disclosed herein include proteins encoded by human κ constant region alleles, including, but not limited to, IGKC*01 (see, e.g., sequence table herein), IGKC*02 (see, e.g., sequence table herein), IGKC*03 (see, e.g., sequence table herein), IGKC*04 (see, e.g., sequence table herein) and IGKC*05 (see, e.g., sequence table herein). In one embodiment, the antibodies or antibody fragments disclosed herein include proteins encoded by human lambda constant region alleles, including but not limited to IGLC1*01 (see, e.g., the sequence listing herein), IGLC1*02 (see, e.g., the sequence listing herein), IGLC2*01 (see, e.g., the sequence listing herein), IGLC2*02 (see, e.g., the sequence listing herein), IGLC2*03 (see, e.g., the sequence listing herein), IGLC3*01 (see, e.g., the sequence listing herein), IGLC3*02 (see, e.g., the sequence listing herein), IGLC3*03 (see, e.g., the sequence listing herein), IGLC3*04 (see, e.g., the sequence listing herein), IGLC6*01 (see, e.g., the sequence listing herein), IGLC7*01 (see, e.g., the sequence listing herein), IGLC7*02 (see, e.g., the sequence listing herein), IGLC7*03 (see, e.g., the sequence listing herein). In another embodiment, the antibodies and antibody fragments disclosed herein include a light chain constant region encoded by a mouse kappa constant region allele, including but not limited to IGKC*01, IGKC*03 or IGKC*03. In another embodiment, the antibodies and antibody fragments disclosed herein include a light chain constant region encoded by a mouse lambda constant region allele, including but not limited to IGLC1*01, IGLC2*01 or IGLC3*01.

[0185] "Percentage (%) of amino acid sequence identity" and "homology" with respect to a peptide, polypeptide or antibody sequence are defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a particular peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percentage of sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be achieved in various ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGN TM (DNASTAR) software. In one embodiment, the % homology is about 70%. In one embodiment, the % homology is about 75%. In one embodiment, the % homology is about 80%. In one embodiment, the % homology is about 85%. In one embodiment, the % homology is about 90%. In one embodiment, the % homology is about 92%. In one embodiment, the % homology is about 95%. In one embodiment, the % homology is about 97%. In one embodiment, the % homology is about 98%. In one embodiment, the % homology is about 99%. In one embodiment, the % homology is 100%.

[0186] The term "naturally occurring" when used in conjunction with biological materials (eg, nucleic acid molecules, polypeptides, host cells, and the like) refers to those found in nature and have not been manipulated by humans.

[0187] As used herein, "packaging" refers to how the components are organized and / or confined into a unit suitable for distribution and / or use. The packaging may include, for example, boxes, bags, syringes, ampoules, vials, test tubes, flip-top packaging, barriers and / or containers to maintain sterility, labeling, etc.

[0188] As used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the US Pharmacopia, the European Pharmacopia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.

[0189] As used herein, the terms "polynucleotide," "nucleotide," "nucleic acid," "nucleic acid molecule" and other similar terms are used interchangeably and include DNA, RNA, mRNA and analogs thereof.

[0190] As used herein, the terms "prevent", "preventing", and "prevention" refer to the administration of a therapy or combination therapy provided herein (e.g., a preventive agent or a therapeutic agent combination, such as an antibody of the invention) such that the development, recurrence, onset, or spread of a hPCSK9-mediated disease and / or symptoms associated therewith is completely or partially inhibited.

[0191] The term "soluble" refers to polypeptides found in native or membrane-bound form that lack one or more transmembrane or cytoplasmic domains, such as PCSK9 and variants or fragments thereof. In one embodiment, a "soluble" form of PCSK9 lacks both a transmembrane domain and a cytoplasmic domain.

[0192] The term "subject" or "patient" refers to any animal, including, but not limited to, mammals. As used herein, the term "mammal" refers to any vertebrate that nurses its young and gives birth to live young (eumammalia or placental mammals) or lays eggs (metatheria or non-placental mammals). Examples of mammalian species include, but are not limited to: humans and other primates, including non-human primates, such as chimpanzees and other apes and monkey species; farm animals, such as cattle, sheep, pigs, goats, and horses; domestic mammals, such as dogs and cats; laboratory animals, including rodents, such as mice, rats (including cotton rats), and guinea pigs; birds, including domestic, wild, and game birds, such as chickens, turkeys, and other gallinaceous birds, ducks, geese, and the like.

[0193] As used herein, "substantially all" means at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or about 100%.

[0194] As used herein, the term "therapeutic agent" refers to any agent that can be used to treat, control or improve a PCSK9-mediated disease and / or symptoms associated therewith. In certain embodiments, the term "therapeutic agent" refers to an antibody of the present invention. In certain other embodiments, the term "therapeutic agent" refers to an agent other than an antibody of the present invention. Preferably, the therapeutic agent is an agent that is known to be suitable for, has been used in, or is currently being used to treat, control or improve a PCSK9-mediated disease or one or more symptoms associated therewith. In specific embodiments, the therapeutic agent is a fully human anti-PCSK9 antibody, such as a fully human anti-PCSK9 monoclonal antibody.

[0195] As used herein, the term "therapy" refers to any regimen, method and / or agent that can be used to prevent, control, treat and / or improve a PCSK9-mediated disease (e.g., cancer). In certain embodiments, the term "therapy" refers to biological therapies, supportive therapies and / or other therapies known to a skilled person in the art (e.g., a medical professional) that are suitable for preventing, controlling, treating and / or improving a PCSK9-mediated disease.

[0196] The term "treat / treatment / treating" refers to reducing or improving the progression, severity and / or duration of a disease mediated by hPCSK9 (e.g., cancer) due to the administration of one or more therapies (including, but not limited to, the administration of one or more prophylactic or therapeutic agents, such as antibodies of the present invention). In specific embodiments, such terms refer to reducing or inhibiting the binding of hPCSK9 to BMP receptors or HJVs, and / or inhibiting or reducing one or more symptoms associated with a disease mediated by PCSK9 (e.g., hyperlipidemia or hypercholesterolemia).

[0197] The term "variable region" or "variable domain" refers to a portion of the light and heavy chains, typically about the amino-terminal 120 to 130 amino acids in the heavy chain and about 100 to 110 amino acids in the light chain, which differ widely in sequence between antibodies and are used in the binding and specificity of each particular antibody for its specific antigen. The variability in the sequence is concentrated in those regions called the complementary determining regions (complimentarily determining regions; CDRs), while the more highly conserved regions in the variable domain are called framework regions (FRs). The CDRs of PCSK9 and the heavy chain are primarily responsible for the interaction of the antibody with the antigen. The numbering of amino acid positions used herein is according to the EU index, as in Kabat et al. (1991) Sequences of proteins of immunological interest. (U.S. Department of Health and Human Services, Washington, D.C.) 5th edition ("Kabat et al."). In a preferred embodiment, the variable region is a human variable region.

[0198] Definitions of common terms in cell biology and molecular biology can be found in: "The Merck Manual of Diagnosis and Therapy", 19th edition, published by Merck Research Laboratories, 2006 (ISBN 0-911910-19-0); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); Benjamin Lewin, Genes X, published by Jones & Bartlett Publishing, 2009 (ISBN-10:0763766321); Kendrew et al. (eds.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8) and Current Protocols in Protein Sciences 2009, Wiley Intersciences, Coligan et al., eds.

[0199] Unless otherwise stated, the present invention was performed using standard procedures as described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual (4th ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA (2012); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (1995); or Methods in Enzymology: Guide to Molecular Cloning Techniques, Vol. 152, SL Berger and AR Kimmel, eds., Academic Press Inc., San Diego, USA (1987); Current Protocols in Protein Science (CPPS) (John E. Coligan et al., eds., John Wiley and Sons, Inc.), Current Protocols in Cell Biology (CPCB) (Juan S. Bonifacino et al., eds., John Wiley and Sons, Inc.), and Culture of Animal Cells: A Manual of Basic Technique, R. Ian Freshney, Publisher: Wiley-Liss; 5th edition (2005), Animal Cell Culture Methods (Methods in Cell Biology, Vol. 57, Jennie P. Mather and David Barnes editors, Academic Press, 1st edition, 1998), all of which are incorporated herein by reference in their entirety.

[0200] Other terms are defined herein in the description of various aspects of the invention.

[0201] Anti-PCSK9 antibodies and fragments

[0202] The present invention provides various anti-PCSK9 antibodies and fragments (eg, Fab or scFv fragments), uses, methods and combinations (eg, with statins). Examples are described in the following numbered items.

[0203] 1. An antibody or fragment comprising a binding site that specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9), wherein the binding site comprises a VH domain encoded by a nucleotide sequence derived from the recombination of a human VH gene segment, a DH gene segment, and a JH gene segment, wherein the VH gene segment is selected from IGHV4-59 and IGHV3-9.

[0204] For example, the VH gene segment is IGHV4-59*01, and the DH gene segment and the JH gene segment are human gene segments. For example, the VH gene segment is IGHV3-9*01, and the DH gene segment and the JH gene segment are human gene segments.

[0205] In one example, the specific binding has a KD, K off and / or K on In one example, the specific binding has a KD of 1 pM to 5 nM.

[0206] The skilled artisan is familiar with databases and other sources of antibody gene segments for humans and other species. For example, the IMGT database ( www.IMGT.org ) is a suitable source, for example as of 1 September 2018.

[0207] With reference to the Examples, antibodies based on IGHV4-59 and IGHV3-9 are shown. Unexpectedly, this human VH gene segment produces anti-PCSK9 antibodies with desirable anti-PCSK9 properties, such as those described in, for example, the Examples.

[0208] For example, the antibodies or fragments of the invention are administered to a subject for reducing plasma total cholesterol and plasma non-HDL-cholesterol in the subject in a dose-dependent manner.

[0209] For example, an antibody or fragment of the invention is administered to a subject for use in lowering total plasma cholesterol in the subject.

[0210] For example, an antibody or fragment of the invention is administered to a subject to lower (optionally in a dose-dependent manner) plasma non-HDL-cholesterol in the subject.

[0211] For example, the antibodies or fragments of the invention are used to administer to a subject to reduce plasma triglyceride levels in the subject).

[0212] In one embodiment of any of these examples, HDL-cholesterol is not reduced or is not significantly reduced in the subject.

[0213] The examples show that the antibodies of the invention are beneficially administered compared to the alirocumab benchmark test. For example, the antibodies or fragments of the invention are used to administer to an individual for the treatment or prevention of a PCSK9-mediated disease or condition (e.g., heterozygous familial hypercholesterolaemia (HeFH) or homozygous familial hypercholesterolaemia (HoFH)), wherein the antibody or fragment is administered at a dose of less than 75 mg / 2 weeks or 300 mg / 4 weeks. For example, the antibodies or fragments of the invention are used to administer to an individual for the treatment or prevention of a PCSK9-mediated disease or condition (e.g., heterozygous familial hypercholesterolaemia (HeFH) or homozygous familial hypercholesterolaemia (HoFH)), wherein the antibody or fragment is administered at a dose of less than 140 mg / 2 weeks or less than 420 mg / 4 weeks. For example, the antibodies or fragments of the invention are used for administration to a subject for the treatment or prevention of a disease or condition mediated by PCSK9, such as heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH), wherein the antibody or fragment is administered at a dose less than once every 2 weeks for Praluent or Repatha. For example, the antibodies or fragments of the invention are used for administration to a subject for the treatment or prevention of a disease or condition mediated by PCSK9, such as heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH), wherein the antibody or fragment is administered at a dose less than once every 4 weeks for Praluent or Repatha. For example, the antibodies or fragments of the invention are used for administration to a subject for the treatment or prevention of a PCSK9-mediated disease or condition (e.g., heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH)), wherein the antibody or fragment is administered at a dose of less than 70, 65, 60, 50, 40, 30 or 25 mg once every 2 weeks or once every 4 weeks.

[0214] So Praluent TM The recommended starting dose of levofloxacin is 75 mg subcutaneously once every 2 weeks, as most patients achieve adequate LDL-C lowering at this dose, or 2 × 150 mg / 4 weeks.

[0215] In adults with established cardiovascular disease or in adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia [HeFH]), Repatha TM The recommended subcutaneous dose of Repatha is 140 mg every 2 weeks or 420 mg once a month. TM The recommended subcutaneous dose is 420 mg once a month.

[0216] For example, the antibody or fragment comprises a CDRH3 sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219, and CL-148489 (e.g., CL-274711 or CL-148219QLT); and optionally a CDRL3 of the selected antibody. For example, the antibody or fragment comprises a CDRH1 and CDRH3 sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219, and CL-148489 (e.g., CL-274711 or CL-148219QLT); and optionally a CDRL2 of the selected antibody. For example, the antibody or fragment comprises the CDRH1 and CDRH2 sequences of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219, and CL-148489 (e.g., CL-274711 or CL-148219QLT). For example, the antibody or fragment comprises the CDRH2 and CDRH3 sequences of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219, and CL-148489 (e.g., CL-274711 or CL-148219QLT). For example, the antibody or fragment comprises an anti-PCSK9 binding site, wherein the binding site comprises a VH domain paired with a VL domain of CL-58838, wherein the VH domain comprises a CDRH3 sequence of CL-58838.

[0217] For example, the antibody or fragment comprises an anti-PCSK9 binding site, wherein the binding site comprises a VH domain comprising SEQ ID NO: 1, optionally paired with a VL domain comprising SEQ ID NO: 33, respectively. For example, the antibody or fragment comprises an anti-PCSK9 binding site, wherein the binding site comprises a VH domain comprising SEQ ID NO: 65, paired with a VL domain comprising SEQ ID NO: 95.

[0218] For example, the antibody or fragment comprises an anti-PCSK9 binding site, wherein the binding site comprises the VH domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT), optionally paired with the VL domain of the selected antibody. For example, the antibody or fragment comprises an anti-PCSK9 binding site, wherein the binding site comprises the VH domain of CL-58838 paired with the VL domain of CL-58838.

[0219] 2. The antibody or fragment according to clause 1, wherein (i) the VH gene segment is IGHV4-59 (eg, IGHV4-59*01) and the DH gene segment is the human gene segment IGHD3-10 (eg, IGHD3-10*01); or (ii) the VH gene segment is IGHV3-9 (eg, IGHV3-9*01) and the DH gene segment is the human gene segment IGHD3-9 (eg, IGHD3-9*01).

[0220] 3. An antibody or fragment according to clause 1 or 2, wherein the JH gene segment is the human gene segment IGHJ6 (eg, JH6*02).

[0221] 4. An antibody or fragment thereof, which specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9) and comprises the CDRH3 sequence of the anti-PCSK9 antibody according to any one of the preceding clauses.

[0222] 5. An antibody or fragment that specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9) and comprises a VH domain comprising the CDRH3 sequence of any anti-PCSK9 antibody disclosed herein (e.g., CL-148219 or CL-148489), or the CDRH3 sequence comprising 3, 2 or 1 amino acid substitutions.

[0223] 6. An antibody or fragment (optionally according to any of the preceding clauses) which specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9) and comprises a VH domain comprising the CDRH3 sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); or comprising 3, 2 or 1 amino acid substitutions of the sequence.

[0224] Optionally, the VH domain comprises a CDRH3 sequence selected from the CDRH3 sequences disclosed herein, or said selected sequence comprising 3, 2 or 1 amino acid substitutions.

[0225] 7. An antibody or fragment according to item 6, wherein the VH domain comprises: (i) a CDRH3 sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said CDRH3 sequence comprising 3, 2 or 1 amino acid substitutions; and (ii) a CDRH1 sequence of said selected antibody; or said CDRH1 sequence comprising 3, 2 or 1 amino acid substitutions.

[0226] 8. An antibody or fragment according to clause 6 or 7, wherein the VH domain comprises: (iii) a CDRH3 sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said CDRH3 sequence comprising 3, 2 or 1 amino acid substitutions; and (iv) a CDRH2 sequence of said selected antibody; or said CDRH2 sequence comprising 3, 2 or 1 amino acid substitutions.

[0227] 9. An antibody or fragment (optionally according to any of the preceding clauses), comprising a binding site that specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9), wherein the binding site comprises a VH domain, the VH domain comprising the amino acid sequence of the VH domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid that is at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0228] For example, the identity is at least 85%. For example, the identity is at least 90%. For example, the identity is at least 95%.

[0229] Optionally, the VH domain of the antibody or fragment comprises a VH amino acid sequence disclosed herein, or a heavy chain variable domain amino acid sequence that is at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto. For example, the identity is at least 85%. For example, the identity is at least 90%. For example, the identity is at least 95%.

[0230] 10. The antibody or fragment according to any one of the preceding clauses, comprising a first copy and a second copy of the VH domain.

[0231] In one example, the antibody or fragment comprises a binding site comprising a VH domain of the invention paired with a VL domain of the invention, wherein the binding site is capable of specifically binding to PCSK9 (e.g., mature PCSK9, e.g., human and / or cynomolgus PCSK9). For example, the antibody or fragment comprises both of such binding sites.

[0232] 11. An antibody or fragment (optionally according to any of the preceding clauses), comprising a binding site that specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9), wherein the binding site comprises a VL domain encoded by a nucleotide sequence derived from the recombination of a human VL gene segment and a JL gene segment, wherein the VL gene segment is selected from IGKV2-28 (eg, IGKV2-28*01) and IGKV2-29 (eg, IGKV2-29*01).

[0233] 12. The antibody or fragment of clause 11, wherein the VL is Vκ and the JL gene segment is a human gene segment selected from IGKJ3 and IGKJ4.

[0234] Optionally, the JL gene segment is selected from IGKJ3*01 and IGKJ4*01.

[0235] 13. An antibody or fragment which specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9) and comprises the CDRL3 sequence of the anti-PCSK9 antibody according to clause 11 or 12.

[0236] 14. An antibody or fragment (optionally according to any of the preceding clauses) that specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9) and comprises a VL domain comprising the CDRL3 sequence of any anti-PCSK9 antibody disclosed herein (e.g., CL-148219 or CL-148489), or the selected CDRL3 sequence comprising 3, 2 or 1 amino acid substitutions.

[0237] 15. The antibody or fragment of clause 14, comprising a VH domain comprising the CDRH3 sequence of the selected antibody.

[0238] 16. An antibody or fragment (optionally according to any of the preceding clauses) which specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9) and comprises a VL domain comprising a CDRL3 sequence selected from the CDRL3 sequences disclosed herein, or comprising 3, 2 or 1 amino acid substitutions of the selected CDRL3 sequence.

[0239] 17. An antibody or fragment (optionally according to any of the preceding clauses) which specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9) and comprises a VL domain comprising the CDRL3 (and optionally CDRH3) sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); or said sequences each comprising 3, 2 or 1 amino acid substitutions.

[0240] 18. An antibody or fragment according to item 17, wherein the VL domain comprises: (i) a CDRL3 sequence (and optionally CDRH3) of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said CDR3 sequence each comprising 3, 2 or 1 amino acid substitutions; and (ii) a CDRL1 (and optionally CDRH1) sequence of said selected antibody; or said CDR1 sequence each comprising 3, 2 or 1 amino acid substitutions.

[0241] 19. An antibody or fragment according to clause 17 or 18, wherein the VL domain comprises: (iii) a CDRL3 (and optionally CDRH3) sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said CDR3 sequence each comprising 3, 2 or 1 amino acid substitutions; and (iv) a CDRL2 (and optionally CDRH2) sequence of said selected antibody; or said CDR2 sequence each comprising 3, 2 or 1 amino acid substitutions.

[0242] 20. An antibody or fragment (optionally according to any of the preceding clauses), comprising a binding site that specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9), wherein the binding site comprises a VL domain, the VL domain comprising the amino acid sequence of the VL domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid that is at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0243] For example, the identity is at least 85%. For example, the identity is at least 90%. For example, the identity is at least 95%.

[0244] 21. The antibody or fragment of any preceding clause, comprising a first copy and a second copy of the VL domain.

[0245] In one example, the antibody or fragment comprises a binding site comprising a VL domain of the invention paired with a VH domain, wherein the binding site is capable of specifically binding to PCSK9 (e.g., mature PCSK9, e.g., human and / or cynomolgus PCSK9). For example, the antibody or fragment comprises both of such binding sites.

[0246] 22. An antibody or fragment (optionally according to any of the preceding clauses) which specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9) and comprises the heavy chain amino acid sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); or an amino acid that is at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0247] In one example, the heavy chain sequence comprises the VH amino acid sequence of CL-148219 or CL-148489 fused to the heavy chain constant region of an antibody disclosed herein (e.g., IgG4-PE constant region, e.g., SEQ ID NO: 3). Additionally or alternatively, in one example, the light chain sequence comprises the VL amino acid sequence of CL-148219 or CL-148489 fused to the light chain constant region of an antibody disclosed herein (e.g., kappa constant region, e.g., SEQ ID NO: 156).

[0248] For example, the identity is at least 85%. For example, the identity is at least 90%. For example, the identity is at least 95%.

[0249] 23. An antibody or fragment (optionally according to any of the preceding clauses) which specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9) and comprises the light chain amino acid sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); or an amino acid that is at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0250] For example, the identity is at least 85%. For example, the identity is at least 90%. For example, the identity is at least 95%.

[0251] 24. An antibody or fragment according to clause 23, comprising the light chain amino acid sequence of the selected antibody; or amino acids at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0252] For example, the identity is at least 85%. For example, the identity is at least 90%. For example, the identity is at least 95%.

[0253] 25. An antibody or fragment (optionally according to any of the preceding clauses) that specifically binds to an epitope of human PCSK9 that is identical to the epitope bound by the antibody according to any of the preceding clauses.

[0254] 26. The antibody or fragment according to clause 25, wherein the epitope is identified by unrelated amino acid scanning, or by X-ray crystallography.

[0255] The contact amino acid residues involved in the interaction between an antibody and an antigen can be determined by various methods known to those skilled in the art.

[0256] In one embodiment, sequential replacement of the amino acids of the antigen sequence (using standard molecular biology techniques to mutate the DNA encoding the antigen's sequence) with another unrelated amino acid (in the case of PCSK9, with alanine (also known as alanine scanning)) can provide residues whose mutation will reduce or eliminate the ability of the antibody to recognize the antigen in question. Binding can be assessed using standard techniques such as (but not limited to) SPR, HTRF, ELISA (which are described elsewhere in this article). Other substitutions can be made to enhance the disruption of binding, such as changing the charge on the side chains of the amino acids of the antigen sequence (e.g., lysine to glutamic acid), exchanging polar and non-polar residues (e.g., serine to leucine). Alanine scanning or other amino substitution methods can be performed on recombinant soluble antigens, or when the target is a cell membrane target, transiently or stably expressed mutant forms can be used directly on cells.

[0257] In one embodiment, protein crystallography can be used to determine the contact residues between the antibody and the antigen (i.e., to determine the epitope to which the antibody binds), and crystallography allows direct observation of the contact residues involved in the antibody-antigen interaction. As with standard X-ray crystallography, cryogenic electron microscopy has been used to determine the contact residues between the antibody and the HIV capsid protein (see Jeong Hyun et al. "Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike.", Nature Communications, 6, (2015)).

[0258] In one embodiment, if the antibody recognizes a linear epitope, short peptides based on the antigen sequence can be generated and the binding of the antibody to such peptides can be assessed using standard techniques such as, but not limited to, SPR, HTRF, ELISA (described elsewhere herein). Further investigation of the epitope can be provided by performing alanine scanning for any peptide that shows binding. As an alternative to linear peptides, conformational scanning can be performed using peptide scanning technology (http: / / www.pepscan.com / ) using chemical ligation of its peptides to the backbone, which has been used to determine discontinuous epitopes on CD20 targeting antibodies (Niederfellner, Gerhard et al. "Epitope characterization and crystal structure of GA101 provide insights into themolecular basis for type I / II distinction of CD20 antibodies.", Blood, 118.2, (2011), 358-367).

[0259] In one embodiment, restricted proteolytic digestion and mass spectrometry can be used to identify binding epitopes. Antibody-antigen complexes are digested by proteases, such as, but not limited to, trypsin. The digested complex peptides are compared with separate antibody and separate antigen digestion mass spectra to determine whether a specific epitope is protected by the complex. Then, other work involving amino acid substitutions and competitive binding can be used to narrow down to individual amino acid residues involved in the interaction (see, for example, Suckau, Detlev et al. "Molecular epitope identification by limited proteolysis of an immobilized antigen-antibody complex and mass spectrometric peptide mapping.", Proceedings of the National Academy of Sciences, 87.24, (1990), 9848-9852).

[0260] Thus, in one embodiment, contact residues of an epitope are identified using an unrelated amino acid scan (e.g., an alanine scan). In another embodiment, an unrelated amino acid scan (e.g., an alanine scan) is performed using a technique selected from the group consisting of SPR, HTRF, ELISA, X-ray crystallography, cryo-electron microscopy, and a combination of restricted proteolytic digestion and mass spectrometry. In one embodiment, an unrelated amino acid scan (e.g., an alanine scan) is performed using HTRF. In one embodiment, an unrelated amino acid scan (e.g., an alanine scan) is performed using ELISA.

[0261] When alanine scanning is performed with ELISA or HTRF, if the signal is reduced to at least 25%, then the amino acid residue is identified as contributing to the epitope. In one embodiment, the signal is reduced to at least 30%. In one embodiment, the signal is reduced to at least 35%. In one embodiment, the signal is reduced to at least 40%. In one embodiment, the signal is reduced to at least 45%. In one embodiment, the signal is reduced to at least 50%. In one embodiment, the signal is reduced to at least 55%. In one embodiment, the signal is reduced to at least 60%. In one embodiment, the signal is reduced to at least 70%. In one embodiment, the signal is reduced to at least 75%. In one embodiment, the signal is reduced to at least 80%. In one embodiment, the signal is reduced to at least 85%. In one embodiment, the signal is reduced to at least 90%.

[0262] When alanine scanning is performed with SPR, an amino acid residue is identified as contributing to an epitope if the affinity is reduced by at least 10 times. In one embodiment, the affinity is reduced by at least 15 times. In one embodiment, the affinity is reduced by at least 20 times. In one embodiment, the affinity is reduced by at least 30 times. In one embodiment, the affinity is reduced by at least 40 times. In one embodiment, the affinity is reduced by at least 50 times. In one embodiment, the affinity is reduced by at least 100 times.

[0263] In one embodiment, the contact residues of the epitope are identified by X-ray crystallography. In one embodiment, the contact residues of the epitope are identified by cryo-electron microscopy. In one embodiment, the contact residues of the epitope are identified by a combination of restricted proteolytic digestion and mass spectrometry.

[0264] 27. An antibody or fragment according to clause 26, wherein the contact residues of the epitope are defined by at least a 10-fold reduction in affinity as determined by SPR in an unrelated amino acid scan, such as an alanine scan.

[0265] In one embodiment, the affinity is reduced by at least 15 times. In one embodiment, the affinity is reduced by at least 20 times. In one embodiment, the affinity is reduced by at least 30 times. In one embodiment, the affinity is reduced by at least 40 times. In one embodiment, the affinity is reduced by at least 50 times. In one embodiment, the affinity is reduced by at least 100 times.

[0266] SPR can be performed as described herein.

[0267] 28. An antibody or fragment (optionally according to any of the preceding clauses) that competes with the antibody according to any of the preceding clauses for binding to human PCSK9.

[0268] Optionally, competition is determined by surface plasmon resonance (SPR) or ELISA. For example, those skilled in the art will be familiar with such techniques and standard conditions.

[0269] In one embodiment, the antibody or fragment competes with hPCSK9 (or its fusion protein) for binding to hPCSK9 expressed on the cell surface (e.g., in a dose-dependent manner). In one embodiment, the antibody or fragment competes with hPCSK9 (or its fusion protein) for binding to soluble hPCSK9 (e.g., in a dose-dependent manner).

[0270] Optionally, competition for binding to hPCSK9 is performed using SPR.SPR may be performed as described herein.

[0271] 29. An antibody or fragment according to any of the preceding clauses, which specifically binds to: human PCSK9, any one of SEQ ID NOs: 189-192; and / or cynomolgus monkey PCSK9, including SEQ ID NO: 193; and / or mouse PCSK9, including SEQ ID NO: 194.

[0272] Optionally, the antibody or fragment of the present invention specifically binds to the amino acid sequence of SEQ ID NO: 189. Optionally, the antibody or fragment of the present invention specifically binds to the amino acid sequence of SEQ ID NO: 193. Optionally, the antibody or fragment of the present invention specifically binds to the amino acid sequence of SEQ ID NO: 194.

[0273] In one example, the PCSK9 herein is human, mouse or cynomolgus monkey PCSK9.

[0274] In one embodiment, the antibody or fragment binds to cynomolgus monkey PCSK9 with an affinity of less than 1 nM (e.g., 1 nM to 0.01 pM, or 1 nM to 0.1 pM, or 1 nM to 1 pM). In one embodiment, the antibody or fragment binds to cynomolgus monkey PCSK9 with an affinity of less than 10 nM (e.g., 10 nM to 0.01 pM, or 10 nM to 0.1 pM, or 10 nM to 1 pM). In one embodiment, the antibody or fragment binds to cynomolgus monkey PCSK9 with an affinity of less than 0.1 nM (e.g., 0.1 nM to 0.01 pM, or 0.1 nM to 0.1 pM, or 0.1 nM to 1 pM). In one embodiment, the antibody or fragment binds to cynomolgus monkey PCSK9 with an affinity of less than 0.01 nM (e.g., 0.011 nM to 0.01 pM, or 0.01 nM to 0.1 pM).

[0275] In one embodiment, the antibody or fragment binds to cynomolgus monkey PCSK9 with an affinity within 2 times of the affinity for hPCSK9. In one embodiment, the antibody or fragment binds to cynomolgus monkey PCSK9 with an affinity within 4 times of the affinity for hPCSK9. In one embodiment, the antibody or fragment binds to cynomolgus monkey PCSK9 with an affinity within 5 times of the affinity for hPCSK9. In one embodiment, the antibody or fragment binds to cynomolgus monkey PCSK9 with an affinity within 6 times of the affinity for hPCSK9. In one embodiment, the antibody or fragment binds to cynomolgus monkey PCSK9 with an affinity within 8 times of the affinity for hPCSK9. In one embodiment, the antibody or fragment binds to cynomolgus monkey PCSK9 with an affinity within 10 times of the affinity for hPCSK9.

[0276] "hPCSK9" herein is human PCSK9, such as human PCSK9 disclosed herein, such as including SEQ ID NO:562.

[0277] In one embodiment, the antibody or fragment does not detectably bind to cynomolgus monkey PCSK9. In one embodiment, the antibody or fragment does not detectably bind to murine (e.g., mouse and / or rat) PCSK9.

[0278] In one embodiment, the antibody or fragment binds to murine (e.g., mouse and / or rat) PCSK9 with an affinity of less than 1 nM (e.g., 1 nM to 0.01 pM, or 1 nM to 0.1 pM, or 1 nM to 1 pM). In one embodiment, the antibody or fragment binds to murine PCSK9 with an affinity of less than 10 nM (e.g., 10 nM to 0.01 pM, or 10 nM to 0.1 pM, or 10 nM to 1 pM). In one embodiment, the antibody or fragment binds to murine PCSK9 with an affinity of less than 0.1 nM (e.g., 0.1 nM to 0.01 pM, or 0.1 nM to 0.1 pM, or 0.1 nM to 1 pM). In one embodiment, the antibody or fragment binds to murine PCSK9 with an affinity of less than 0.01 nM (e.g., 0.011 nM to 0.01 pM, or 0.01 nM to 0.1 pM).

[0279] Optionally, the antibody or fragment includes a constant region with effector function or an effector-disabled constant region, such as a human constant region, such as a human constant region lacking an effector, such as an IgG4 constant region or an IgG1 constant region, optionally wherein the constant region is IgG4-PE or a disabled IgG1. Optionally, the antibody or fragment includes a murine (e.g., mouse and / or rat) constant region. Optionally, the antibody or fragment includes any one of the heavy chain constant region sequences described herein.

[0280] Optionally, the constant region has CDC and / or ADCC activity.

[0281] 30. The antibody or fragment according to any one of the preceding clauses, wherein the antibody or fragment comprises a human constant region, such as an IgG4 constant region or an IgG1 constant region.

[0282] For example, the constant region includes the heavy chain constant region disclosed herein.

[0283] In one example (optionally in addition to a heavy chain region according to the above paragraph), the constant region comprises a light chain constant region comprising a light chain constant region amino acid sequence disclosed herein.

[0284] 31. The antibody or fragment of clause 30, wherein the constant region is an IgG4-PE constant region.

[0285] An anti-PCSK9 antibody or fragment according to the invention may comprise a constant region, such as a human constant region, such as a human constant region lacking an effector, such as an IgG4 constant region or an IgG1 constant region, optionally wherein the constant region is IgG4-PE or a disabled IgG1 as defined in the sequence listing herein.

[0286] In other embodiments, the antibody or fragment is any of the isotypes or constant regions as defined herein. In one embodiment, the constant region is a wild-type human IgG1. For example, the constant region is an IgG1 constant region with effector function, optionally with ADCC and / or CDC activity. In one embodiment, the constant region is engineered to enhance ADCC and / or CDC and / or ADCP. In another embodiment, the constant region is engineered to enhance effector function.

[0287] The IgG4 constant region may be any one of the IgG4 constant region amino acid sequences, or may be encoded by any one of the nucleic acid sequences of the sequence table herein. The heavy chain constant region may be an IgG4 comprising both a Leu235Glu mutation and a Ser228Pro mutation. This "IgG4-PE" heavy chain constant region (see, e.g., sequence table) is effector-deficient.

[0288] The human constant region of the alternatively deleted effector is a disabled IgG1, which is an IgG1*01 allele (e.g., LAGA, see sequence listing) comprising L235A and / or G237A mutations. In one embodiment, the antibodies or antibody fragments disclosed herein include an IgG1 heavy chain constant region, wherein the sequence contains alanine at position 235 and / or 237 (EU index numbering).

[0289] The performance of Fc-mediated effects can be enhanced by engineering the Fc domain in any of the techniques as will be apparent to the skilled artisan. In another embodiment, the antibodies and fragments disclosed herein may include a triple mutation (M252Y / S254T / T256E) that enhances binding to FcRn.

[0290] 32. The antibody or fragment (eg, bispecific antibody) of any preceding clause, further comprising an antigen binding site that specifically binds another target antigen (eg, ANGPTL3, eg, human ANGPTL3).

[0291] In one example, the other binding site is an agonist binding site for the other antigen. In one example, the other binding site is an antagonist binding site for the other antigen.

[0292] In one example, the other binding site is an antibody binding site comprising VH and VL; a binding site comprised by an antibody constant domain (e.g., an Fcab binding site) or a non-immunoglobulin binding site (e.g., a fibronectin domain). Optionally, the antigen binding site is any antigen binding site disclosed herein.

[0293] For example, the antibody or fragment is a bispecific antibody or fragment. For example, the antibody or fragment is a dual binding antibody or fragment, or comprises an antibody or fragment thereof as defined in any of the preceding clauses. Dual binding antibody has the meaning as set out above.

[0294] In one embodiment, the antibody or fragment comprises a bispecific format selected from the group consisting of DVD-Ig, mAb 2 , FIT-Ig, mAb-dAb, lock-key structure, SEED body, sc diabody-Fc, diabody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intrabody, BiTE, diabody, DART, TandAb, sc diabody, sc diabody-CH3, diabody-CH3, minibody, knob-hole, knob-hole with common light chain, knob-hole with common light chain and charge pair, charge pair, charge pair and common light chain, specifically mAb 2 , knob-hole, knob-hole with common light chain, knob-hole with common light chain and charge pair, and FIT-Ig, such as mAb 2 and FIT-Ig.

[0295] In one embodiment, the bispecific format is selected from the group consisting of: DVD-Ig, mAb 2 , FIT-Ig, mAb-dAb, lock-key structure, Fab-arm exchange, SEED body, trifunctional mAb, LUZ-Y, Fcab, κλ-body, orthogonal Fab, sc bifunctional antibody-Fc, bifunctional antibody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intracellular antibody, BiTE, bifunctional antibody, DART, TandAb, sc bifunctional antibody, sc bifunctional antibody-CH3, bifunctional antibody-CH3, triple body, miniantibody, miniantibody, TriBi miniantibody, scFv-CH3 KIH, scFv-CH-CL-scFv, F(ab')2-scFv, scFv-KIH, Fab-scFv-Fc, tetravalent HCab, ImmTAC, knob-hole, knob-hole with common light chain, knob-hole with common light chain and charge pair, charge pair, charge pair and common light chain, DT-IgG, DutaMab, IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig and zybody.

[0296] In one embodiment, the bispecific format is selected from the following: DVD-Ig, FIT-Ig, mAb-dAb, lock-key structure, Fab-arm exchange, SEED body, trifunctional mAb, LUZ-Y, Fcab, κλ-body, orthogonal Fab, sc bifunctional antibody-Fc, bifunctional antibody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intracellular antibody, BiTE, bifunctional antibody, DART, TandAb, sc bifunctional antibody, sc bifunctional antibody-CH3, bifunctional antibody-CH3, triple body, miniantibody, miniantibody, TriBi miniantibody, scFv-CH3 KIH, scFv-CH-CL-scFv, F(ab')2-scFv, scFv-KIH, Fab-scFv-Fc, tetravalent HCab, ImmTAC, knob-hole, knob-hole with common light chain, knob-hole with common light chain and charge pair, charge pair, charge pair and common light chain, DT-IgG, DutaMab, IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, and zybodies, such as DVD-Ig, FIT-Ig, mAb-dAb, lock-key structures, SEED bodies, scdiabody-Fc, diabody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intrabody, BiTE, diabody, DART, TandAb, scdiabody, scdiabody-CH3, diabody-CH3, minibody, knob-hole, knob-hole with common light chain, knob-hole with common light chain and charge pair, charge pair, charge pair and common light chain, specifically knob-hole, knob-hole with common light chain, knob-hole with common light chain and charge pair, and FIT-Ig, such as FIT-Ig.

[0297] In one embodiment, the bispecific format is selected from the group consisting of: DVD-Ig, mAb 2, mAb-dAb, lock-key structure, Fab-arm exchange, SEED body, trifunctional mAb, LUZ-Y, Fcab, κλ-body, orthogonal Fab, sc bifunctional antibody-Fc, bifunctional antibody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intracellular antibody, BiTE, bifunctional antibody, DART, TandAb, sc bifunctional antibody, sc bifunctional antibody-CH3, bifunctional antibody-CH3, triple body, miniantibody, miniantibody, TriBi miniantibody, scFv-CH3 KIH, scFv-CH-CL-scFv, F(ab')2-scFv, scFv-KIH, Fab-scFv-Fc, tetravalent HCab, ImmTAC, knob-hole, knob-hole with common light chain, knob-hole with common light chain and charge pair, charge pair, charge pair and common light chain, DT-IgG, DutaMab, IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig and zybodies, such as DVD-Ig, mAb 2 , mAb-dAb, lock-key structure, SEED body, sc diabody-Fc, diabody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intrabody, BiTE, diabody, DART, TandAb, sc diabody, sc diabody-CH3, diabody-CH3, minibody, knob-hole, knob-hole with common light chain, knob-hole with common light chain and charge pair, charge pair, charge pair and common light chain, specifically mAb 2 , a knob-and-hole, a knob-and-hole with a common light chain and a charge pair, and a knob-and-hole with a common light chain, such as mAb 2 .

[0298] In one embodiment, the bispecific format is selected from the following: DVD-Ig, mAb-dAb, lock-key structure, Fab-arm exchange, SEED body, trifunctional mAb, LUZ-Y, Fcab, κλ-body, orthogonal Fab, sc bifunctional antibody-Fc, bifunctional antibody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intracellular antibody, BiTE, bifunctional antibody, DART, TandAb, sc bifunctional antibody, sc bifunctional antibody-CH3, bifunctional antibody-CH3, triple body, miniantibody, miniantibody, TriBi miniantibody, scFv-CH3 KIH, scFv-CH-CL-scFv, F(ab')2-scFv, scFv-KIH, Fab-scFv-Fc, tetravalent HCab, ImmTAC, knob-hole, knob-hole with common light chain, knob-hole with common light chain and charge pair, charge pair, charge pair and common light chain, DT-IgG, DutaMab, IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, and zybodies, such as DVD-Ig, mAb-dAb, lock-key structures, SEED bodies, scdiabody-Fc, diabody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intrabody, BiTE, diabody, DART, TandAb, scdiabody, scdiabody-CH3, diabody-CH3, minibody, knob-hole, knob-hole with common light chain, knob-hole with common light chain and charge pair, charge pair, charge pair and common light chain, specifically knob-hole, knob-hole with common light chain and charge pair, and knob-hole with common light chain.

[0299] 33. An anti-PCSK9 antibody or fragment as defined in any preceding clause for use in treating or preventing a PCSK9-mediated disease or condition (eg, hyperlipidemia or hypercholesterolemia) in a subject.

[0300] In one example, the subject is a human. In an alternative example, the subject is a non-human animal. In one example, the subject is an adult. In one example, the subject is a pediatric human. In one example, the subject is a human CKD patient undergoing dialysis treatment. In one example, the subject is a human with end-stage renal disease.

[0301] In one example, the antibody or fragment herein is used to treat or prevent a disease or condition selected from the following: hypercholesterolemia, hyperlipidemia, hypercholesterolemia, dyslipidemia, cholestatic liver disease, nephrotic syndrome, hypothyroidism, obesity, diabetes, atherosclerosis or cardiovascular disease. In one example, the disease or condition is selected from lipid disorders, hyperlipoproteinemia, hyperlipidemia; dyslipidemia; hypercholesterolemia, heart attack, stroke, coronary heart disease, atherosclerosis, peripheral vascular disease, claudication, type II diabetes, hypertension and cardiovascular disease or condition. For example, the disease or condition is hyperlipidemia. For example, the disease or condition is hypercholesterolemia. For example, the disease or condition is diabetes. For example, the disease or condition is stroke. For example, the disease or condition is atherosclerosis. For example, the disease or condition is CNS disorder. For example, the disease or condition is a neurological disorder. For example, the disease or condition is depression.

[0302] In one example, the disease or condition is in a human. In one example, the disease or condition is in an animal.

[0303] In one example, the PCSK9-mediated disease or condition is a neurodegenerative disease, disorder or condition, such as selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, primary progressive multiple sclerosis, secondary progressive multiple sclerosis, corticobasal degeneration, Rett syndrome, a retinal degeneration disorder selected from age-related macular degeneration and retinitis pigmentosa; anterior ischemic neuropathy, glaucoma, uveitis, depression, trauma-related stress or post-traumatic stress disorder, frontotemporal dementia, Lewy body dementia, bodydementias), mild cognitive impairment, posterior cortical atrophy, primary progressive aphasia and progressive supranuclear palsy or senile dementia, in particular the neurodegenerative disease, disorder or condition is selected from Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease and Huntington's disease, such as Alzheimer's disease.

[0304] In one example, the antibody, fragment, combination of the invention is administered intravenously to a subject; or it is used for intravenous administration to a subject. In one example, the antibody, fragment, combination of the invention is administered subcutaneously to a subject; or it is used for subcutaneous administration to a subject.

[0305] 34. The antibody or fragment according to clause 33, wherein the antibody or fragment is administered to the subject simultaneously or sequentially with a statin.

[0306] 35. A combination of an amount of an anti-PCSK9 antibody or fragment and an amount of a statin (eg comprising multiple doses of said antibody and / or statin), wherein said antibody or fragment is according to any one of clauses 1 to 34.

[0307] Also provided is a medical kit comprising the combination, a first sterile container containing the amount of the antibody or fragment and a second sterile container containing the amount of the statin, and optionally instructions for using the combination to treat hyperlipidemia or hypercholesterolemia in an individual.

[0308] Also provided is a medical kit comprising the combination, a first sterile container containing the amount of the antibody or fragment and a second sterile container containing the amount of the ANGPTL3 inhibitor, and optionally instructions for using the combination to treat hyperlipidemia or hypercholesterolemia in a subject.

[0309] In one embodiment, the combination is used to treat or prevent hyperlipidemia or hypercholesterolemia in a subject, wherein a total dose of the antibody and a total dose of a statin are administered to the subject at a ratio of X:Y over a period of four consecutive weeks, wherein X is 10 to 2×10 6 and Y=4, for example, X is 10 to 2×10 6 micrograms and Y=4 micrograms.

[0310] 36. An antibody, fragment or combination according to the invention for use in a method of treating or preventing hypercholesterolemia in an individual who has previously been treated with a statin regimen at a first dose, wherein the method comprises reducing the dose of statin administered to the individual or not administering a statin to the individual, wherein the method comprises administering the antibody or fragment to the individual.

[0311] 37. The combination according to clause 35 or 36, wherein it comprises a statin in a daily dose of 10 to 20 mg (e.g. 10 mg); or <60 mg (e.g. 40 mg).

[0312] 38. An antibody, fragment or combination according to any of the preceding clauses for administration to a human or animal subject suffering from elevated cholesterol for reducing plasma low-density lipoprotein cholesterol (LDL-C) levels in the subject after the subject has received the anti-PCSK9 antibody or fragment.

[0313] 39. Use of an antibody, fragment or combination as defined in any of the preceding clauses for the manufacture of a medicament for administration to a subject for the treatment or prevention of a PCSK9-mediated disease or condition, such as hyperlipidemia or hypercholesterolemia.

[0314] 40. A method for treating or preventing a PCSK9-mediated disease or condition (e.g., hyperlipidemia or hypercholesterolemia) in an individual, the method comprising administering to the individual a therapeutically effective amount of an antibody, fragment or combination as defined in any one of clauses 1 to 38, wherein the PCSK9-mediated disease or condition is thereby treated or prevented.

[0315] The disease or condition may be any of those disclosed herein.

[0316] 41. The use according to clause 39 or the method according to clause 40, wherein the PCSK9-mediated disease or condition is hyperlipidemia or hypercholesterolemia.

[0317] 42. The antibody, fragment, combination, use or method according to any one of clauses 33 to 41, further comprising administering to the individual an additional therapy, such as an additional therapeutic agent, optionally wherein the additional therapeutic agent is selected from the group consisting of:

[0318] a. Statins;

[0319] b. ANGPTL3 inhibitors (eg, anti-ANGPTL3 antibodies, such as envenomab)

[0320] c. Fibrate;

[0321] d. Bile acid sequestrants;

[0322] e. niacin; and

[0323] f. Niacin.

[0324] The present invention actually encompasses generic forms of brand name drugs, and the disclosures of such generic drugs are incorporated herein by reference for possible use in the present invention, e.g., as part of a combination.

[0325] 43. A pharmaceutical composition comprising an antibody, fragment or combination as defined in any one of clauses 1 to 38 and 42, and a pharmaceutically acceptable excipient, diluent or carrier and optionally in combination with an additional therapeutic agent selected from those mentioned above (e.g. in clause 42).

[0326] 44. A pharmaceutical composition according to clause 43 for use in the treatment and / or prevention of a PCSK9-mediated condition or disease, such as hyperlipidemia or hypercholesterolemia.

[0327] 45. A pharmaceutical composition according to clause 43 or 44, in combination with a label or instructions for use to treat and / or prevent said disease or condition in a human; optionally wherein said label or instructions comprises a marketing authorization number (e.g., an FDA or EMA authorization number); optionally wherein said kit comprises an IV or injection device containing said antibody or fragment.

[0328] 46. ​​A nucleic acid encoding the VH domain and / or VL domain of an antibody or fragment as defined in any one of clauses 1 to 32.

[0329] 47. A nucleic acid encoding a VH domain comprising the amino acid sequence of the VH domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0330] For example, the identity is at least 85%. For example, the identity is at least 90%. For example, the identity is at least 95%.

[0331] Optionally, a nucleic acid is provided that encodes a VH domain comprising the amino acid sequence of SEQ ID NO: 114, or an amino acid that is at least 70, 80, 85, 90, 95, 96, 97, 98, or 99% identical thereto. For example, the identity is at least 85%. For example, the identity is at least 90%. For example, the identity is at least 95%.

[0332] 48. A nucleic acid encoding a VL domain comprising the amino acid sequence of the VL domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0333] Optionally, the nucleic acid also encodes a VH domain that includes the amino acid sequence of the VH domain of the selected antibody; or amino acids that are at least 70, 80, 85, 90, 95, 96, 97, 98, or 99% identical thereto. For example, the identity is at least 85%. For example, the identity is at least 90%. For example, the identity is at least 95%.

[0334] 49. A nucleic acid (eg, in a host cell, such as a CHO or HEK293 or Cos cell) comprising a nucleotide sequence that is at least 70% identical to the sequence of SEQ ID NO: 2 or 66.

[0335] In this document, in any example where % identity is mentioned, in an instance there is 100% identity.

[0336] 50. A nucleic acid encoding the heavy and / or light chain of an antibody or fragment as defined in any one of clauses 1 to 32.

[0337] 51. A nucleic acid encoding a heavy chain comprising: a VH amino acid sequence at least 70% identical to SEQ ID NO: 22 or 66; and a C region amino acid sequence at least 70% identical to an IGHG4 sequence, optionally at least 70% identical to SEQ ID NO: 3 or 152.

[0338] 52. A nucleic acid encoding a light chain comprising: a VL amino acid sequence that is at least 70% identical to SEQ ID NO:93 or 95; and a C region amino acid sequence that is at least 70% identical to an IGKC sequence, optionally at least 70% identical to SEQ ID NO:156.

[0339] 53. A nucleic acid (e.g., in a host cell, such as a CHO or HEK293 or Cos cell) comprising

[0340] a. a nucleotide sequence that is at least 70% identical to the heavy chain sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); and / or

[0341] b. A nucleotide sequence that is at least 70% identical to the light chain sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT), respectively.

[0342] 54. A vector comprising a nucleic acid (eg, a nucleic acid according to any one of clauses 46 to 53); optionally wherein the vector is a CHO or HEK293 vector.

[0343] All nucleic acids of the invention herein are expressible in host cells, such as CHO or HEK293 or Cos cells, for example to express the variable domains or chains of the antibodies or fragments of the invention.

[0344] 55. A host cell comprising a nucleic acid (eg, a nucleic acid according to any one of clauses 46 to 53) or a vector according to clause 54.

[0345] In one example, the antibody or fragment comprises a HCDR3 of 9, 10, 11 or 12 residues in length, such as 10, such as 11. In one example, the antibody or fragment comprises a LCDR3 of 7, 8 or 9 residues in length, such as 8, such as 9. In one example, each VH domain of the antibody or fragment comprises 1-11 non-germline residues, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 non-germline residues. In one example, each VL domain of the antibody or fragment comprises 3-8 non-germline residues, such as 3, 4, 5, 6, 7 or 8 non-germline residues.

[0346] In one embodiment, the CDR sequences herein are determined according to Kabat. In an alternative embodiment, the CDR sequences are determined according to IMGT.

[0347] In one example, the selected antibody is CL- 148219. In one example, the selected antibody is CL-148489.

[0348] In one example, the selected antibody comprises the heavy chain of CL-148219 or CL-148489.

[0349] In one example, the heavy chain of the antibody or fragment of the present invention is human γ-1, γ-2, γ-3, γ-4, μ, δ, ε or α isotype, preferably γ isotype (e.g., IgG4 isotype). In one example, the light chain of the antibody or fragment of the present invention includes a human κ constant region. Alternatively, in one example, the light chain of the antibody or fragment of the present invention includes a human λ constant region.

[0350] Optionally, the antibody is a 4-chain antibody comprising a heavy chain dimer combined with a light chain dimer. In one example, the heavy chain includes one or more heavy chain CDRs or CDR combinations as disclosed herein, and / or the light chain includes one or more heavy chain CDRs or CDR combinations as disclosed herein, for example, from the same selected antibody. In one example, the heavy chain includes a VH domain as disclosed herein, and / or the light chain includes a VL as disclosed herein, for example, from the same selected antibody. In one example, the heavy chain and the light chain are from the same selected antibody, such as any antibody disclosed in the sequence table herein or in the table in the examples herein.

[0351] In one example, the selected antibody includes the light chain (and optionally the heavy chain) of CL-148219 or CL-148489.

[0352] In one example, the selected antibody includes the variable domain of CL-148219 or CL-148489.

[0353] In one example, the selected antibody comprises the VH domain of CL-148219 or CL-148489.

[0354] In one example, the selected antibody includes the VH and VL domains of CL-148219 or CL-148489.

[0355] Optionally, VH is encoded by a nucleotide sequence derived from the recombination of human IGHV4-59 (eg, IGHV4-59*01), D gene segment (eg, IGHD3-10, eg, IGHD3-10*01) and IGHJ6 (eg, IGHJ6*02) gene segments. Optionally, additionally or alternatively, VL is encoded by a nucleotide sequence derived from the recombination of human IGKV2-28 (eg, IGKV2-28*01) and IGKJ3 (eg, IGKJ3*01).

[0356] Optionally, VH is encoded by a nucleotide sequence derived from the recombination of human IGHV3-9 (eg, IGHV3-9*01), D gene segment (eg, IGHD3-9, eg, IGHD3-9*01) and IGHJ6 (eg, IGHJ6*02) gene segments. Optionally, additionally or alternatively, VL is encoded by a nucleotide sequence derived from the recombination of human IGKV2-29 (eg, IGKV2-29*01 or IGKV2D-29*01) and IGKJ4 (eg, IGKJ4*01).

[0357] In one example, the antibody or fragment comprises a HCDR3 of 9-12 residues in length, and / or the antibody or fragment comprises a LCDR3 of 7-9 residues in length. In one example, the antibody or fragment comprises a HCDR3 of 9, 10, 11 or 12 residues in length, such as 10, such as 11. In one example, the antibody or fragment comprises a LCDR3 of 7, 8 or 9 residues in length, such as 8, such as 9. In one example, each VH domain of the antibody or fragment comprises 1-11 non-germline residues, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 non-germline residues. In one example, each VL domain of the antibody or fragment comprises 3-8 non-germline residues, such as 3, 4, 5, 6, 7 or 8 non-germline residues.

[0358] Optionally, the antibody or fragment competes with CL-148219 (eg, CL-148219 in IgG format, eg, IgG4-PE) for binding to PCSK9 (eg, human PCSK9) as determined by SPR.

[0359] Optionally, the antibody or fragment competes with CL-148489 (eg, CL-148489 in IgG format, eg, IgG4-PE) for binding to PCSK9 (eg, human PCSK9) as determined by SPR.

[0360] Optionally, the amino acid substitution is a conservative amino acid substitution, optionally wherein each conservative substitution is from group (1) to (6):

[0361] 1) Alanine (A), serine (S), threonine (T);

[0362] 2) Aspartic acid (D), glutamic acid (E);

[0363] 3) Asparagine (N), glutamine (Q);

[0364] 4) Arginine (R), Lysine (K);

[0365] 5) isoleucine (I), leucine (L), methionine (M), valine (V); and

[0366] 6) Phenylalanine (F), tyrosine (Y), tryptophan (W).

[0367] Any SPR herein is, for example, surface plasmon resonance (SPR) at 37°C and pH 7.6.

[0368] Optionally, any PCSK9 herein is (eg, in an in vitro assay) human PCSK9.

[0369] In one embodiment, the antibody or fragment of the invention is expressed in an amount of, for example, 5×10 6 M -1 ×s -1 ; or about 5×10 6 M -1 ×s -1 In one embodiment, the antibody or fragment of the invention binds to human PCSK9 with a Ka of 4 or 5 s -1 ; or about 4 or 5s -1 In one example, the antibody or fragment of the invention binds to human PCSK9 with a KD of, for example, 0.07 or 0.14 nM; or about 0.07 or 0.14 nM. In one embodiment, the fragment is a Fab fragment. In one embodiment, the fragment is a scFv.

[0370] As used herein, "inhibits", "inhibition", "inhibiting" and the like as used herein, refer to the ability of an antagonist (e.g., an antibody or fragment thereof) to bind to an epitope (e.g., an epitope of hPCSK9) that partially or completely prevents binding of another antigen, completely prevents ligand binding if the epitope to which the antagonist binds completely blocks the binding site of the ligand (which may be a physical block in the case of overlapping epitopes, or a steric block in the case where the antagonist is large, such that it prevents binding of a ligand to a different epitope from it), and does not remove the ligand from circulation. Thus, the concentration of circulating ligand may appear to be increased. If the epitope to which the antagonist binds partially blocks the binding site of the ligand, the ligand may be able to bind, but only weakly (in the case of partial inhibition), or block the native binding interaction in a different orientation. In this case, some ligand may be removed from circulation, but not as much as when the ligand binding site is completely free and available for binding. Thus, inhibition refers to the physical interaction of the ligand with the receptor. Inhibition can be measured by HTRF as described in more detail elsewhere herein and in Mathis (1995) Clinical Chemistry 41(9), 1391-1397. Inhibition can also be measured by flow cytometry (in the case where the receptor is expressed on cells) or by ELISA (in the case where the receptor is adsorbed to a culture dish).

[0371] Optionally, an antibody of the invention has an affinity (KD) for binding to PCSK9 of 1 pM to 5 nM, optionally wherein binding is determined by SPR using a Fab of said antibody at 37°C, pH 7.6.

[0372] Optionally, the antibody against PCSK9 has a 1×10 -5 to 1×10 -3 S -1 The dissociation rate (K off ), optionally wherein binding is determined by SPR using a Fab of said antibody at 37° C., pH 7.6.

[0373] Optionally, the antibody against PCSK9 has a 1×10 5 to 1×10 7 M -1 S -1 The binding rate (K on ), optionally wherein binding is determined by SPR using a Fab of said antibody at 37°C, pH 7.6.

[0374] In one example, the antibody (e.g., such as a Fab) or fragment has the following affinity (KD) for binding to PCSK9 (e.g., human PCSK9):

[0375] (a) 2, 3, 4, 5 or 10 pM to 3, 4 or 5 nM;

[0376] (b) 1-10 pM to 5 nM;

[0377] (c) 10 pM to 3, 4 or 5 nM;

[0378] (d) 50 or 80 pM to 200 nM;

[0379] (e) 50 or 80 pM to 150 nM; or

[0380] (f) 50 or 80 pM to 100 nM.

[0381] In one example, the KD is (or is about) 5-15 pM (e.g., 10 pM). In one example, the KD is (or is about) 2-5 nM (e.g., 3 nM). In one example, the KD is (or is about) 100-400 pM (e.g., 140 or 390 pM).

[0382] In one example, the antibody (eg, such as a Fab) or fragment has a dissociation rate (K) of off ):

[0383] (a)1×10 -5 to 5×10 -4 S -1 ;

[0384] (b)1×10 -5 to 6×10 -4 S -1 ;

[0385] (c)1×10 -5 to 7×10 -4 S -1 ;

[0386] (d)1×10 -5 to 8×10 -4 S -1 ;

[0387] (e)2×10 -5 to 1×10 -3 S -1 ;

[0388] (f)2×10 -5 to 5×10 -4 S -1 ;

[0389] (g)2×10 -5 to 6×10 -4 S -1 ;

[0390] (h)2×10 -5 to 7×10 -4 S -1 ;or

[0391] (i)2×10 -5 to 8×10 -4 S -1 .

[0392] In one example, K off is (or is approximately) 5×10 -4 S -1 (For example, when KD is (or is about) 2nM to 400pM; when KD is (or is about) 2-5nM (for example, 3nM); or when KD is (or is about) 100-400pM (for example, 140 or 390pM). In one example, K off is (or about) 3×10 -5 S -1 (For example, when KD is (or is about) 5-15 pM (eg, 10 pM)).

[0393] In one example, the antibody (eg, Fab) or fragment has an association rate (K) of on ):

[0394] (a)1×10 5 to 1×10 6 M -1 S -1 ;

[0395] (b)1×10 5 to 2×10 6 M -1 S -1 ;

[0396] (c)1×10 5 to 3×10 6 M -1 S -1 ;

[0397] (d)1×10 5 to 4×10 6 M -1 S -1 ;

[0398] (e)1×10 5 to 5×106 M -1 S -1 ;

[0399] (f)2×10 5 to 5×10 6 M -1 S -1 ;

[0400] (g)3×10 5 to 5×10 6 M -1 S -1 ;

[0401] (h)4×10 5 to 5×10 6 M -1 S -1 ;

[0402] (i)5×10 5 to 5×10 6 M -1 S -1 ;or

[0403] (j)6×10 5 to 5×10 6 M -1 S -1 .

[0404] In one example, K on is (or is approximately) 1 or 2×10 -5 M -1 S -1 (For example, when KD is 2-5nM (for example, 3nM)). In one example, K on is (or is about) 1-4, 1, 2, 3 or 4×10 -6 M -1 S -1 (For example, when KD is (or is about) 5-400 pM (eg, 140 or 390 pM) or 5-15 pM (eg, 10 pM)).

[0405] As provided in the clauses or other aspects herein, the anti-PCSK9 antibody or fragment may have a K of less than 50 nM, less than 40 nM, less than 30 nM. D Binds to PCSK9, such as human PCSK9, as determined by surface plasmon resonance. In another embodiment, the anti-PCSK9 antibody or fragment may have a K of less than 20 nM, less than 15 nM, less than 10 nM, or less than 10 nM. DBinds to PCSK9, e.g., human PCSK9, as determined by surface plasmon resonance. The anti-PCSK9 antibody or fragment may have a K of less than 8 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, or less than 1 nM. D Binding to PCSK9, e.g., human PCSK9 (as determined by surface plasmon resonance). D It may be 0.9 nM or less, 0.8 nM or less, 0.7 nM or less, 0.6 nM or less, 0.5 nM or less, 0.4 nM or less, 0.3 nM or less, 0.2 nM or less, or 0.1 nM or less.

[0406] In another embodiment, K D In the range of 0.01 to 1 nM, or in the range of 0.05 to 2 nm, or in the range of 0.05 to 1 nM. K D It may be with respect to hPCSK9, cynomolgus monkey (ie, "cyno") PCSK9, and / or mouse PCSK9.

[0407] In another embodiment, the anti-PCSK9 antibodies described herein have a K of about 0.5 to 10 μM, such as about 1 to 8 μM or about 1 to 7 μM. ON In another embodiment, K ON The rate is about 1 to 5 μM, such as about 1 μM, about 1.5 μM, about 2 μM, about 2.5 μM, or about 3 μM. In another embodiment, K ON The rate is approximately 3.5 μM, approximately 4 μM, approximately 4.5 μM, approximately 5 μM, or approximately 5.5 μM.

[0408] In another embodiment, the anti-PCSK9 antibodies described herein have a K of about 0.01 to 100 mM, such as about 0.1 to 50 mM or about 0.5 to 50 mM. OFF In another embodiment, K OFF The rate is about 0.5 to 10 mM or about 0.5 to 10 mM, such as about 1 mM, about 2 mM, about 3 mM, about 4 mM, or about 5 mM. In another embodiment, K OFF The rate is approximately 0.6 mM, approximately 0.7 mM, approximately 0.8 mM, or approximately 0.9 mM.

[0409] Optionally, an antibody of the invention comprises a human IgG4 constant region.

[0410] Preferably, an antibody or fragment thereof that specifically binds to hPCSK9 does not cross-react with other antigens (but may optionally cross-react with different PCSK9 species (e.g., rhesus monkey, cynomolgus monkey, or mouse)). An antibody or fragment thereof that specifically binds to the PCSK9 antigen can be detected, for example, by immunoassay, BIAcore TM Or other techniques known to those skilled in the art. When the antibody or its fragment binds to the hPCSK9 antigen with a higher affinity than to any cross-reactive antigen, as determined using experimental techniques such as radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA), the antibody or its fragment specifically binds to the hPCSK9 antigen. Typically, the specific or selective reaction will be at least twice the background signal or noise, and more typically greater than 10 times the background. For a discussion of antibody specificity, see, for example, Paul, ed., 1989, Fundamental Immunology Second Edition, Raven Press, New York, pp. 332-336.

[0411] The contact amino acid residues involved in the interaction of an antibody with an antigen (eg, PCSK9) can be determined by various methods known to those skilled in the art.

[0412] In one embodiment, if the antibody recognizes a linear epitope, short peptides based on the antigen sequence can be generated and binding of the antibody to such peptides can be assessed using standard techniques.

[0413] In one embodiment, restricted proteolytic digestion and mass spectrometry can be used to identify binding epitopes.

[0414] In one embodiment, the contact residues of the epitope are identified by X-ray crystallography. In one embodiment, the contact residues of the epitope are identified by cryo-electron microscopy. In one embodiment, the contact residues of the epitope are identified by a combination of restricted proteolytic digestion and mass spectrometry.

[0415] In another embodiment, the anti-PCSK9 antibodies (and fragments) described herein provide improved transient expression levels relative to other anti-PCSK9 antibodies and fragments. Thus, in one embodiment, the anti-PCSK9 antibody (or fragment) is expressed in HEK293 cells, such as HEK293T cells, at an expression level of approximately 100 μg / mL or in the range of approximately 100 to 350 μg / mL. In another embodiment, the expression level is greater than approximately 350 μg / mL.

[0416] In another embodiment, the anti-PCSK9 antibody (or fragment) is expressed in CHO cells, such as Expi-CHO cells, at an expression level of about 100 μg / mL or in the range of about 100 to 350 μg / mL. In another embodiment, the expression level is greater than about 350 μg / mL.

[0417] In another embodiment, the anti-PCSK9 antibody (or fragment) is expressed in CHO cells, such as Expi-CHO cells or CHO-E7 EBNA cells, at an expression level of approximately 100 μg / mL or in the range of approximately 100 to 350 μg / mL. In another embodiment, the expression level is greater than approximately 350 μg / mL. The antibody, for example, comprises the VH and VL domains of any of CL-58838 formatted as human IgG1 or human IgG4 (e.g., IgG4-PE).

[0418] In any of these expression systems, expression is performed at a scale of approximately between 0.5 mL and 3 mL, for example, approximately between 0.5 mL and 2 mL. In any of these expression systems, the anti-PCSK9 antibody (or fragment) can be expressed from a pTT5 vector. In any of these expression systems, the anti-PCSK9 antibody (or fragment) can be expressed in conjunction with a lipid transfection reagent and can optionally be expressed in CHO cells, such as Expi-CHO cells. In any of these expression systems, the anti-PCSK9 antibody (or fragment) can be expressed in conjunction with a PEI transfection reagent and can optionally be expressed in CHO cells, such as CHO-E7 EBNA cells. In any of these expression systems, the anti-PCSK9 antibody (or fragment) can be expressed in conjunction with a helper plasmid (e.g., an AKT helper plasmid) and can optionally be expressed in CHO cells, such as CHO-E7 EBNA cells.

[0419] In any of these expression systems, the expression level is between approximately 100 μg / mL and approximately 1500 μg / mL, for example, between approximately 100 μg / mL and approximately 1000 μg / mL, or between approximately 200 μg / mL and approximately 1000 μg / mL, or between approximately 350 μg / mL and approximately 1000 μg / mL. In any of these expression systems, the lower limit of expression may be approximately 100 μg / mL, approximately 200 μg / mL, approximately 300 μg / mL, or approximately 400 μg / mL. In another embodiment, the lower limit of expression may be approximately 500 μg / mL, approximately 600 μg / mL, approximately 700 μg / mL, or approximately 800 μg / mL. In any of these expression systems, the upper limit of expression may be approximately 2000 μg / mL, approximately 1800 μg / mL, approximately 1600 μg / mL, or approximately 1500 μg / mL. In another embodiment, the upper limit of expression may be approximately 1250 μg / mL, approximately 1000 μg / mL, approximately 900 μg / mL, or approximately 800 μg / mL.

[0420] In another embodiment, the expression system is a Lonza expression system, such as the Lonza System. In the Lonza expression system, expression can be performed on a scale of approximately 30 mL to 2 L, such as 50 mL to 1 L or 1 L to 2 L. In the Lonza expression system, the anti-PCSK9 antibody (or fragment) can be expressed in combination with electroporation, and optionally without any auxiliary plasmids. In the Lonza expression system, the anti-PCSK9 antibody (or fragment) can be expressed at a level of approximately 1 g / L, or approximately 900 mg / L, or approximately 800 mg / L, or approximately 700 mg / L. In another embodiment, in the Lonza expression system, the anti-PCSK9 antibody (or fragment) can be expressed at a level of approximately 600 mg / L, or approximately 500 mg / L, or approximately 400 mg / L. In the Lonza expression system, the anti-PCSK9 antibody (or fragment) can be expressed at a level between approximately 400 mg / L and approximately 2 g / L, such as between approximately 500 mg / L and approximately 1.5 g / L, or between approximately 500 mg / L and approximately 1 g / L. In another embodiment, the expression level is above 1 g / L. In another embodiment, the anti-PCSK9 antibody provides improved half-life relative to other anti-PCSK9 antibodies.

[0421] In one embodiment, the antibody or fragment is a human antibody or fragment. In one embodiment, the antibody or fragment is a fully human antibody or fragment. In one embodiment, the antibody or fragment is a fully human monoclonal antibody or fragment.

[0422] In one embodiment, the antibody or fragment is a humanized antibody or fragment. In one embodiment, the antibody or fragment is a humanized monoclonal antibody or fragment.

[0423] Contact amino acid residues involved in antibody and antigen interactions can be determined by various methods known to those skilled in the art, such as alanine scanning, protein crystallography, mass spectrometry, or any other technique as will be apparent to the skilled person.

[0424] In one embodiment, the described CDR includes one amino acid substitution, which may be a conservative amino acid substitution. In one embodiment, the described CDR includes two amino acid substitutions, which may be conservative amino acid substitutions. In one embodiment, the described CDR includes three amino acid substitutions, which may be conservative amino acid substitutions. In one embodiment, the described CDR includes four amino acid substitutions, which may be conservative amino acid substitutions. In one embodiment, the described CDR includes five amino acid substitutions, which may be conservative amino acid substitutions. In one embodiment, the described CDR includes six amino acid substitutions, which may be conservative amino acid substitutions.

[0425] Amino acid substitutions include changes in the replacement of an amino acid with a different naturally occurring amino acid residue. Such substitutions may be classified as "conservative" when other naturally occurring amino acids with similar characteristics related to polarity, side chain functionality, or size are substituted for an amino acid residue contained in a polypeptide. Such conservative substitutions are well known in the art. Substitutions encompassed by the present invention may also be "non-conservative" when an amino acid residue present in a peptide is substituted with an amino acid having different properties (e.g., a naturally occurring amino acid from a different group) (e.g., a charged or hydrophobic amino acid is substituted with alanine), or alternatively when a naturally occurring amino acid is substituted with an unconventional amino acid.

[0426] In one embodiment, conservative amino acid substitutions are as described herein. For example, the substitution may be F for Y, S or K for T, A for P, D or Q for E, D or G for N, K for R, N or A for G, S or K for T, N or E for D, L or V for I, Y for F, T or A for S, K for R, N or A for G, R for K, S, K or P for A. In another embodiment, conservative amino acid substitutions may be as follows: wherein F replaces Y, A or S replaces T, L or V replaces I, Y replaces W, L replaces M, D replaces N, A replaces G, A or S replaces T, N replaces D, L or V replaces I, Y or L replaces F, A or T replaces S, and S, G, T or V replaces A.

[0427] In one embodiment, the present invention provides a pharmaceutical composition comprising an anti-PCSK9 antagonist of the present invention (e.g., an antibody or a PCSK9 binding fragment thereof) and an acceptable carrier, diluent, or excipient. More specifically, the composition of the present invention further comprises one or more additional therapeutic agents, such as a statin. As referred to herein, a "statin" (also known as an HMG-CoA reductase inhibitor) is an inhibitor of the enzyme HMG-coA reductase, which mediates cholesterol production in the liver. By competitively binding to HMG-CoA reductase, statins prevent HMG-CoA from binding to the enzyme and thereby inhibit the activity of the reductase (e.g., the production of mevalonate). Non-limiting examples of statins may include atorvastatin (LIPITOR TM ), fluvastatin (LESCOL TM ), lovastatin (MEVACOR TM 、ALTOCOR TM ), pitavastatin (LIVALO TM ), pravastatin (PRAVACHOL TM ), rosuvastatin (CRESTOR TM ) and simvastatin (ZOCOR TM Statins can be administered in combination with other agents, such as a combination of ezetimibe and simvastatin.

[0428] In one embodiment, the anti-PCSK9 antagonist, antibody or fragment is present in an amount of less than about 1×10 -8 M, preferably less than about 1×10 -9 M binds to PCSK9 with a KD as determined by common methods known in the art, such as by using a surface plasmon resonance (SPR) biosensor at 37°C.

[0429] "Effective amount" means the amount of an antagonist (e.g., antibody) of the invention or a pharmaceutical composition of the invention that will elicit the biological or medical response or desired therapeutic effect in an individual, mammal or human being that a researcher, physician or other clinician is seeking. The effective amount may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody and / or statin to elicit the desired response in the individual. An effective amount is also an amount in which the beneficial effects of the treatment outweigh any toxic or adverse effects.

[0430] The anti-PCSK9 antagonist antibodies or antigen-binding fragments thereof, combinations thereof or pharmaceutical compositions of the present invention may be administered parenterally (e.g., subcutaneously, intravenously, intraperitoneally, intramuscularly or transdermally). It may be administered to an individual in a single or multiple dose, alone or in combination with a pharmaceutically acceptable carrier and / or diluent. The pharmaceutical compositions, combinations or antagonists of the present invention may be prepared by methods well known in the art (e.g., Remington: The Science and Practice of Pharmacy, 19th edition (1995), A. Gennaro et al., Mack Publishing Co.), and may include one or more pharmaceutically acceptable carriers, diluents or excipients or in combination therewith.

[0431] In one embodiment, the subject is a human male, such as an adult or an infant. In one embodiment, the subject is a human female, such as an adult or an infant, such as a non-pregnant female or a pregnant female. In one example, the human is a dialysis patient. The infant may be a human >1 month old. In one example, the subject is an adult with established cardiovascular disease or with primary hyperlipidemia (e.g., heterozygous familial hypercholesterolemia [HeFH]). In one example, the subject is a human, such as an adult, with HoFH.

[0432] The subject may be a subject who has been previously diagnosed with or identified as suffering from or having a condition in need of treatment or one or more complications associated with such a condition, and optionally the subject has been treated for the condition or one or more complications associated with the condition. Alternatively, the subject may also be a subject who has not been previously diagnosed as having a condition or one or more complications associated with the condition. For example, the subject may be a subject who exhibits one or more risk factors for a condition or one or more complications associated with the condition, or a subject who does not exhibit risk factors.

[0433] The present invention may include simultaneous or sequential administration of an anti-PCSK9 antagonist and a statin. In one example, the antagonist and statin are administered no more than 1 month, 4 weeks, 3 weeks, 2 weeks, 1 week, 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day apart. As exemplified herein, administration of an antagonist and a statin may be effective if no more than 7 days (e.g., no more than one day) apart. In one example, an anti-PCSK9 antagonist and a statin are administered to an individual no more than 10, 14, 21, or 28 days apart.

[0434] In one example, the statin is administered 2, 3, or 4 times per week. In another example, the statin is administered 1, 2, 3, or 4 times per month or over an 8-week period.

[0435] In one example, the statin and / or antibody or fragment is administered intravenously or subcutaneously to a subject.

[0436] In one example, the hyperlipidemia or hypercholesterolemia is in an individual who is receiving or has received statin therapy, such as a patient who is low-responder or non-responder to statin therapy.

[0437] In one embodiment, the present invention provides a use of an anti-PCSK9 antagonist and a statin for use in the manufacture of a medicament. In another embodiment, the present invention provides a use of an anti-PCSK9 antagonist and a statin for use in the manufacture of a medicament for treating or preventing, for example, hyperlipidemia or hypercholesterolemia, such as moderate to severe hyperlipidemia or hypercholesterolemia, in an individual who has a low or no response to statin therapy.

[0438] In one example, the anti-PCSK9 antibody of the invention is an antibody that competes with a reference antibody in an HTRF assay. For example, wherein in an HTRF assay, the antibody of the invention is a labeled antibody that is pre-incubated with human PCSK9 and then combined with an unlabeled reference antibody (according to Section I or II), wherein competition between the antibodies is detected by the assay. In one example, the assay uses a AlexaFluor TM In an alternative embodiment, human PCSK9 is labeled (e.g., with AlexaFluor TM 647 labeling, for binding to Eu3+ cryptate-streptavidin, the test antibody is labeled with biotin and the reference antibody is unlabeled). Example reference antibodies are preferably CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT). Alternatives are alirocumab or evolocumab.

[0439] Optionally, an anti-PCSK9 antibody of the invention (test antibody) competes with a reference antibody for binding to human PCSK9 (or binds to the same epitope of human PCSK9 as the reference antibody) in an HTRF assay, wherein the assay uses a directly or indirectly labeled test antibody labeled with a donor (e.g., Eu3+ cryptate) or an acceptor fluorophore (e.g., AlexaFluor TM 647) directly or indirectly labeled, and using a target PCSK9 labeled with a donor or acceptor fluorophore, so that energy transfer can be performed between the donor and the acceptor, thereby generating a fluorescent signal and detecting it. In one example, AlexaFluor TM647 labeling, competition is detected by a decrease in fluorescence signal at 665 nM of at least 20% when the test antibody is in the presence of the reference antibody relative to the signal without the reference antibody. Optionally, the signal at 665 nM is reduced by at least 20, 30, 40, 50, 60, 70, 80 or 90%.

[0440] In one example, the antibody or fragment is used to reduce the total dose administered to a human or animal subject over a 4 week period to treat or prevent hyperlipidemia or hypercholesterolemia or any other disease or condition disclosed herein.

[0441] In one example, the antibody or fragment is used to reduce to 1 / 2 to 1 / 3 the total dose required in a control subject who receives consistent treatment over a 4 week period except that a statin is administered to a human or animal subject without an anti-PCSK9 antagonist (e.g., antibody or fragment) to treat or prevent hyperlipidemia or hypercholesterolemia or any other disease or condition disclosed herein.

[0442] In one example, the antibody or fragment is used to reduce the dosage of a statin administered to a human or animal subject by 1 / 2 to 1 / 3 over a treatment period, such as a 4 week period, for the treatment or prevention of hyperlipidemia or hypercholesterolemia, osteoporosis or any other disease or condition disclosed herein.

[0443] Optionally, the antibody is an IgG4 antibody.

[0444] Optionally, the dose of statin administered to the individual is ineffective when administered in the absence of an anti-PCSK9 antagonist (eg, an antibody or fragment of the invention).

[0445] In one example, the individual herein is refractory to statin doses, but responds to treatment for hyperlipidemia or hypercholesterolemia or another disease or condition when administered an antibody or fragment of the invention with a statin dose.

[0446] Thus, in one example, an antibody or fragment of the invention is administered to a human or animal subject in combination with a statin dose for treating a PCSK9-associated disease or condition in the subject, wherein the subject is treated with the combination but is not treatable for the disease or condition by administering a statin dose in the absence of the antibody or fragment.

[0447] The disease or condition can be hyperlipidemia or hypercholesterolemia or any other disease or condition disclosed herein, for example selected from lipid disorders, hyperlipoproteinemia, hyperlipidemia; dyslipidemia; hypercholesterolemia, heart attack, stroke, coronary heart disease, atherosclerosis, peripheral vascular disease, claudication, type II diabetes, hypertension and cardiovascular diseases or conditions.

[0448] The present invention provides an antibody or fragment that specifically binds to PCSK9. Optionally, the antibody or fragment comprises a CDRH1 sequence as disclosed herein, or a sequence that is at least 70, 80, 85, 90, 95, 96, 97, 98, or 99% identical thereto. Optionally, the antibody or fragment comprises a CDRH2 sequence as disclosed herein, or a sequence that is at least 70, 80, 85, 90, 95, 96, 97, 98, or 99% identical thereto. Optionally, the antibody or fragment comprises a CDRH3 sequence as disclosed herein, or a sequence that is at least 70, 80, 85, 90, 95, 96, 97, 98, or 99% identical thereto. Optionally, the antibody or fragment comprises a CDRL1 sequence as disclosed herein, or a sequence that is at least 70, 80, 85, 90, 95, 96, 97, 98, or 99% identical thereto. Optionally, the antibody or fragment comprises a CDRL2 sequence as disclosed herein, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto. Optionally, the antibody or fragment comprises a CDRL3 sequence as disclosed herein, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0449] Optionally, the antibody or fragment comprises: a CDRH1 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; a CDRH2 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; and a CDRH3 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto. Optionally, the antibody or fragment comprises: the CDRL1 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; the CDRL2 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; and the CDRL3 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0450] Optionally, the antibody or fragment comprises: a CDRH1 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; a CDRH2 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; and a CDRH3 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto. Optionally, the antibody or fragment comprises: the CDRL1 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; the CDRL2 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; and the CDRL3 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0451] Optionally, the antibody or fragment comprises: a VH FR1 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; a VH FR2 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; a VH FR3 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; and a VH FR4 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto. Additionally or alternatively, optionally the antibody or fragment comprises: a VL FR1 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; a VL FR2 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; a VL FR3 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; and a VL FR4 sequence of CL-148219, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0452] Optionally, the antibody or fragment comprises: a VH FR1 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98, or 99% identical thereto; a VH FR2 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98, or 99% identical thereto; a VH FR3 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98, or 99% identical thereto; and a VH FR4 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98, or 99% identical thereto. Additionally or alternatively, optionally the antibody or fragment comprises: a VL FR1 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; a VL FR2 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; a VL FR3 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto; and a VL FR4 sequence of CL-148489, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0453] In one example, each CDR and FR1-4 herein is according to the IMGT nomenclature. In an alternative example, each CDR and FR1-4 herein is according to the Kabat nomenclature.

[0454] Optionally, the antibody or fragment comprises a human gamma-1 heavy chain constant region, such as a gamma-1 heavy chain constant region sequence disclosed herein, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto. For example, the C region comprises SEQ ID NO: 126, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0455] Optionally, the antibody or fragment includes a human gamma-2 heavy chain constant region, such as a gamma-2 heavy chain constant region sequence disclosed herein, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto. For example, the C region includes SEQ ID NO: 136, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0456] Optionally, the antibody or fragment comprises a human gamma-3 heavy chain constant region.

[0457] Optionally, the antibody or fragment includes a human gamma-4 heavy chain constant region, such as a gamma-4 heavy chain constant region sequence disclosed herein, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto. For example, the C region includes SEQ ID NO: 3, 144, 152 or 154, or a sequence at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto.

[0458] Optionally, the antibody or fragment includes a human kappa light chain constant region, such as a kappa light chain constant region sequence disclosed herein, or a sequence that is at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto. For example, the C region includes SEQ ID NO: 156, or a sequence that is at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto. In one embodiment, the antibody or fragment includes a human gamma-4 heavy chain constant region, such as an IgG4-PE constant region.

[0459] Optionally, the antibody or fragment includes a human lambda light chain constant region, such as a lambda light chain constant region sequence disclosed herein, or a sequence that is at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto. For example, the C region includes SEQ ID NO: 166, or a sequence that is at least 70, 80, 85, 90, 95, 96, 97, 98 or 99% identical thereto. In one embodiment, the antibody or fragment includes a human gamma-4 heavy chain constant region, such as an IgG4-PE constant region.

[0460] Target binding capacity, specificity and affinity (Kd, K off and / or K on ) can be determined by any conventional method in the art, such as by surface plasmon resonance (SPR). As used herein, the term "Kd" is intended to refer to the equilibrium dissociation constant for a particular antibody-antigen interaction.

[0461] In one embodiment, surface plasmon resonance (SPR) is performed at 25° C. In another embodiment, SPR is performed at 37° C.

[0462] In one embodiment, SPR is performed at physiological pH, such as about pH 7 or at pH 7.6 (eg, using Hepes buffered saline (also known as HBS-EP) at pH 7.6).

[0463] In one embodiment, SPR is performed at physiological salt levels, such as 150 mM NaCl.

[0464] In one embodiment, SPR is performed at a detergent level of no greater than 0.05% by volume, such as 0.05% P20 (polysorbate 20; e.g., Tween-20 TM ) and 3 mM EDTA.

[0465] In one example, SPR is performed at 25°C or 37°C in a buffer at pH 7.6, 150 mM NaCl, 0.05% detergent (e.g., P20), and 3 mM EDTA. The buffer may contain 10 mM Hepes. In one example, SPR is performed at 25°C or 37°C in HBS-EP. HBS-EP is obtained from Teknova Inc (California; Catalog No. H8022).

[0466] In one example, the affinity of a ligand (e.g., an antibody) is determined using SPR by the following steps:

[0467] 1. Anti-mouse (or species-matched other relevant human, rat or non-human vertebrate antibody constant region) IgG (e.g. Biacore TM BR-1008-38) is coupled to a biosensor chip (e.g., a GLM chip), for example, via primary amine coupling;

[0468] 2. Expose anti-mouse IgG (or other matching species antibody) to the test IgG antibody to capture the test antibody on the chip;

[0469] 3. Pass the test antigen over the capture surface of the chip at 1024 nM, 256 nM, 64 nM, 16 nM, 4 nM, and 0 nM (ie, buffer only); and

[0470] 4. and determining the affinity of the binding of the test antibody to the test antigen using surface plasmon resonance, e.g., under SPR conditions as discussed above (e.g., at 25° C. in physiological buffer). SPR can be performed using any standard SPR equipment, e.g., by Biacore TM Or use ProteOn XPR36 TM

[0471] Regeneration of the capture surface can be performed using 10 mM glycine at pH 1.7. This removes the captured antibodies and makes the surface available for other interactions. Binding data can be fitted to an intrinsic 1:1 model using standard techniques, such as using ProteOn XPR36 TM Models inherent in analytical software.

[0472] In one example, the antagonist (e.g., antibody or fragment) of the invention is contained in a medical container, such as a vial, syringe, IV container, or injection device (e.g., intraocular or intravitreal injection device). In one example, the antagonist is in vitro, such as in a sterile container. In one example, the invention provides a kit comprising an antagonist of the invention, packaging, and instructions for use for treating or preventing or diagnosing a PCSK9-mediated disease or condition in a human. In one example, the instructions indicate that the human should genotype the PCSK9 variant sequence of the invention before administering the antagonist to the human. In one example, the instructions indicate that the human should phenotype the PCSK9 variant of the invention before administering the ligand to the human. In one example, the human is of Chinese (e.g., Han) ethnicity and the instructions are in Chinese (e.g., Mandarin).

[0473] In one example, the antagonist is (or has been determined to be) a neutralizer of PCSK9. In one example, the assay is performed in humans (e.g., in a clinical trial). In one example, the assay is performed in non-humans, such as mice, rats, rabbits, pigs, dogs, sheep, or non-human primates (e.g., cynomolgus monkeys, rhesus monkeys, or baboons).

[0474] Variants of PCSK9 may include forms described as a, f, c, r, p, m, e, h, aj and q in WO2015092393. Sequences of these variants are provided therein and in Tables 1, 2 or 6, see, for example, SEQ ID NO: 1-27. The disclosure of this reference and these sequences are incorporated herein by reference for possible use in the present invention. In one example, the antagonist specifically binds to a PCSK9 variant disclosed in WO2015092393. In one example, additionally or alternatively, a human subject expresses such a PCSK9 variant.

[0475] In one example, the antagonist specifically binds to a PCSK9 variant comprising amino acid E670G. In one example, additionally or alternatively, the human subject expresses such a PCSK9 variant.

[0476] In one example, the antagonist specifically binds to a PCSK9 variant comprising amino acid I474V. In one example, additionally or alternatively, the human subject expresses such a PCSK9 variant.

[0477] Antagonists of the invention are useful, for example, in specific binding assays, genotyping or phenotyping humans, affinity purification of PCSK9, and screening assays to identify other antagonists of PCSK9 activity. Some antagonists of the invention are useful for inhibiting the binding of PCSK9 to a cognate human receptor or protein, or inhibiting PCSK9-mediated activity.

[0478] The present invention encompasses anti-PCSK9 (e.g., PCSK9) antibody antagonists with modified glycosylation patterns. In some applications, modifications to remove non-desired glycosylation sites may be useful, or, for example, to remove trehalose moieties to increase antibody-dependent cellular cytotoxicity (ADCC) function (see Shield et al. (2002) JBC 277:26733). In other applications, galactosylation modifications may be performed to modulate complement-dependent cytotoxicity (CDC).

[0479] In one example, the present invention provides a pharmaceutical composition comprising an antagonist of the present invention, wherein the antagonist is or comprises a recombinant human antibody or fragment thereof that specifically binds to PCSK9 (e.g., a rare variant as described herein), and a pharmaceutically acceptable carrier. In one embodiment, the present invention provides a composition that is a combination of an antibody antagonist or antigen-binding fragment of an antibody of the present invention and a second therapeutic agent. The second therapeutic agent may be any of the following: an anti-inflammatory agent, an anti-angiogenic agent, an analgesic agent, a diuretic, a chemotherapeutic agent, an anti-neoplastic agent, a vasodilator, a vasoconstrictor, a statin, a beta blocker, a nutrient, an adjuvant, an anti-obesity agent, and an anti-diabetic agent.

[0480] In one example, the invention provides a method for inhibiting PCSK9 activity using an anti-PCSK9 antagonist of the invention (e.g., an antibody of the invention or an antigen-binding portion of an antibody of the invention), wherein the method of treatment comprises administering a therapeutically effective amount of a pharmaceutical composition comprising an antagonist. The condition treated is any disease or condition that is improved, ameliorated, inhibited or prevented by removing, inhibiting or reducing PCSK9 activity.

[0481] paragraph:

[0482] The present invention provides the following aspects set out in paragraphs 1 et seq.

[0483] 1. An antibody or fragment comprising a binding site that specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9), wherein the binding site comprises a VH domain encoded by a nucleotide sequence derived from the recombination of a human VH gene segment, a DH gene segment, and a JH gene segment, wherein the VH gene segment is selected from IGHV4-31, IGHV4-59, IGHV4-4, and IGHV3-9.

[0484] 2. The antibody or fragment according to paragraph 1, wherein (i) the VH gene segment is IGHV4-31 and the DH gene segment is the human gene segment IGHD3-9; or (ii) the VH gene segment is IGHV4-59 and the DH gene segment is the human gene segment IGHD3-10; or (iii) the VH gene segment is IGHV4-4 and the DH gene segment is the human gene segment IGHD2-15; or (iv) the VH gene segment is IGHV3-9 and the DH gene segment is the human gene segment IGHD3-9.

[0485] 3. The antibody or fragment according to paragraph 1 or 2, wherein the JH gene segment is the human gene segment IGHJ6.

[0486] 4. The antibody or fragment of any of the preceding paragraphs, wherein the binding site comprises a CDRH3 sequence selected from SEQ ID NO: 271, 285, 15, 77, 29, 91, 211 and 225.

[0487] 5. The antibody or fragment of any of the preceding paragraphs, wherein the binding site comprises a VH domain comprising SEQ ID NO: 259, 1, 65 or 199.

[0488] 6. The antibody or fragment of any of the preceding paragraphs, wherein the binding site comprises a VH domain comprising SEQ ID NO: 259 paired with a VL domain comprising SEQ ID NO: 289.

[0489] 7. The antibody or fragment of any one of paragraphs 1 to 5, wherein the binding site comprises a VH domain comprising SEQ ID NO: 319 paired with a VL domain comprising SEQ ID NO: 349.

[0490] 8. An antibody or fragment that specifically binds to PCSK9 and comprises the CDRH3 sequence of the anti-PCSK9 antibody according to any one of the preceding paragraphs, or the CDRH3 sequence comprising 3, 2 or 1 amino acid substitutions.

[0491] 9. An antibody or fragment (optionally according to any one of the preceding paragraphs) that specifically binds to PCSK9 and comprises a VH domain comprising the CDRH3 sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said sequence comprising 3, 2 or 1 amino acid substitutions.

[0492] 10. The antibody or fragment of paragraph 9, wherein the VH domain comprises: (i) a CDRH3 sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said CDRH3 sequence comprising 3, 2 or 1 amino acid substitutions; and (ii) a CDRH1 sequence of said selected antibody; or said CDRH1 sequence comprising 3, 2 or 1 amino acid substitutions.

[0493] 11. The antibody or fragment of paragraph 9 or 10, wherein the VH domain comprises: (iii) a CDRH3 sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said CDRH3 sequence comprising 3, 2 or 1 amino acid substitutions; and (iv) a CDRH2 sequence of said selected antibody; or said CDRH2 sequence comprising 3, 2 or 1 amino acid substitutions.

[0494] 12. An antibody or fragment (optionally according to any one of the preceding paragraphs), comprising a binding site that specifically binds to PCSK9, wherein the binding site comprises a VH domain, the VH domain comprising the amino acid sequence of the VH domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid that is at least 70% identical thereto.

[0495] 13. The antibody or fragment of paragraph 9, 10, 11 or 12, wherein the selected antibody is CL-274711 or CL-148219QLT.

[0496] 14. The antibody or fragment according to any of the preceding paragraphs, comprising a first copy and a second copy of the VH domain.

[0497] 15. An antibody or fragment (optionally according to any one of the preceding paragraphs), comprising a binding site that specifically binds to PCSK9, wherein the binding site comprises a VL domain encoded by a nucleotide sequence derived from the recombination of a human VL gene segment and a JL gene segment, wherein the VL gene segment is selected from IGKV3-11, IGKV2-28 and IGKV2-29.

[0498] 16. The antibody or fragment according to paragraph 15, wherein the JL gene segment is a human gene segment selected from IGKJ4, IGJK3 and IGKJ1.

[0499] 17. An antibody or fragment that specifically binds to PCSK9 and comprises the CDRL3 sequence of the anti-PCSK9 antibody according to any of the preceding paragraphs, or the CDRL3 sequence comprising 3, 2 or 1 amino acid substitutions.

[0500] 18. An antibody or fragment (optionally according to any one of the preceding paragraphs) that specifically binds to PCSK9 and comprises a VL domain comprising a CDRL3 sequence selected from SEQ ID NO: 301, 315, 47, 107, 61, 121, 241 and 255, or the selected CDRL3 sequence comprising 3, 2 or 1 amino acid substitutions.

[0501] 19. An antibody or fragment (optionally according to any one of the preceding paragraphs) that specifically binds to PCSK9 and comprises a VL domain comprising the CDRL3 (and optionally CDRH3) sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said sequences each comprising 3, 2 or 1 amino acid substitutions.

[0502] 20. The antibody or fragment of paragraph 19, wherein the VL domain comprises: (i) a CDRL3 sequence (and optionally CDRH3) of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said CDR3 sequence each comprising 3, 2 or 1 amino acid substitutions; and (ii) a CDRL1 (and optionally CDRH1) sequence of said selected antibody; or said CDR1 sequence each comprising 3, 2 or 1 amino acid substitutions.

[0503] 21. An antibody or fragment according to paragraph 19 or 20, wherein the VL domain comprises: (iii) a CDRL3 (and optionally CDRH3) sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said CDR3 sequence each comprising 3, 2 or 1 amino acid substitutions; and (iv) a CDRL2 (and optionally CDRH2) sequence of said selected antibody; or said CDR2 sequence each comprising 3, 2 or 1 amino acid substitutions.

[0504] 22. An antibody or fragment (optionally according to any one of the preceding paragraphs), comprising a binding site that specifically binds to PCSK9, wherein the binding site comprises a VL domain, the VL domain comprising the amino acid sequence of the VL domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid that is at least 70% identical thereto.

[0505] 23. An antibody or fragment (optionally according to any one of the preceding paragraphs) that specifically binds to PCSK9 and comprises the heavy chain amino acid sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid that is at least 70% identical thereto.

[0506] 24. An antibody or fragment (optionally according to any one of the preceding paragraphs) that specifically binds to PCSK9 and comprises the light chain amino acid sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid that is at least 70% identical thereto.

[0507] 25. The antibody or fragment according to paragraph 23, comprising the light chain amino acid sequence of the selected antibody; or amino acids at least 70% identical thereto.

[0508] 26. An antibody or fragment (optionally according to any one of the preceding paragraphs) that specifically binds to an epitope of human PCSK9 that is identical to the epitope bound by the antibody of any one of the preceding paragraphs.

[0509] 27. The antibody or fragment according to paragraph 26, wherein the epitope is identified by unrelated amino acid scanning, or by X-ray crystallography.

[0510] 28. The antibody or fragment according to paragraph 27, wherein the contact residues of the epitope are defined by at least a 10-fold decrease in affinity as determined by SPR in an unrelated amino acid scan, such as an alanine scan.

[0511] 29. An antibody or fragment (optionally according to any of the preceding paragraphs) that competes with the antibody according to any of the preceding paragraphs for binding to human PCSK9.

[0512] 30. The antibody or fragment according to any of the preceding paragraphs, which specifically binds to PCSK9 comprising an amino acid sequence selected from SEQ ID NOs: 189-194.

[0513] 31. The antibody or fragment according to any of the preceding paragraphs, wherein the antibody or fragment comprises a human constant region, optionally an IgG4 constant region or an IgG1 constant region.

[0514] 32. The antibody or fragment according to paragraph 31, wherein the constant region is an IgG4-PE constant region, optionally comprising the amino acid sequence of SEQ ID NO: 3 or 152.

[0515] 33. The antibody or fragment according to any of the preceding paragraphs, further comprising an antigen binding site that specifically binds to another target antigen, optionally ANGPTL3.

[0516] 34. An anti-PCSK9 antibody or fragment as defined in any of the preceding paragraphs for use in treating or preventing a PCSK9-mediated disease or condition (optionally hypercholesterolemia) in a subject.

[0517] 35. The anti-PCSK9 antibody or fragment of paragraph 34, wherein the disease or condition is selected from hypercholesterolemia, hyperlipidemia, hypercholesterolemia, dyslipidemia, cholestatic liver disease, nephrotic syndrome, hypothyroidism, obesity, diabetes, atherosclerosis or cardiovascular disease.

[0518] 36. The antibody or fragment of paragraph 34 or 35, wherein the antibody or fragment is administered to the subject simultaneously or sequentially with a statin.

[0519] 37. A combination of an amount of an anti-PCSK9 antibody or fragment and an amount of a statin (optionally comprising multiple doses of said antibody and / or statin), wherein said antibody or fragment is according to any one of paragraphs 1 to 36.

[0520] 38. The antibody, fragment or combination of any one of paragraphs 1 to 37 for use in a method of treating or preventing hypercholesterolemia in an individual who has been previously treated with a statin regimen at a first dose, wherein the method comprises reducing the dose of a statin administered to the individual or not administering a statin to the individual, wherein the method comprises administering the antibody or fragment to the individual.

[0521] 39. The combination according to paragraph 37 or 38, comprising a daily dose of 10 to 20 mg (eg 10 mg); or <60 mg (eg 40 mg) of a statin.

[0522] 40. An antibody, fragment or combination according to any of the preceding paragraphs for administration to a human or animal subject suffering from elevated cholesterol for reducing plasma low-density lipoprotein cholesterol (LDL-C) levels in the subject after the subject has received an anti-PCSK9 antibody or fragment.

[0523] 41. Use of an antibody, fragment or combination as defined in any of the preceding paragraphs for the manufacture of a medicament for administration to a subject for the treatment or prevention of a PCSK9-mediated disease or condition, optionally hypercholesterolemia.

[0524] 42. A method for treating or preventing a PCSK9-mediated disease or condition (optionally hypercholesterolemia) in an individual, the method comprising administering to the individual a therapeutically effective amount of an antibody, fragment or combination as defined in any one of paragraphs 1 to 40, wherein the PCSK9-mediated disease or condition is thereby treated or prevented.

[0525] 43. The use according to paragraph 41 or the method according to paragraph 42, wherein the PCSK9-mediated disease or condition is hypercholesterolemia.

[0526] 44. The antibody, fragment, combination, use or method according to any one of paragraphs 34 to 43, further comprising administering to the subject an additional therapy, such as an additional therapeutic agent, optionally wherein the additional therapeutic agent is selected from the group consisting of:

[0527] a. Statins;

[0528] b. ANGPTL3 inhibitors (eg, anti-ANGPTL3 antibodies, such as envenomab)

[0529] c. Fibrate;

[0530] d. Bile acid sequestrants;

[0531] e. niacin; and

[0532] f. Niacin.

[0533] 45. A pharmaceutical composition comprising an antibody, fragment or combination as defined in any one of paragraphs 1 to 40 and 44, and a pharmaceutically acceptable excipient, diluent or carrier, and optionally in combination with another therapeutic agent selected from the agents recited in paragraph 44.

[0534] 46. ​​A pharmaceutical composition according to paragraph 45 for use in the treatment and / or prevention of a PCSK9-mediated condition or disease, optionally hypercholesterolemia.

[0535] 47. A pharmaceutical composition according to paragraph 45 or 46, in combination with a label or instructions for use to treat and / or prevent said disease or condition in a human; optionally wherein said label or instructions comprises a marketing authorization number (optionally an FDA or EMA authorization number); optionally wherein said kit comprises an IV or injection device comprising said antibody or fragment.

[0536] 48. A nucleic acid encoding the VH domain and / or VL domain of an antibody or fragment as defined in any one of paragraphs 1 to 33.

[0537] 49. A nucleic acid encoding a VH domain comprising the amino acid sequence of the VH domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); or an amino acid at least 70% identical thereto.

[0538] 50. A nucleic acid encoding a VL domain comprising the amino acid sequence of the VL domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); or an amino acid at least 70% identical thereto.

[0539] 51. A nucleic acid comprising a nucleotide sequence that is at least 70% identical to the sequence of SEQ ID NO: 260 or 320.

[0540] Alternatively:

[0541] A nucleic acid comprising a nucleotide sequence that is at least 70% identical to the sequence of SEQ ID NO: 2, 66 or 200.

[0542] 52. A nucleic acid encoding the heavy and / or light chain of an antibody or fragment as defined in any one of paragraphs 1 to 33.

[0543] 53. A nucleic acid encoding a heavy chain comprising: a VH amino acid sequence at least 70% identical to SEQ ID NO: 259 or 319; and a C region amino acid sequence at least 70% identical to an IGHG4 sequence, optionally at least 70% identical to SEQ ID NO: 3 or 152.

[0544] Alternatively:

[0545] A nucleic acid encoding a heavy chain comprising: a VH amino acid sequence that is at least 70% identical to SEQ ID NO: 1, 65, or 152; and a C region amino acid sequence that is at least 70% identical to an IGHG4 sequence, optionally at least 70% identical to SEQ ID NO: 3 or 152.

[0546] 54. A nucleic acid encoding a light chain comprising: a VL amino acid sequence at least 70% identical to SEQ ID NO: 289 or 349; and a C region amino acid sequence at least 70% identical to an IGKC sequence, optionally at least 70% identical to SEQ ID NO: 156.

[0547] Alternatively:

[0548] A nucleic acid encoding a light chain comprising: a VL amino acid sequence at least 70% identical to SEQ ID NOs: 33, 95 and 229; and a C region amino acid sequence at least 70% identical to an IGKC sequence, optionally at least 70% identical to SEQ ID NO: 156.

[0549] 55. A nucleic acid (e.g., in a host cell, such as a CHO or HEK293 or Cos cell) comprising

[0550] a. a nucleotide sequence that is at least 70% identical to the heavy chain sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); and / or

[0551] b. A nucleotide sequence that is at least 70% identical to the light chain sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT), respectively.

[0552] 56. A vector comprising a nucleic acid (eg, a nucleic acid according to any one of paragraphs 48 to 55); optionally wherein the vector is a CHO or HEK293 vector.

[0553] 57. A host cell comprising a nucleic acid (eg, a nucleic acid according to any one of paragraphs 48 to 55) or a vector according to paragraph 56.

[0554] 58. An antibody, fragment, combination, vector, host cell, use or method as described herein.

[0555] In any of the embodiments herein, preferably the antibody selected is CL-274711.

[0556] Therapeutic administration and formulations

[0557] The present invention provides therapeutic compositions comprising an anti-PCSK9 antagonist, such as an antibody or antigen-binding fragment thereof of the present invention. Administration of the therapeutic composition according to the present invention will be administered with suitable carriers, excipients, and other agents incorporated into the formulation to provide improved transfer, delivery, tolerance, and the like. Numerous suitable formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania. Such formulations include, for example, powders, pastes, ointments, gels, waxes, oils, lipids, vesicles containing lipids (cationic or anionic) (e.g., LIPOFECTINT TM ), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, polyethylene glycol emulsions (polyethylene glycol of various molecular weights), semisolid gels, and semisolid mixtures containing polyethylene glycol. See also Powell et al. "Compendium of excipients for parenteral formulations" PDA (1998) "Journal of Pharmaceutical Science and Technology ( ...

[0558] The dosage may vary depending on the age and stature of the individual to be administered, the target disease, the condition, the route of administration, and the like. When using an antagonist, such as an antibody of the present invention to treat various conditions and diseases associated with PCSK9 in adult patients, it is advantageous to administer the antibody of the present invention intravenously, usually at a single dose of about 0.01 to about 20 mg / kg body weight, more preferably about 0.02 to about 7, about 0.03 to about 5, or about 0.05 to about 3 mg / kg body weight. Depending on the severity of the condition, the frequency and duration of treatment may be adjusted.

[0559] Various delivery systems are known and can be used to administer the antagonists or pharmaceutical compositions of the invention, such as antagonists provided by receptor-mediated endocytosis, for example, encapsulated in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses (see, e.g., Wu et al. (1987) J. Biol. Chem. 262:4429-4432. Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The antagonists or compositions can be administered by any convenient route, such as by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered together with other biologically active agents. Administration can be systemic or local.

[0560] The antagonist or drug composition can also be delivered in vesicles, specifically liposomes (see Langer (1990) Science 249: 1527-1533; Treat et al. (1989) Liposomes in the Therapy of Infectious Disease and Cancer, Lopez Berestein and Fidler (eds.), Liss, New York, pp. 353-365; Lopez-Berestein, supra, pp. 317-327; see generally supra).

[0561] In some cases, the antagonist or pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump can be used (see Langer, supra; Sefton (1987) "Review of Biomedical Engineering (CRC Crit. Ref. Biomed. Eng)". 14: 201). In another embodiment, a polymeric material can be used; see "Medical Applications of Controlled Release", Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974). In yet another embodiment, the controlled release system can be placed close to the target of the composition, so only a portion of the systemic dose is required (see, for example, Goodson, "Medical Applications of Controlled Release", supra, Vol. 2, pp. 115-138, 1984).

[0562] Injectable preparations may include dosage forms for intravenous, subcutaneous, intradermal and intramuscular injections; drip infusions, etc. Such injectable preparations can be prepared by well-known methods. For example, injectable preparations can be prepared, for example, by dissolving, suspending or emulsifying the antibody described above or its salt in a sterile aqueous medium or an oily medium conventionally used for injection. There are, for example, physiological saline, isotonic solutions containing glucose and other adjuvants, etc., which can be used in combination with appropriate solubilizers, such as alcohols (e.g., ethanol), polyols (e.g., propylene glycol, polyethylene glycol), nonionic surfactants [e.g., polysorbate 80, HCO-50 (polyethylene oxide (50 mol) adduct of hydrogenated castor oil)], etc., as aqueous media for injection. For example, sesame oil, soybean oil, etc. are used as oily media, which can be used in combination with solubilizers (e.g., benzyl benzoate, benzyl alcohol, etc.). The injection thus prepared is preferably filled in an appropriate ampoule. The pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously with a standard needle and syringe. In addition, pen delivery devices are readily applicable to the delivery of the pharmaceutical compositions of the present invention with respect to subcutaneous delivery. Such pen delivery devices may be reusable or disposable. Reusable pen delivery devices generally utilize a replaceable sleeve containing the pharmaceutical composition. After all of the pharmaceutical composition in the sleeve has been administered and the sleeve is empty, the empty sleeve can be easily discarded and replaced with a new sleeve containing the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable sleeve. In fact, the disposable pen delivery device is pre-filled with a pharmaceutical composition stored in a reservoir within the device. After the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.

[0563] Many reusable pen and auto-injector delivery devices are used for subcutaneous delivery of the antagonists or pharmaceutical compositions of the present invention. Examples include (but are certainly not limited to) AUTOPEN, to name a few. TM (Owen Mumford, Inc., Woodstock, UK), DISETRONIC TM Pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75 / 25 TM Pen, HUMALOG TM Pen, HUMALIN 70 / 30 TM Pen (Eli Lilly and Co., Indianapolis, Indiana), NOVOPEN TM I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR TM (NovoNordisk, Copenhagen, Denmark), BD TMPEN (Becton Dickinson, Franklin Lakes, NJ), OPTIPENT TM 、OPTIPEN PRO TM 、OPTIPEN STARLET TM and OPTICLIKT TM (Sanofi-Aventis, Frankfurt, Germany). Examples of disposable pen delivery devices useful for subcutaneous delivery of the pharmaceutical compositions of the present invention include (but are certainly not limited to) SOLOSTAR TM Pen (Sanofi-Aventis), FLEXPEN TM (Novo Nordisk) and KWIKPEN TM (Eli Lilly).

[0564] Advantageously, the pharmaceutical composition for oral or parenteral use described above is prepared into a unit dosage form suitable for matching the antagonist dosage. Such unit dosage forms include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc. The amount of the aforementioned antibody contained is generally about 5 to about 500 mg per unit dosage form; especially in the form of an injection, it is preferred that the aforementioned antibody is contained in about 5 to about 100 mg and about 10 to about 250 mg of another dosage form.

[0565] For convenience, the meanings of some terms and phrases used in this specification, examples and the appended claims are provided below. Unless otherwise stated or implied by the context, the following terms and phrases include the meanings provided below. The definitions are provided to assist in describing specific embodiments and are not intended to limit the claimed invention, as the scope of the present invention is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the present invention belongs. If there is an obvious inconsistency between the usage of a term in the art and its definition provided herein, the definition provided in this specification should prevail.

[0566] For convenience, certain terms employed herein, in the specification, examples, and appended claims are collected here.

[0567] "Decrease / reduced / reduction" are all used herein to mean a statistically significant reduction. In some embodiments, "reduce / reduction / decrease" generally means a reduction of at least 10% compared to a reference level (e.g., in the absence of a given treatment), and may include, for example, a reduction of at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99% or more. As used herein, "reduce" does not encompass a complete reduction compared to a reference level. The reduction may preferably be reduced to an acceptable level within the normal range for individuals without a given disease. For example, however, for the purposes of reducing or lowering cholesterol levels, a decrease of, for example, about 5-10 points may be considered a "decrease" or "reduction."

[0568] In certain aspects of all embodiments of the invention, the term "inhibit" is used. Inhibit refers to a decrease of at least 10% compared to a reference level (e.g., in the absence of a given treatment), and may include, for example, a decrease of at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99% or more, including 100% inhibition compared to a reference level. "Complete inhibition" refers to 100% inhibition compared to a reference level.

[0569] The terms "increased / increase", "enhance" or "activate" are all used herein to mean an increase in a statistically significant amount. In some embodiments, the terms "increased / increase", "enhance" or "activate" may mean an increase of at least 10% compared to a reference level, such as an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including 100% increase compared to a reference level, or any increase between 10%-100% compared to a reference level, or at least about 2-fold, or at least about 3-fold, or at least about 4-fold, or at least about 5-fold or at least about 10-fold increase, or any increase between 2-fold and 10-fold or greater compared to a reference level. In the context of a marker or symptom, an "increase" is a statistically significant increase in such levels.

[0570] As used herein, the term "substantially" refers to the qualitative condition of presenting all or nearly all limits or degrees of a feature or characteristic of interest. It will be understood by those of ordinary skill in the biological field that biological and chemical phenomena rarely, if ever, proceed to completion and / or proceed to completion or to achieve or avoid an absolute result. The term "substantially" is therefore used herein to capture the possible lack of integrity inherent in many biological and chemical phenomena. To remove doubt, "substantially" may refer to at least 90% limits or degrees of a feature or characteristic of interest, such as at least 90%, at least 92%, at least 95%, at least 98%, at least 99% or greater.

[0571] All patents and other disclosures cited throughout this application, including references, issued patents, published patent applications, and patent applications pending, are expressly incorporated herein by reference for the purpose of describing and disclosing methods such as those described in such disclosures that can be used in conjunction with the technology described herein. These disclosures only provide their disclosures prior to the filing date of this application. In this regard, it should not be understood as an admission that the inventor has no right to disclose this prior to prior invention or for any other reason. All statements about dates or representations about the contents of these documents are based on information available to the applicant and do not constitute any admission of the correctness of the dates or contents of these documents.

[0572] The description of the embodiments of the present invention is not intended to be exhaustive or to limit the disclosure to the exact form disclosed. Although specific embodiments and examples of the present invention are described herein for illustrative purposes, those skilled in the relevant art will recognize that various equivalent modifications can be made within the scope of the present invention. For example, although the method steps or functions are presented in a specified order, alternative embodiments can perform functions in different orders, or can perform functions substantially simultaneously. The teachings of the present invention provided herein can be applied to other programs or methods as needed. The various embodiments described herein can be combined to provide other embodiments. Aspects of the present invention can be modified (if necessary) to adopt the compositions, functions and concepts of the above references and applications to obtain other embodiments of the present invention. In addition, due to biological functional equivalence considerations, some changes can be made to the protein structure without affecting the type or amount of biological or chemical effects. These and other changes can be made to the present invention in view of the embodiments. All such modifications are intended to be included within the scope of the appended claims.

[0573] The specific elements of any of the foregoing embodiments may be combined or replaced with elements in other embodiments. In addition, although the advantages associated with certain embodiments of the present invention have been described in the context of these embodiments, other embodiments may also present such advantages, and not all embodiments necessarily need to present such advantages within the scope of the present invention.

[0574] It should be understood that the specific configurations, aspects, examples, clauses and embodiments described herein are shown in an illustrative manner and are not intended to be limiting of the present invention. The main features of the present invention may be employed in various embodiments without departing from the scope of the present invention. A skilled person in the art should recognize or be able to determine many equivalents of the specific procedures described herein using only routine research. Such equivalents are considered to be within the scope of the present invention and are covered by the claims. All publications and patent applications mentioned in this specification indicate the technical level of skilled persons in the art to which the present invention belongs. All publications and patent applications are incorporated herein by reference to the extent that each individual publication or patent application is specifically and individually indicated as being incorporated by reference. When used in conjunction with the term "including" in the claims and / or the specification, the use of the word "a / an" may mean "one", but it is also consistent with the meaning of "one or more", "at least one" and "one or more than one". Although the present invention supports definitions involving only substitution and "and / or", unless it is explicitly indicated as only substitution or substitution mutually exclusive, the use of the term "or" in the claims is used to mean "and / or".

[0043] Throughout this application, the term "about" is used to indicate that a value includes the inherent variation for the device, the method employed to determine the value, or the variation that exists among the study subjects.

[0575] As used in the specification and claims, the words "comprising" (and any form of comprising, such as "comprise / comprises"), "having" (and any form of having, such as "have / has"), "including" (and any form of including, such as "includes / include"), or "containing" (and any form of containing, such as "contains / contain") are inclusive or open-ended and do not exclude additional unrecited elements or method steps.

[0576] Unless otherwise apparent from the context, any part of the present invention may be read in combination with any other part of the present invention.

[0577] All compositions and / or methods disclosed or claimed herein can be prepared and performed according to the present invention without undue experimentation. Although the compositions and methods of the present invention have been described in terms of preferred embodiments, it should be clear to those skilled in the art that variations can be applied to the compositions and / or methods and steps or sequence of steps of the methods described herein without departing from the concept, spirit and scope of the present invention. All such similar substitutions and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the present invention as defined by the appended claims.

[0578] The present invention is described in more detail in the following non-limiting examples.

[0579] Examples

[0580] Plasma LDL cholesterol (LDL-C) is a major risk factor for cardiovascular disease, which causes 4 million deaths per year in Europe. The clearance of plasma LDL-C is mainly carried out in the liver through LDL receptors (LDLR). LDLR continuously internalizes LDL-C from plasma into hepatocytes, and continues to absorb LDL-C by recycling back to the cell surface. The surface level of LDLR is negatively regulated by PCSK9, which directly binds to LDLR and promotes lysosome-mediated LDLR degradation. The reduction of LDLR surface exposure to LDL-C reduces LDL-C internalization in hepatocytes, and thus increases plasma LDL-C, which can cause plaque formation and blood flow blockage. In recent years, targeting PCSK9 has become a promising strategy for controlling plasma LDL-C levels.

[0581] We developed monoclonal antibodies that block PCSK9 function and have therapeutic potential. We first immunized Kymice with human and mouse PCSK9 proteins. TM (See, e.g., WO 2011 / 004192 and Lee et al., Nat Biotechnol. 2014 Apr;32(4):356-63. doi:10.1038 / nbt.2825. Epub 2014 Mar 16, “Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody research”. In order to avoid the undesired effects of the His tag, we made a cell line that actively secretes native forms of human and mouse PCSK9 proteins without the His tag for immunization. After immunization, antibody sequences from antigen-specific B cells are retrieved by next-generation sequencing and computer analysis is performed to identify favorable antibodies for development. After expression, antibodies are screened and selected based on cross-reactive binding, affinity and function through a sequential in vitro screening cascade. Binding to human PCSK9 variants is confirmed to ensure efficacy in a large part of the human population. Based on the feasibility of development point of view, characterize the physiological characteristics of the selected antibodies. In a mouse model of hyperlipidemia, two prominent antibodies (CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT)) showed superior function in reducing plasma non-HDL cholesterol without changing HDL cholesterol, and the duration of action was longer than that of the benchmark test antibodies. In summary, we successfully induced cross-reactive antibodies against PCSK9 and identified at least two superior fully human monoclonal antibodies that blocked PCSK9 function in vitro and in vivo.

[0582] Example 1: Identification of Antibodies by In Vitro Assays

[0583] In Kymice TM Five immunization campaigns were performed in vitro and the following selection criteria were included:

[0584] (a) selecting cross-reactive binders against human PCSK9 (hPCSK9), cynomolgus monkey PCSK9 (cynoPCSK9) and mouse PCSK9 (mPCSK9);

[0585] (b) determining the affinity of antibodies against hPCSK9a and mPCSK9, and giving priority to antibodies with higher affinity;

[0586] (c) demonstrated in an in vitro cell-based assay that neutralization of the antibody reduced internalization of fluorescent hPCSK9 in a human hepatocyte cell line (HepG2); and

[0587] (d) In parallel, in the same in vitro cell-based assay as (c), the function of the antibodies to restore LDL uptake in HepG2 cells was determined.

[0588] Two antibodies (CL-274711, CL-148219QLT, CL-274698, CL-148219, and CL-148489 (eg, CL-274711 or CL-148219QLT)) showed particularly promising functions both in vitro and in vivo (Example 2).

[0589] CL-148219

[0590] CL-148219 showed stronger neutralizing activity and greater ability to restore in vitro LDL uptake compared to the benchmark, indicating that CL-148219 directly blocks the interaction between PCSK9 and LDLR. In a mouse model of hyperlipidemia (E3L.CETP mice; de ​​Knijff, Westerterp, Ason, van den Hoek, and Kühnast), CL-148219 reduced plasma non-HDL cholesterol better than the benchmark test Ab and with a longer duration of action. Figure 1-4 .

[0591] CL-148489

[0592] In an in vitro cell-based assay, CL-148489 moderately neutralized hPCSK9 but had a significant ability to restore LDL uptake, suggesting that this antibody may indirectly interfere with the binding of PCSK9 to the LDLR, possibly by blocking HSPG binding to PCSK9. In a mouse model of hyperlipidemia (E3L.CETP mice), this antibody also lowered plasma non-HDL cholesterol more potently than baseline, with a similar duration of action. See Figure 5-8 .

[0593] Benchmarks were: Alirocumab hIgG4-PE (SEQ ID Nos: 195 and 196) and "Regeneron pH-D" (a pH-dependent (differential PCSK9 binding inside vs. outside lysosomes) anti-PCSK9 hIgG4-PE antibody) (SEQ ID Nos: 197 and 198).

[0594] The VH and VL regions of the antibody are derived from the recombination of the following gene segments:

[0595]

[0596] References:

[0597] de Knijff, P. et al., 1991, "Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree," J. Clin. Invest. 88: 643-655;

[0598] Westerterp, M. et al., 2006, “Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leidenmice,” Arterioscler. Thromb. Vasc. Biol. 26:2552-2559;

[0599] Ason, B. et al., 2011, “PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE”, J Lipid Res., April 2011, 52(4): 679-687;

[0600] van den Hoek AM. et al., 2014, “APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome”, Diabetes Obes Metab. 2014 Jun; 16(6): 537-44; and

[0601] Kühnast, S et al., 2014, “Alirocumab inhibits atherosclerosis, improves the plaquemorphology, and enhances the effects of a statin”, J Lipid Res., Oct 2014, 55(10): 2103-2112.

[0602] Example 2: In vivo analysis

[0603] In this study, we used APOE*3Leiden.cholesteryl ester transfer protein (CETP) mice, which contain mouse ApoE, human mutant APOE3*Leiden, and functional LDLR. These mice have shown excellent translational value, with the cholesterol increases seen in the model being treatable by the same therapies that are effective in patients, and showing reductions in maximal LDL levels similar to those that can be obtained in the clinic.

[0604] CETP mice were fed a high-fat diet for 4 weeks and then received a single dose of antibody, isotype control, or standard of care (alirocumab, an FDA-approved PCSK9 inhibitor) on day 0. Then, on day 18, mice received a second higher dose (half-log). Individual animal cholesterol levels were measured on days 0, 3, 7, 14, 21, and 28. On day 28, pooled group samples from terminal bleeds were analyzed for complete lipid profiling.

[0605] Of the 10 antibodies we tested, two (CL-148219 and CL148489) lowered cholesterol levels more than an equivalent dose of alirocumab, with one, CL-148219, showing a longer duration of action. In summary, we have identified two that are potentially the most preferred in the class of PCSK9 inhibitors.

[0606] method

[0607] For study design, see Fig. 9 One hundred and twenty-eight female 8-14 week old APOE*3Leiden.CETP transgenic mice were placed on a Western-type diet (WTD) containing 0.15% cholesterol and 15% saturated fat. After a 4-week run-in period, 24 low-responding mice were removed from the study and the animals were divided into groups (n=6-8) and matched for age, weight, plasma cholesterol, triglycerides, and HDL-cholesterol after a 4-h fast (t=0). At t=0, mice were subcutaneously administered 3 mg / kg of isotype control, benchmark test, or our anti-PCSK9 antibody. Four of our antibodies (previously identified as excellent by in vitro screening) had an additional 1 mg / kg dose group at t=0. At t=18 days, mice received a second subcutaneous dose of the same antibody at a 1 / 2 log dose higher than the first dose (i.e., first dose 3 mg / kg, second dose 10 mg / kg).

[0608] Body weight and food intake were measured twice a week. On days 0, 3, 7, 14, 21 and 28 after the initial dose, 4h fasting plasma samples were collected for determination of plasma total cholesterol, HDL-cholesterol and triglycerides. Plasma non-HDL-cholesterol values ​​were calculated. At t = 28 days, after the last blood collection, mice were sacrificed and plasma and liver tissue were collected. Lipoprotein profiles were determined on FPLC fractions from group pooled plasma samples.

[0609] Statistics: Two-way annova and Dunnetts post hoc analysis - Graphpad Prism TM .

[0610] result

[0611] Total cholesterol ( Fig.10 )

[0612] During the study period, the isotype control group showed plasma total cholesterol levels of 16-22 mmol / L.

[0613] Compared to the isotype control antibody, alirocumab significantly reduced total cholesterol on day 3 at the 3 mg / kg dose (-34.9%) and on days 21 and 28 (3 and 10 days after the second injection, respectively) at the 10 mg / kg dose (-33.2% and -32.3%, respectively).

[0614] On day 3, CL-148219 significantly reduced total cholesterol at 1 and 3 mg / kg doses (-36.4% and -47.0%, respectively); and on day 7, at 3 mg / kg dose (-32.6%). After the second dose, on days 21 and 3, CL-148219 significantly reduced total cholesterol at 3 mg / kg doses (-33.4% and -27.1%, respectively) and 10 mg / kg doses (-46.3% and -49.6%, respectively).

[0615] CL-148489 significantly reduced total cholesterol at the 3 mg / kg dose (47.3% and -32.3%, respectively) on days 3 and 21 (3 days after the second injection); and after the second dose, at the 10 mg / kg dose (-42.9% and -56.0%, respectively) on days 21 and 28.

[0616] Total non-HDL cholesterol ( Fig.11 )

[0617] During the study period, the isotype control group showed non-HDL-cholesterol levels of 15.2-21.3 mmol / L.

[0618] Compared to the isotype control antibody, alirocumab significantly reduced non-HDL-cholesterol on day 3 at the 3 mg / kg dose (-36.5%) and on days 21 and 28 (3 and 10 days after the second injection, respectively) at the 10 mg / kg dose (-35.5% and 34.3%, respectively).

[0619] CL-148219 significantly reduced non-HDL-cholesterol at 1 and 3 mg / kg doses (-37.7% and -49.1%, respectively) on day 3 and at 3 mg / kg dose (-33.5%) on day 7. After the second injection, CL-148219 significantly reduced non-HDL-cholesterol at 3 mg / kg (-34.4% and -29.2%, respectively) and 10 mg / kg doses (-49.6% and -51.8%, respectively) on days 21 and 28.

[0620] CL-148489 significantly reduced non-HDL-cholesterol on days 3 and 21 (3 days after the second injection) at the 3 mg / kg dose (-49.4% and -35.0%, respectively); and after the second dose, on days 21 and 28 at the 10 mg / kg dose (-45.5% and -58.5%, respectively).

[0621] HDL cholesterol ( Fig.12 )

[0622] None of the antibodies had an effect on HDL cholesterol.

[0623] Triglycerides ( Fig.13 )

[0624] Plasma triglyceride levels in the isotype control group remained stable during the study. Although none of the antibodies significantly affected plasma triglycerides compared to the isotype control group, CL-148219, Cl-148489 and alirocumab showed a trend toward lower triglyceride levels at day 28.

[0625] Phospholipid and cholesterol profile (Figure 14)

[0626] The phospholipid (A) and cholesterol (B) profiles of the pooled samples are shown as follows: fractions 4-8 were considered VLDL, 9-15 were considered LDL and 16-24 were considered HDL. No statistics were performed because each group was measured using one pooled sample. The lipoprotein profiles confirmed that alirocumab, CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT) reduced VLDL-cholesterol and LDL-cholesterol, and had no effect on HDL-cholesterol.

[0627] in conclusion

[0628] Our antibodies were well tolerated by the animals, who showed normal behavior and no signs of discomfort during the study;

[0629] · Tissue sections showed no gross pathology;

[0630] Body weight and food intake were not significantly affected by either antibody.

[0631] Liver weight was not significantly affected by either of the antibodies;

[0632] CL-148219 and CL-148489 significantly reduced plasma total cholesterol and plasma non-HDL-cholesterol in a dose-dependent manner compared to isotype control groups. Lipoprotein profiles showed a reduction in plasma VLDL-cholesterol in mice treated with these antibodies;

[0633] None of our antibodies significantly affected HDL-cholesterol compared to isotype controls.

[0634] None of the antibodies significantly affected plasma triglyceride levels, although alirocumab, CL-274711, CL-148219QLT, CL-274698, CL-148219, and CL-148489 (eg, CL-274711 or CL-148219QLT) showed a trend toward lowering plasma triglyceride levels compared to the isotype control group.

[0635] Examples 3 and 4

[0636] Mouse

[0637] For Example 3, female APOE*3Leiden.CETP transgenic mice were bred. The mice were housed in macrolon cages (3 or 4 mice / cage) in an animal room; relative humidity 40-70%, temperature 20-24°C, light cycle 7am to 7pm. Food and sterile tap water were provided ad libitum to the mice.

[0638] For Example 4, C57BL / 6 mice weighing 18-22 g on the day of the experiment were used. Animals were housed in groups of 2-4 in polysulfone cages (floor area = 1500 cm2) under standard conditions: room temperature (22±2°C), humidity (55±10%), light / dark cycle (12h / 12h), air replacement (15-20 vol / h), water and food ad libitum.

[0639] Plasma cholesterol, lipoprotein, and triglyceride analysis

[0640] Total plasma cholesterol was determined using a cholesterol CHOD-PAP kit (Roche, Mannheim, Germany), and triglycerides were determined using a triglyceride GPO-PAP kit (Roche, Mannheim, Germany). In order to determine plasma HDL-cholesterol, lipids containing ApoB were precipitated using PEG-6000 / glycine and subsequently quantified using a cholesterol CHOD-PAP kit (Roche, Mannheim, Germany). Lipoprotein profiles were measured by FPLC analysis using an AKTA device (GE Healthcare). The combined samples were analyzed for the combined group. Fractions were collected based on retention time, and cholesterol and phospholipids in each fraction were measured using a cholesterol CHOD-PAP kit and a phospholipid kit (Instruchemie, Delfzijl, The Netherlands) from (Roche, Mannheim, Germany).

[0641] Serum antibody concentration

[0642] Serum antibody concentrations were determined using a capture ELISA. Plates were coated with anti-human IgG (Fc specific) antibodies overnight at 2-8°C. The next day, the assay plates were washed three times with 300 μl / well of PBS + 0.1% Tween (PBS-T) using a plate washer. Plates were then blocked with 250 μl / well 2.5% milk / well for at least 1 hour at room temperature. Standards and QCs were prepared in Eppendorf tubes. Standards, samples, and QCs were then diluted 1 / 20 in assay buffer in Eppendorf tubes. Plates were washed three times with 300 μl / well of PBS-T using a plate washer. Samples and QCs were added to the assay plates according to the plate map with a standard curve of 100 μl / well. Plates were incubated for 1 hour at RT, 300 RPM shaking. Using a culture dish washer, the culture dish was washed five times with 300 microliters / well of PBS-T, and 100 μL of anti-human IgG (Fc specificity)-peroxidase diluted in PBS at 1 / 5000 was added to each well, and then the culture dish was incubated for 1 hour at RT, 300RPM vibration. Then, using a culture dish washer, the culture dish was washed five times with 300 μL PBS-T. 100 μL of TMB substrate was added to each well, and the culture dish was incubated in the dark at room temperature for 15 minutes. Then, with 100 microliters / well, stop solution (1M sulfuric acid) was added to each well, and the optical density was determined using a microplate reader set to 450nm, wherein the reference reading was at 540nm. Then, using the disc reader software, the reference reading was subtracted from the 450nm reading. Then, using regression analysis and 4PL curve fitting, Softmax Pro was used to analyze the data. Concentration was measured according to the standard curve.

[0643] Example 3

[0644] Female 8-14 week old APOE*3Leiden.CETP transgenic mice were placed on a Western-type diet (WTD) containing 0.15% cholesterol and 15% saturated fat. After a 4-week run-in period, low-responding mice were removed from the study. The remaining mice were matched for age, weight, plasma cholesterol and triglycerides. The animals were divided into 6 groups (isotype control group) or 10 groups.

[0645] On day 0, animals received subcutaneous injection (5mL / kg). Antibodies (isotype control, benchmark test antibody F, CL-148218 and CL-274711) were administered at 1, 3 or 10 mg / kg. Blood samples were obtained from the tail vein of animals after fasting for 4 hours at days 0, 3, 7, 14, 18, 21 and 28 after treatment. Blood was collected using CB 300K2E microvettes (Sarstedt, Neubrecht, Germany) containing EDTA-dipotassium salt for total cholesterol, triglycerides (days 0, 7 and 28) and HDL-cholesterol measurements. Then, test tubes or capillaries were placed on ice. After centrifugation at 4°C (10min, 6000rpm), EDTA plasma was obtained. Immediately after the last tail vein blood sampling point, mice were killed by CO2 asphyxiation on day 28. For the 28th day sample, the group lipoprotein profile was confirmed.

[0646] The purpose of this experiment was to evaluate the pharmacodynamic effects of the dose response of antibodies CL-274711, CL-148219QLT and benchmark antibody F on total / non-HDL cholesterol and lipoprotein profiles in APOE*3Leiden.CETP transgenic mice fed a Western-type diet containing 0.15% cholesterol and 15% saturated fat.

[0647] All three antibodies reduced cholesterol levels at all doses tested (see Figure 15-17 ), and increasing doses increased the cholesterol reduction and duration of action seen. At 1 and 3 mg / kg, CL-148219QLT was more effective than the benchmark test antibody F in lowering cholesterol levels; and at all doses tested, CL-148219QLT had a longer duration of action than the benchmark test antibody F ( Figure 15-17 Additional analyses showed that CL-148219QLT lowered cholesterol levels as well as a 3-fold higher dose of benchmark test antibody F and had the same duration of action as the higher dose of benchmark test antibody F ( Figure 18-19 CL-274711 reduced cholesterol levels to levels comparable to those seen with the benchmark test antibody F at the same dose, but with a longer duration of action ( Figure 16-17 ).

[0648] The antibodies showed equivalent reductions in non-HDL cholesterol levels at all tested doses (see Figure 20), with increasing doses causing incremental increases in non-HDL cholesterol reduction and incremental increases in duration of response. At 1 and 3 mg / kg, CL-148219QLT was more effective than benchmark test antibody F for reducing cholesterol levels; and at all tested doses, CL-148219QLT had a longer duration of action than benchmark test antibody F (Figure 20). Other analyses showed that CL-148219QLT reduced cholesterol levels as well as a 3-fold higher dose of benchmark test antibody F, and had the same duration of action as the higher dose of benchmark test antibody F (Figure 21). CL-274711 reduced cholesterol levels to the same levels as those seen with the same dose of benchmark test antibody F, but with a longer duration of action (Figure 21).

[0649] Evaluation of the phospholipid profile at day 28 (Figure 22) showed that both CL-274711 and CL-148219QLT reduced VLDL / LDL cholesterol and phospholipids in a dose-dependent manner. Compared to the benchmark antibody F, CL-274711 and CL-148219QLT were more effective at reducing VLDL / LDL cholesterol and phospholipids at 10 mg / kg

[0650] Example 4

[0651] Male C57BL / 6 mice (JANVIER LABS, CS4105, Saint-Berthevin F-53941, France) weighing 18-22 g on the day of the experiment were used. On day 0, animals received a subcutaneous injection of 3 mg / kg CL-148219QLT, CL-274711 or Benchmark F (10 mL / kg). Blood sampling was performed 1, 3, 7, 14, 21 and 28 days after dosing (n=3 / sampling point). Serum was then prepared from each blood sample, which was then used to determine the antibody concentration at each time point.

[0652] The purpose of the experiment was to evaluate the pharmacokinetics of CL-148219QLT, CL-274711, and benchmark antibody F over a 28-day time course. Evaluation of the PK profiles showed that both CL-274711 and CL-148218 had higher initial serum antibody concentrations than benchmark antibody F, and this higher serum antibody concentration was maintained over the 28-day study ( Fig.23 ). CL-148219QLT initially had higher serum antibody concentrations than CL-274711, but CL-274711 had a slower clearance from serum.

[0653] Other data:

[0654] References Fig.24 The first figure shows the efficacy of the antibodies of the present invention. Reference is also made to Table 1, which shows the antibody affinity for human PCSK9 variants, cynomolgus PCSK9 and mouse PCSK9 at neutral pH (7.6) and acidic pH (5.8). TM SPR analysis system was used to measure KD.

[0655] We included six PCSK9 benchmark antibodies as controls for comparison. Three benchmark antibodies were commercially available antibody forms (benchmark antibodies A, B, and F), and three were selected from antibodies in clinical trials (benchmark antibodies C, D, and E). Benchmark antibodies A, B, C, D, and E were prepared as human IgG4PE format. Benchmark antibody F was a human IgG1 format.

[0656] Antigens used for immunization and / or screening include 4 human PCSK9 variants, cynomolgus PCSK9, and mouse PCSK9. Here, we refer to the 4 human PCSK9 variants as follows: human PCSK9 reference (hPCSK9 Ref), human PCSK9 variant (hPCSK9a), human PCSK9 variant b (hPCSK9b), and human PCSK9 D374Y gain-of-function mutant (hPCSK9GOF). Relative to the human PCSK9 reference sequence, the human variant has V474I and G670E amino acid substitutions, and human variant b has A53V, V474I, and G670E amino acid substitutions. We include these 4 human variants for analytical screening in order to find antibodies that can neutralize all 4 variants and mutants in the human population.

[0657] CL-148219

[0658] CL-148219 showed stronger neutralizing activity and greater ability to restore in vitro LDL uptake compared to the benchmark, indicating that CL-148219 directly blocks the interaction between PCSK9 and LDLR. In a mouse model of hyperlipidemia (E3L.CETP mice; de ​​Knijff, Westerterp, Ason, van den Hoek, and Kühnast), CL-148219 reduced plasma non-HDL cholesterol better than the benchmark test Ab and with a longer duration of action. Figure 24-27 and Table 1.

[0659] CL-148219QLT mutant

[0660] By computer analysis of the sequence, an N-glycosylation motif was found in the heavy chain of CL-148219. The NLT motif, located in the framework 3 region of the heavy chain, can be glycosylated and can have an adverse effect on developability. It was later confirmed by mass spectrometry that the NLT motif in CL-148219 is in fact N-glycosylated. Therefore, we introduced a mutation into the NLT motif by replacing the N with a Q residue, thereby generating the CL-148219QLT mutant that disrupts glycosylation. The removal of glycosylation was further confirmed by mass spectrometry. When compared to the parental CL-148219, the CL-148219QLT mutant showed similar affinity and in vitro functionality. Similar to the parental CL-148219, in a hyperlipidemia mouse model (E3L.CETP mice), the QLT mutant lowered plasma non-HDL cholesterol better than the baseline, as well as with a longer duration of action. See Figure 27-31 and Table 1.

[0661] CL-148489

[0662] In an in vitro cell-based assay, CL-148489 moderately neutralized hPCSK9 but had a significant ability to restore LDL uptake, suggesting that this antibody may indirectly interfere with the binding of PCSK9 to the LDLR, possibly by blocking HSPG binding to PCSK9. In a mouse model of hyperlipidemia (E3L.CETP mice), this antibody also lowered plasma non-HDL cholesterol more potently than baseline, with a similar duration of action. See Figure 32-35 and Table 1.

[0663] CL-274698

[0664] Unlike CL-148219 and CL-148489, which are derived from mice with humanized antibody loci and without knockout of the PCSK9 gene, CL-274698 is derived from PCSK9 knockout mice. In the absence of PCSK9, the mice produce high affinity antibodies to the immunogen, including both human and mouse PCSK9. Therefore, CL-274698 was generated and screened. CL-274698 not only shows high affinity for PCSK9, with KD in the sub-nM range, but also exhibits excellent function of neutralizing hPCSK9 in vitro and restoring LDL absorption. In an in vivo efficacy study using E3L.CETP mice, CL-274698 reduced plasma non-HDL cholesterol greater than baseline within 3 days after Ab injection, with the fact that after day 7, the level of non-HDL cholesterol was similar to baseline. See Figure 36-39 and Table 1.

[0665] CL-274711

[0666] Similar to CL-274698, CL-274711 was generated by immunizing PCSK9 knockout mice. In an in vitro cell-based assay, CL-274711 neutralized hPCSK9 and restored LDL uptake better than the baseline. In an in vivo efficacy assay using E3L.CETP mice, CL-274711 showed slightly superior plasma non-HDL cholesterol lowering function and longer duration of action compared to the baseline. See Figure 40-43 and Table 1.

[0667] method

[0668] In vitro cell-based functional assays

[0669] 6×10 4 HepG2 cells were seeded into 96-well transparent flat-bottomed cell culture dishes (Costar) in complete medium containing 10% FBS, 1× penicillin / streptomycin and 1×NEAA in MEMα. To allow attachment, cells were cultured for 24 hours at 37°C in a 5% CO2 incubator. The next day, the culture medium was replaced with serum-free medium (MEMα containing 1×NEAA and 1× penicillin / streptomycin), and the cells were kept in the incubator overnight (16-18 hours). The next day, cells were treated with various concentrations of anti-PCSK9 monoclonal antibodies that had been pre-cultured with 5 μg / ml of hPCSK9 GOF antigen labeled with AF647. The antibody was diluted from 60 μg / ml using a 3-fold serial dilution. After incubation with hPCSK9GOF plus anti-PCSK9 antibody for 1 hour, BODIPY LDL (Invitrogen) was added to the cells at a final concentration of 10 μg / ml. LDL uptake was allowed by incubating the cells for an additional 3 hours. At the end of the treatment, cells were stripped by accutase (BD) and then fixed overnight at 4°C with 2% paraformaldehyde diluted in PBS (Alfa Aesar). After washing, cells were resuspended in PBS containing 5 mM EDTA and fluorescent cells were detected by CytoFlex flow cytometry.

[0670] ProteOn SPR Analysis

[0671] Using ProteOn TMXPR36 (Bio-Rad) was used to measure antibody binding affinities for antigens (human PCSK9 variants, cynomolgus PCSK9, and mouse PCSK9) in neutral (HBS-EP+, pH 7.6) and acidic buffers (30 mM sodium acetate, 150 mM NaCl, 0.05% P20, pH 5.8) at 25°C. SPR runs were performed using a GLC chip (Bio-Rad) immobilized with anti-human Fc antibodies. Analyte human antibodies were captured on the chip surface at 2 μg / ml. PCSK9 proteins at 100 nM, 25 nM, 6.25 nM, 1.56 nM, and 0.39 nM were injected for 180 seconds, and dissociation at a flow rate of 30 μL / min was monitored for 600 seconds. The chip surface was regenerated using two injections of 10 mM glycine pH 1.5 for 160 seconds at 30 μl / min. Next, the sensorgrams were fitted with a 1:1 model (Langmuir kinetic model), in which ka and kd were fitted, and KD was calculated by ProteOn software.

[0672] Table 1:

[0673]

[0674]

[0675] *1e-5 is the detection limit

[0676] **KD cannot be accurately determined.

[0677] Variable region sequence overview

[0678]

[0679]

[0680] Overview of constant region sequences

[0681]

[0682]

[0683]

[0684] sequence:

[0685] CL-148219

[0686] CL-148219 Heavy Chain

[0687] Variable region amino acid sequence (SEQ ID NO: 1)

[0688]

[0689] Variable region nucleotide sequence (SEQ ID NO: 2)

[0690] caggtgcacctgcaggagtcgggcccaggactggtgaagccttcggagaccctgtccctc

[0691] acgtgcactgtctctggtggctccatcagtagttactactggagctggatccggcagtac

[0692] ccaggaaagggactggagtggattggatatatctcttacagtgggagcagcaattataat

[0693] ccctccctcaagaggcgagtcaccatatcacgagacacgtccaagaaccagttctccctg

[0694] aatctgacctctgtaatcgctgcggacacggccgtttattactgtgcgagaaatcttatg

[0695] attcggggagcctacggcatggacgtctggggccaagggaccacggtcaccgtctcctca

[0696] FR1-IMGT amino acid sequence (SEQ ID NO: 5)

[0697] Q V H L Q E S G P G L V K P S E T L S L T C T V S FR1-IMGT nucleotide sequence (SEQ ID NO:6)

[0698] CAGGTGCACCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGT

[0699] CCCTCACGTGCACTGTCTCT CDR1-IMGT amino acid sequence (SEQ ID NO:7)

[0700] G G S I S S Y Y CDR1-IMGT nucleotide sequence (SEQ ID NO: 8)

[0701] GGTGGCTCCATCAGTAGTTACTAC FR2-IMGT amino acid sequence (SEQ ID NO:9)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0702] <h2 style=";text-align:left;direction:ltr"> WSWIRQYPGKGLEWIGY<h2 style=";text-align:left;direction:ltr"> FR2-IMGT nucleotide sequence (SEQ ID NO: 10) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0703] <h2 style=";text-align:left;direction:ltr"> TGGAGCTGGATCCGGCAGTACCCAGGAAAGGGACTGGAGTGGATTGGATAT<h2 style=";text-align:left;direction:ltr"> CDR2-IMGT amino acid sequence <h2 style=";text-align:left;direction:ltr"> Column(SEQ ID NO:11) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0704] <h2 style=";text-align:left;direction:ltr"> ISYSGSS<h2 style=";text-align:left;direction:ltr"> CDR2-IMGT nucleotide sequence (SEQ ID NO: 12) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0705] <h2 style=";text-align:left;direction:ltr"> ATCTCTTACAGTGGGAGCAGC<h2 style=";text-align:left;direction:ltr"> FR3-IMGT amino acid sequence (SEQ ID NO: 13) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0706] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0707] <h2 style=";text-align:left;direction:ltr"> FR3-IMGT nucleotide sequence (SEQ ID NO: 14) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0708] <h2 style=";text-align:left;direction:ltr"> AATTATAATCCCTCCCTCAAGAGGCGAGTCACCATATCACGAGACACGTCCAAGAA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0709] <h2 style=";text-align:left;direction:ltr"> CCAGTTCTCCCTGAATCTGACCTCTGTAATCGCTGCGGACACGGCCGTTATTACTGT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0710] <h2 style=";text-align:left;direction:ltr"> CDR3-IMGT amino acid sequence (SEQ ID NO: 15) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0711] <h2 style=";text-align:left;direction:ltr"> ARNLMIRGAYGMDV<h2 style=";text-align:left;direction:ltr"> CDR3-IMGT nucleotide sequence (SEQ ID NO: 16) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0712] <h2 style=";text-align:left;direction:ltr"> GCGAGAAATCTTATGATTCGGGGAGCCTACGGCATGGACGTC<h2 style=";text-align:left;direction:ltr"> FR4-IMGT amino acid sequence (SEQ ID <h2 style=";text-align:left;direction:ltr"> NO:17) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0713] <h2 style=";text-align:left;direction:ltr"> WGQGTTVTVSS<h2 style=";text-align:left;direction:ltr"> FR4-IMGT nucleotide sequence (SEQ ID NO: 18) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0714] <h2 style=";text-align:left;direction:ltr"> TGGGGCCAAGGGACCACGGTCACCGTCTCCTCA<h2 style=";text-align:left;direction:ltr"> FR1-KABAT amino acid sequence (SEQ ID NO: 19) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0715] <h2 style=";text-align:left;direction:ltr"> QVHLQESGPG LV KPSETLSLTCT VS GGSIS<h2 style=";text-align:left;direction:ltr"> FR1-KABAT nucleus <h2 style=";text-align:left;direction:ltr"> N-nucleotide sequence (SEQ ID NO: 20) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0716] <h2 style=";text-align:left;direction:ltr">CAGGTGCACCTGCAGGAGTCGGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0717] <h2 style=";text-align:left;direction:ltr"> CCCTCACGTGCACTGTCTCTGGTGGCTCCATCAGT<h2 style=";text-align:left;direction:ltr"> CDR1-KABAT amino acid sequence (SEQ ID NO:21) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0718] <h2 style=";text-align:left;direction:ltr"> SYYWS<h2 style=";text-align:left;direction:ltr"> CDR1-KABAT nucleotide sequence (SEQ ID NO: 22) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0719] <h2 style=";text-align:left;direction:ltr"> AGTTACTACTGGAGC<h2 style=";text-align:left;direction:ltr"> FR2-KABAT amino acid sequence (SEQ ID NO:23) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0720] <h2 style=";text-align:left;direction:ltr"> WIRQYPGKGLEWIG<h2 style=";text-align:left;direction:ltr"> FR2-KABAT nucleotide sequence (SEQ ID NO:24) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0721] <h2 style=";text-align:left;direction:ltr"> TGGATCCGGCAGTACCCAGGAAAGGGACTGGAGTGGATTGGA<h2 style=";text-align:left;direction:ltr"> CDR2-KABAT amino acid sequence (SEQ ID <h2 style=";text-align:left;direction:ltr"> NO:25) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0722] <h2 style=";text-align:left;direction:ltr"> YISYSGSSNYNPSLKR<h2 style=";text-align:left;direction:ltr"> CDR2-KABAT nucleotide sequence (SEQ ID NO: 26) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0723] <h2 style=";text-align:left;direction:ltr"> TATATCTCTTACAGTGGGAGCAGCAATTATAATCCCTCCCTCAAGAGG<h2 style=";text-align:left;direction:ltr"> FR3-KABAT amino acid sequence <h2 style=";text-align:left;direction:ltr"> (SEQ ID NO:27) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0724] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0725] <h2 style=";text-align:left;direction:ltr"> FR3-KABAT nucleotide (SEQ ID NO:28) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0726] <h2 style=";text-align:left;direction:ltr"> CGAGTCACCATATCACGAGACACGTCCAAGAACCAGTTCTCCCTGAATCTGACCTC TGTAATCGCTGCGGACACGGCCGTTTATTACTGTGCGAGA<h2 style=";text-align:left;direction:ltr"> CDR3-KABAT amino acid sequence (SEQ ID NO: 29) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0727] <h2 style=";text-align:left;direction:ltr"> NLMIRGAYGMDV<h2 style=";text-align:left;direction:ltr"> CDR3-KABAT nucleotide sequence (SEQ ID NO:30) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0728] <h2 style=";text-align:left;direction:ltr"> AATCTTATGATTCGGGGAGCCTACGGCATGGACGTC<h2 style=";text-align:left;direction:ltr"> FR4-KABAT amino acid sequence (SEQ ID NO: <h2 style=";text-align:left;direction:ltr"> 31) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0729] <h2 style=";text-align:left;direction:ltr"> WGQGTTVTVSS<h2 style=";text-align:left;direction:ltr"> FR4-KABAT nucleotide sequence (SEQ ID NO:32) <h2 style=";text-align:left;direction:ltr">

[0730] TGGGGCCAAGGGACCACGGTCACCGTCTCCTCA CL-148219 Light Chain Kappa

[0731] Variable region amino acid sequence (SEQ ID NO: 33)

[0732]

[0733] Variable region nucleotide sequence (SEQ ID NO: 34)

[0734] gatactgtgatgactcagtctccactctccctgcccgtcacccctggagagccggcctcc

[0735] atctcctgcaggtctagtcagagcctcctgcatagtaatggatacaattatttggattgg

[0736] tacctgcagaaggcaggacagtctccacaactcctgatctatttgggttctaatcgggcc

[0737] tccggggtccctgacaggttcagtggcagtgtatcaggcacagatttcacactgaaaatc

[0738] agcagagtggaggctgaggatgttgggatttattactgcatgcaagctctacaaactcca

[0739] ttcactttcggccctgggaccaaagtggatatcaaa C region amino acid sequence (SEQ ID NO:35)

[0740]

[0741] C region nucleotide sequence (SEQ ID NO: 36)

[0742] cgtacggtggccgctccctccgtgttcatcttcccaccttccgacgagcagctgaagtcc

[0743] ggcaccgcttctgtcgtgtgcctgctgaacaacttctacccccgcgaggccaaggtgcag

[0744] <h2 style=";text-align:left;direction:ltr">tggaaggtggacaacgccctgcagtccggcaactcccaggaatccgtgaccgagcaggac<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0745] <h2 style=";text-align:left;direction:ltr"> tccaaggacagcacctactccctgtcctccaccctgaccctgtccaaggccgactacgag<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0746] <h2 style=";text-align:left;direction:ltr"> aagcacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaag<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0747] <h2 style=";text-align:left;direction:ltr"> tctttcaaccggggcgagtgt<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0748] <h2 style=";text-align:left;direction:ltr"> FR1-IMGT amino acid sequence (SEQ ID NO: 37) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0749] <h2 style=";text-align:left;direction:ltr"> DTVMTQSPLSLPVTPGEPASI SCRSS<h2 style=";text-align:left;direction:ltr"> FR1-IMGT nucleotide sequence <h2 style=";text-align:left;direction:ltr"> Column (SEQ ID NO:38) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0750] <h2 style=";text-align:left;direction:ltr"> GATACTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCGGCCTCCATCTCCTGCAGGTCTAGT<h2 style=";text-align:left;direction:ltr"> CDR1-IMGT amino acid sequence (SEQ ID NO: 39) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0751] <h2 style=";text-align:left;direction:ltr"> QSLLHSNGYNY<h2 style=";text-align:left;direction:ltr"> CDR1-IMGT nucleotide sequence (SEQ ID NO:40) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0752] <h2 style=";text-align:left;direction:ltr"> CAGAGCCTCCTGCATAGTAATGGATACAATTAT<h2 style=";text-align:left;direction:ltr"> FR2-IMGT amino acid sequence (SEQ ID NO:41) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0753] <h2 style=";text-align:left;direction:ltr"> LDWYLQKAGQSPQLLIY<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0754] <h2 style=";text-align:left;direction:ltr"> FR2-IMGT nucleotide sequence (SEQ ID NO:42) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0755] <h2 style=";text-align:left;direction:ltr"> TTGGATTGGTACCTGCAGAAGGCAGGACAGTCTCCACAACTCCTGATCTAT<h2 style=";text-align:left;direction:ltr"> CDR2-IMGT amino acid sequence <h2 style=";text-align:left;direction:ltr"> Column (SEQ ID NO:43) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0756] <h2 style=";text-align:left;direction:ltr"> LGS<h2 style=";text-align:left;direction:ltr"> CDR2-IMGT nucleotide sequence (SEQ ID NO:44) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0757] <h2 style=";text-align:left;direction:ltr"> TTGGGTTCT<h2 style=";text-align:left;direction:ltr"> FR3-IMGT amino acid sequence (SEQ ID NO:45) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0758] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0759] <h2 style=";text-align:left;direction:ltr"> FR3-IMGT nucleotide sequence (SEQ ID NO:46) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0760] <h2 style=";text-align:left;direction:ltr"> AATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGTATCAGGCACAGATTT CACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGATTTATTACTGC<h2 style=";text-align:left;direction:ltr"> CDR3-IMGT amino acid sequence (SEQ ID NO:47) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0761] <h2 style=";text-align:left;direction:ltr"> MQ AL QTPFT<h2 style=";text-align:left;direction:ltr"> CDR3-IMGT nucleotide sequence (SEQ ID NO:48) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0762] <h2 style=";text-align:left;direction:ltr"> ATGCAAGCTCTACAAACTCCATTCACT<h2 style=";text-align:left;direction:ltr"> FR4-IMGT amino acid sequence (SEQ ID NO:49) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0763] <h2 style=";text-align:left;direction:ltr"> FGPGTKVDIK<h2 style=";text-align:left;direction:ltr"> FR4-IMGT nucleotide sequence (SEQ ID NO: 50) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0764] <h2 style=";text-align:left;direction:ltr"> TTCGGCCCTGGGACCAAAGTGGATATCAAA<h2 style=";text-align:left;direction:ltr"> FR1-KABAT amino acid sequence (SEQ ID NO:51) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0765] <h2 style=";text-align:left;direction:ltr"> DTVMTQSPLSLPVTPGEPASI SC<h2 style=";text-align:left;direction:ltr"> FR1-KABAT nucleotide sequence (SEQ <h2 style=";text-align:left;direction:ltr"> ID NO:52) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0766] <h2 style=";text-align:left;direction:ltr"> GATACTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCGGCCTCCATCTCCTGC<h2 style=";text-align:left;direction:ltr"> CDR1-KABAT amino acid sequence (SEQ ID NO:53) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0767] <h2 style=";text-align:left;direction:ltr"> RSSQSLLHSNGYNYLD<h2 style=";text-align:left;direction:ltr"> CDR1-KABAT nucleotide sequence (SEQ ID NO:54) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0768] <h2 style=";text-align:left;direction:ltr"> AGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAATTATTTTGGAT<h2 style=";text-align:left;direction:ltr"> FR2-KABAT amino acid sequence <h2 style=";text-align:left;direction:ltr"> (SEQ ID NO:55) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0769] <h2 style=";text-align:left;direction:ltr"> WYLQKAGQSPQLLIY<h2 style=";text-align:left;direction:ltr"> FR2-KABAT nucleotide sequence (SEQ ID NO:56) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0770] <h2 style=";text-align:left;direction:ltr"> TGGTACCTGCAGAAGGCAGGAACAGTCTCCACAACTCCTGATCTAT<h2 style=";text-align:left;direction:ltr"> CDR2-KABAT amino acid sequence <h2 style=";text-align:left;direction:ltr"> (SEQ ID NO:57) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0771] L G S N R AS CDR2-KABAT nucleotide sequence (SEQ ID NO:58)

[0772] TTGGGTTCTAATCGGGCCTCC FR3-KABAT amino acid sequence (SEQ ID NO:59)

[0773]

[0774] FR3-KABAT nucleotide sequence (SEQ ID NO:60)

[0775] GGGGTCCCTGACAGGTTCAGTGGCAGTGTATCAGGCACAGATTTCACACTGAAAAT CAGCAGAGTGGAGGCTGAGGATGTTGGGATTTATTACTGC CDR3-KABAT amino acid sequence (SEQ ID NO:61)

[0776] M Q AL Q T P F T CDR3-KABAT nucleotide sequence (SEQ ID NO:62)

[0777] ATGCAAGCTCTACAAACTCCATTCACT FR4-KABAT amino acid sequence (SEQ ID NO:63)

[0778] F G P G T K V D I K FR4-KABAT nucleotide sequence (SEQ ID NO:64)

[0779] TTCGGCCCTGGGACCAAAGTGGATATCAAA

[0780] CL-148489

[0781] CL-148489 Heavy Chain

[0782] Variable region amino acid sequence (SEQ ID NO: 65)

[0783]

[0784] Variable region nucleotide sequence (SEQ ID NO: 66)

[0785] gaagtgcagctggtagagtctgggggaggcttggtacagcctggcaggtccctgagactc

[0786] tcctgtacagcctctggattcacctttgctgattatgtcatgcactgggtccggcaaact

[0787] ccagggaagggcctggagtgggtctcaggtattagttggaatagttatagtataaattat

[0788] gcggactctgtgaagggccgattcaccatctccagagacaacgcccagaactccctgtat

[0789] ctgcaaatgaacagtctgagagctgaggacacggccttgtatttttgtgcaaaagatata

[0790] acttacgatcttttgactggttataactacaactacggtttagacgtctggggccaaggg

[0791] accacggtcaccgtctcctca FR1-IMGT amino acid sequence (SEQ ID NO:67)

[0792]

[0793] FR1-IMGT nucleotide sequence (SEQ ID NO:68)

[0794] GAAGTGCAGCTGGTAGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTACAGCCTCT CDR1-IMGT amino acid sequence (SEQ ID NO: 69)

[0795] G F T F AD Y V

[0796] CDR1-IMGT nucleotide sequence (SEQ ID NO:70)

[0797] GGATTCACCTTTGCTGATTATGTC FR2-IMGT amino acid sequence (SEQ ID NO:71)

[0798] M H W V R Q T P G K G L E W V S G FR2-IMGT nucleotide sequence (SEQ ID NO:72)

[0799] ATGCACTGGGTCCGGCAAACTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGT CDR2-IMGT amino acid sequence Column (SEQ ID NO:73)

[0800] I S W N S Y S I CDR2-IMGT nucleotide sequence (SEQ ID NO: 74)

[0801] ATTAGTTGGAATAGTTATAGTATA FR3-IMGT amino acid sequence (SEQ ID NO:75)

[0802]

[0803] <h2 style=";text-align:left;direction:ltr"> FR3-IMGT nucleotide sequence (SEQ ID NO:76) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0804] <h2 style=";text-align:left;direction:ltr"> AATTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCCAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCTTGTATTTTTGT<h2 style=";text-align:left;direction:ltr"> CDR3-IMGT amino acid sequence (SEQ ID NO: <h2 style=";text-align:left;direction:ltr"> 77) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0805] <h2 style=";text-align:left;direction:ltr"> AKDITYDLLTGYNYNYGLDV<h2 style=";text-align:left;direction:ltr"> CDR3-IMGT nucleotide sequence (SEQ ID NO: <h2 style=";text-align:left;direction:ltr"> 78) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0806] <h2 style=";text-align:left;direction:ltr"> GCAAAAGATATAACTTACGATCTTTTGACTGGTTATAACTACAACTACGGTTTAGAC GTC<h2 style=";text-align:left;direction:ltr"> FR4-IMGT <h2 style=";text-align:left;direction:ltr"> Amino acid sequence (SEQ ID NO:79) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0807] <h2 style=";text-align:left;direction:ltr"> WGQGTTVTVSS<h2 style=";text-align:left;direction:ltr"> FR4-IMGT nucleotide sequence (SEQ ID NO:80) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0808] <h2 style=";text-align:left;direction:ltr"> TGGGGCCAAGGGACCACGGTCACCGTCTCCTCA<h2 style=";text-align:left;direction:ltr"> FR1-KABAT amino acid sequence (SEQ ID NO:81) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0809] <h2 style=";text-align:left;direction:ltr"> EVQLVESGGGLVQPGRSLRLS CT AS GFTFA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0810] <h2 style=";text-align:left;direction:ltr"> FR1-KABAT nucleotide sequence (SEQ ID NO:82) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0811] <h2 style=";text-align:left;direction:ltr"> GAAGTGCAGCTGGTAGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGA GACTCTCCTGTACAGCCTCTGGATTCACCTTTGCT<h2 style=";text-align:left;direction:ltr"> CDR1-KABAT amino acid sequence (SEQ ID NO:83) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0812] <h2 style=";text-align:left;direction:ltr"> DYVMH<h2 style=";text-align:left;direction:ltr"> CDR1-KABAT nucleotide sequence (SEQ ID NO:84) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0813] <h2 style=";text-align:left;direction:ltr"> GATTATGTCATGCAC<h2 style=";text-align:left;direction:ltr"> FR2-KABAT amino acid sequence (SEQ ID NO:85) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0814] <h2 style=";text-align:left;direction:ltr"> WVRQTPGKGLEWVS<h2 style=";text-align:left;direction:ltr"> FR2-KABAT nucleotide sequence (SEQ ID NO:86) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0815] <h2 style=";text-align:left;direction:ltr">TGGGTCCGGCAAACTCCAGGGAAAGGGCCTGGAGTGGGTCTCA<h2 style=";text-align:left;direction:ltr"> CDR2-KABAT amino acid sequence (SEQ <h2 style=";text-align:left;direction:ltr"> ID NO:87) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0816] <h2 style=";text-align:left;direction:ltr"> GISWNSYSINYADSVKG<h2 style=";text-align:left;direction:ltr"> CDR2-KABAT nucleotide sequence (SEQ ID NO: 88) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0817] <h2 style=";text-align:left;direction:ltr"> GGTATTAGTTGGAATAGTTATAGTATAAATTATGCGGACTCTGTGAAGGGC<h2 style=";text-align:left;direction:ltr"> FR3-KABAT amino acid sequence <h2 style=";text-align:left;direction:ltr"> Column (SEQ ID NO:89) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0818] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0819] <h2 style=";text-align:left;direction:ltr"> FR3-KABAT nucleotide sequence (SEQ ID NO:90) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0820] <h2 style=";text-align:left;direction:ltr"> CGATTCACCATCTCCAGAGACAACGCCCAGAACTCCCTGTATCTGCAAATGAACAG TCTGAGAGCTGAGGACACGGCCTTGTATTTTTGTGCAAAA<h2 style=";text-align:left;direction:ltr"> CDR3-KABAT amino acid sequence (SEQ ID NO:91) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0821] <h2 style=";text-align:left;direction:ltr"> DITYDLLTGYNYNYGLDV<h2 style=";text-align:left;direction:ltr"> CDR3-KABAT nucleotide sequence (SEQ ID NO:92) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0822] <h2 style=";text-align:left;direction:ltr"> GATATAACTTACGATCTTTTGACTGGTTATAACTACAACTACGGTTTAGACGTC<h2 style=";text-align:left;direction:ltr"> FR4-KABAT amino <h2 style=";text-align:left;direction:ltr"> Acid sequence (SEQ ID NO:93) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0823] <h2 style=";text-align:left;direction:ltr"> WGQGTTVTVSS<h2 style=";text-align:left;direction:ltr"> FR4-KABAT nucleotide sequence (SEQ ID NO:94) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0824] <h2 style=";text-align:left;direction:ltr"> TGGGGCCAAGGGACCACGGTCACCGTCTCCTCA<h2 style=";text-align:left;direction:ltr"> CL-148489 Light Chain Kappa <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0825] <h2 style=";text-align:left;direction:ltr"> Variable region amino acid sequence (SEQ ID NO:95) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0826] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0827] <h2 style=";text-align:left;direction:ltr"> Variable region nucleotide sequence (SEQ ID NO:96) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0828] <h2 style=";text-align:left;direction:ltr"> gatattgtgatgacccagactccactctctctgtccgtcacccctggacagccggcctcc<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0829] atctcctgcaggtctagtcagagcctcctacatagtgatggaaagacctatttgtattgg

[0830] tacctgcagaagcccggccagcctccacagctcctgatctatgaagtttccaaccgtttc

[0831] tctggagtgccagataggttcagtggcagcgggtcagggacagatttcacactgaagatc

[0832] agccgggtggaggctgaagatgttggcctttattactgcatgcaaagtatacagcttccg

[0833] ctcactttcggcggagggaccaaggtagagatcaaa FR1-IMGT amino acid sequence (SEQ ID NO:97)

[0834]

[0835] FR1-IMGT nucleotide sequence (SEQ ID NO:98)

[0836] GATATTGTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCCTGGACAGCCGGCCTCCATCTCCTGCAGGTCTAGT CDR1-IMGT amino acid sequence (SEQ ID NO:99)

[0837] Q S L L H SD G K T Y CDR1-IMGT nucleotide sequence (SEQ ID NO: 100)

[0838] CAGAGCCTCCTACATAGTGATGGAAAGACCTAT FR2-IMGT amino acid sequence (SEQ ID NO: 101)

[0839] L Y W Y L Q K P G Q P P Q L L I Y FR2-IMGT nucleotide sequence (SEQ ID NO: 102)

[0840] TTGTATTGGTACCTGCAGAAGCCCGGCCAGCCTCCACAGCTCCTGATCTAT CDR2-IMGT amino acid sequence Column (SEQ ID NO:103)

[0841] E V S CDR2-IMGT nucleotide sequence (SEQ ID NO: 104)

[0842] GAAGTTTCC FR3-IMGT amino acid sequence (SEQ ID NO: 105) <h2 style=";text-align:left;direction:ltr">

[0843] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0844] <h2 style=";text-align:left;direction:ltr"> FR3-IMGT nucleotide sequence (SEQ ID NO: 106) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0845] <h2 style=";text-align:left;direction:ltr"> AACCGTTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGACAGATTT CACACTGAAGATCAGCCGGGTGGAGGCTGAAGATTGTTGGCCTTTATTACTGC<h2 style=";text-align:left;direction:ltr"> CDR3-IMGT amino acid sequence (SEQ ID NO: 107) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0846] <h2 style=";text-align:left;direction:ltr"> MQS IQ LPLT<h2 style=";text-align:left;direction:ltr"> CDR3-IMGT nucleotide sequence (SEQ ID NO: 108) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0847] <h2 style=";text-align:left;direction:ltr"> ATGCAAAGTATACAGCTTCCGCTCACT<h2 style=";text-align:left;direction:ltr"> FR4-IMGT amino acid sequence (SEQ ID NO: 109) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0848] <h2 style=";text-align:left;direction:ltr"> FGGGTKVEIK<h2 style=";text-align:left;direction:ltr"> FR4-IMGT nucleotide sequence (SEQ ID NO: 110) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0849] <h2 style=";text-align:left;direction:ltr"> TTCGGCGGAGGGACCAAGGTAGAGATCAAA<h2 style=";text-align:left;direction:ltr"> FR1-KABAT amino acid sequence (SEQ ID NO: 111) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0850] <h2 style=";text-align:left;direction:ltr"> DIVMTQTPLSLSVTPGQPASI SC<h2 style=";text-align:left;direction:ltr"> FR1-KABAT nucleotide sequence (SEQ <h2 style=";text-align:left;direction:ltr"> ID NO:112) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0851] <h2 style=";text-align:left;direction:ltr"> GATATTGTGATGACCCAGACTCCACTCTCTCTTGTCCGTCACCCCTGGACAGCCGGCCTCCATCTCCTGC<h2 style=";text-align:left;direction:ltr"> CDR1-KABAT amino acid sequence (SEQ ID NO: 113) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0852] <h2 style=";text-align:left;direction:ltr"> RSSQSLLH SD GKTYLY<h2 style=";text-align:left;direction:ltr"> CDR1-KABAT nucleotide sequence (SEQ ID NO: 114) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0853] <h2 style=";text-align:left;direction:ltr"> AGGTCTAGTCAGAGCCTCCTACATAGTGATGGAAAGACCTATTTGTAT<h2 style=";text-align:left;direction:ltr"> FR2-KABAT amino acid sequence <h2 style=";text-align:left;direction:ltr"> (SEQ ID NO:115) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0854] <h2 style=";text-align:left;direction:ltr"> WYLQKPGQPPQLLIY<h2 style=";text-align:left;direction:ltr"> FR2-KABAT nucleotide sequence (SEQ ID NO: 116) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0855] <h2 style=";text-align:left;direction:ltr"> TGGTACCTGCAGAAGCCCGGCCAGCCTCCACAGCTCCTGATCTAT<h2 style=";text-align:left;direction:ltr"> CDR2-KABAT amino acid sequence <h2 style=";text-align:left;direction:ltr"> (SEQ ID NO:117)

[0856] E V S N R F S CDR2-KABAT nucleotide sequence (SEQ ID NO: 118)

[0857] GAAGTTTCCAACCGTTTCTCT FR3-KABAT amino acid sequence (SEQ ID NO: 119)

[0858]

[0859] FR3-KABAT nucleotide sequence (SEQ ID NO: 120)

[0860] GGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGACAGATTTCACACTGAAGA TCAGCCGGGTGGAGGCTGAAGATGTTGGCCTTTATTACTGC CDR3-KABAT amino acid sequence (SEQ ID NO: 121)

[0861] M Q S IQ L P L T CDR3-KABAT nucleotide sequence (SEQ ID NO: 122)

[0862] ATGCAAAGTATACAGCTTCCGCTCACT FR4-KABAT amino acid sequence (SEQ ID NO: 123)

[0863] F G G G T K V E I K FR4-KABAT nucleotide sequence (SEQ ID NO: 124) TTCGGCGGAGGGACCAAGGTAGAGATCAAA

[0864] CL-274698

[0865] CL-274698 Heavy Chain

[0866] Variable region amino acid sequence (SEQ ID NO: 199)

[0867]

[0868] Variable region nucleotide sequence (SEQ ID NO: 200)

[0869]

[0870] FR1-IMGT amino acid sequence (SEQ ID NO: 201)

[0871] QVQLQESGPG LVKPSGTLSL TCAVS FR1-IMGT nucleotide sequence (SEQ ID NO: : 202)

[0872] CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGGGACCCTGTCCCTCACCTGCGCTGTCTCT CDR1-IMGT amino acid sequence (SEQ ID NO: 203)

[0873] GGSIS SSKW CDR1-IMGT nucleotide sequence (SEQ ID NO: 204)

[0874] GGTGGCTCCATCAGCAGTAGTAAATGG FR2-IMGT amino acid sequence (SEQ ID NO: 205)

[0875] WSWVRQ PPGKGLEWIG E FR2-IMGT nucleotide sequence (SEQ ID NO: 206)

[0876] TGGAGTTGGGTCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGGAA CDR2-IMGT amino acid sequence Column (SEQ ID NO:207)

[0877] THYSGST CDR2-IMGT nucleotide sequence (SEQ ID NO: 208)

[0878] ACCCATTATAGTGGGAGCACC FR3-IMGT amino acid sequence (SEQ ID NO: 209)

[0879] NY NPSLKSRVTI SVDKSKNQFS LKLRSVTAAD TAVYYC FR3-IMGT nucleotide sequence (SEQ ID NO:210)

[0880] AACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACAAGTCCAAGAA

[0881] CCAGTTCTCCCTGAAGCTGAGGTCTGTGACCGCCGCGGACACGGCCGTTTATTACT

[0882] GT CDR3-IMGT amino acid sequence (SEQ ID NO: 211)

[0883] ARVGATENF CDR3-IMGT nucleotide sequence (SEQ ID NO: 212)

[0884] GCGAGAGTGGGTGCTACTGAGAACTTC FR4-IMGT amino acid sequence (SEQ ID NO: 213)

[0885] WGQGT LVTVSS FR4-IMGT nucleotide sequence (SEQ ID NO: 214)

[0886] TGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG FR1-KABAT amino acid sequence (SEQ ID NO: 215)

[0887] QVQLQESGPG LVKPSGTLSL TCAVSGGSIS FR1-KABAT nucleotide sequence (SEQ ID NO: 216)

[0888] CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGGGACCCTGT CCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGC CDR1-KABAT amino acid sequence (SEQ ID NO: 217)

[0889] SSKWWS CDR1-KABAT nucleotide sequence (SEQ ID NO: 218)

[0890] AGTAGTAAATGGTGGAGT FR2-KABAT amino acid sequence (SEQ ID NO: 219)

[0891] WVRQ PPGKGLEWIG FR2-KABAT nucleotide sequence (SEQ ID NO: 220)

[0892] TGGGTCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGG CDR2-KABAT amino acid sequence (SEQ ID NO:221)

[0893] ETHYSGSTNY NPSLKS CDR2-KABAT nucleotide sequence (SEQ ID NO: 222)

[0894] GAAACCCATTATAGTGGGAGCACCAACTACAACCCGTCCCTCAAGAGT FR3-KABAT amino acid sequence (SEQ ID NO:223)

[0895] RVTI SVDKSKNQFS LKLRSVTAAD TAVYYCAR FR3-KABAT nucleotide sequence (SEQ ID NO: 224)

[0896] CGAGTCACCATATCAGTAGACAAGTCCAAGAACCAGTTCTCCCTGAAGCTGAGGTCTGTGACCGCGCGGACAGGCCGTTTATTACTGTGCGAGA CDR3-KABAT amino acid sequence (SEQ ID NO: 225)

[0897] VGATENF CDR3-KABAT nucleotide sequence (SEQ ID NO: 226)

[0898] GTGGGTGCTAGAACTTC FR4-KABAT amino acid sequence (SEQ ID NO: 227)

[0899] WGQGT LVTVSS FR4-KABAT nucleotide sequence (SEQ ID NO: 228)

[0900] TGGGGCCAGGAACCCTGGTCACCGTCTCCTCAG CL-274698 Light Chain Kappa

[0901] Variable region amino acid sequence (SEQ ID NO: 229)

[0902]

[0903] Variable region nucleotide sequence (SEQ ID NO: 230)

[0904]

[0905] FR1-IMGT amino acid sequence (SEQ ID NO: 231)

[0906] EIVLTQSPAT LSLSPGERAT LSCRAS FR1-IMGT nucleotide sequence (SEQ ID NO: 232)

[0907] GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGT CDR1-IMGT amino acid sequence (SEQ ID NO: 233)

[0908] QSVF RY CDR1-IMGT nucleotide sequence (SEQ ID NO: 234)

[0909] CAGAGTGTTTTCAGGTAC FR2-IMGT amino acid sequence (SEQ ID NO: 235)

[0910] LAWYQQKP GQAPRLLIY FR2-IMGT nucleotide sequence (SEQ ID NO: 236)

[0911] TTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT CDR2-IMGT amino acid sequence Column (SEQ ID NO:237)

[0912] D AS CDR2-IMGT nucleotide sequence (SEQ ID NO: 238)

[0913] GATGCATCC FR3-IMGT amino acid sequence (SEQ ID NO: 239)

[0914] TRATDIPARFSGSGSGTD FTLTISSLEP EDFAVYYC FR3-IMGT nucleotide sequence (SEQ ID NO: 240)

[0915] ACCAGGGCCACTGACATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGT CDR3-IMGT amino acid sequence (SEQ ID NO: 241)

[0916] QQ RSNWPPT CDR3-IMGT nucleotide sequence (SEQ ID NO: 242)

[0917] CAGCAACGTAGCAACTGGCCTCCGACG FR4-IMGT amino acid sequence (SEQ ID NO: 243)

[0918] FGQ GTKVEIK FR4-IMGT nucleotide sequence (SEQ ID NO: 244)

[0919] TTCGGCCAAGGGACCAAGGTGGAAATCAAA FR1-KABAT amino acid sequence (SEQ ID NO: 245)

[0920] EIVLTQSPAT LSLSPGERAT LSC FR1-KABAT nucleotide sequence (SEQ ID NO: 246)

[0921] GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGC CDR1-KABAT amino acid sequence (SEQ ID NO: 247)

[0922] RASQSVF RYLA CDR1-KABAT nucleotide sequence (SEQ ID NO: 248)

[0923] AGGGCCAGTCAGAGTGTTTTCAGGTACTTAGCC FR2-KABAT amino acid sequence (SEQ ID NO: 249)

[0924] WYQQKP GQAPRLLIY FR2-KABAT nucleotide sequence (SEQ ID NO: 250)

[0925] TGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT CDR2-KABAT amino acid sequence (SEQ ID NO:251)

[0926] It's ASTRATE CDR2-KABAT nucleotide sequence (SEQ ID NO: 252)

[0927] GATGCATCCCACCAGGGCCACT FR3-KABAT amino acid sequence (SEQ ID NO: 253)

[0928] DIPA RFSGSGSGTD FTLTISSLEP EDFAVYYC FR3-KABAT nucleotide sequence (SEQ ID NO: 254)

[0929] GACATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGT CDR3-KABAT amino acid sequence (SEQ ID NO: 255)

[0930] QQ RSNWPPT CDR3-KABAT nucleotide sequence (SEQ ID NO: 256)

[0931] CAGCAACGTAGCAACTGGCCTCCGACG FR4-KABAT amino acid sequence (SEQ ID NO: 257)

[0932] FGQ GTKVEIK FR4-KABAT nucleotide sequence (SEQ ID NO: 258)

[0933] TTCGGCCAAGGGACCAAGGTGGAAATCAAA

[0934] CL-274711

[0935] CL-274711 heavy chain

[0936] Variable region amino acid sequence (SEQ ID NO: 259)

[0937]

[0938] Variable region nucleotide sequence (SEQ ID NO: 260)

[0939]

[0940] FR1-IMGT amino acid sequence (SEQ ID NO: 261)

[0941] QVQLQESGPG LVKPSQTLSL TCTVS FR1-IMGT nucleotide sequence (SEQ ID NO: 262)

[0942] CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCACTGTCTCT CDR1-IMGT amino acid sequence (SEQ ID NO: 263)

[0943] GGSIS SGGYY CDR1-IMGT nucleotide sequence (SEQ ID NO: 264)

[0944] GGTGGCTCCATCAGCAGTGGTGGTTACTAC FR2-IMGT amino acid sequence (SEQ ID NO: 265)

[0945] WSWIR QHPGKGLEWI GH FR2-IMGT nucleotide sequence (SEQ ID NO: 266)

[0946] TGGAGCTGGATCCGCCAGCACCCAGGGAAGGGCCTGGAGTGGATTGGGCAC CDR2-IMGT amino acid sequence Column (SEQ ID NO:267)

[0947] IFYSGST CDR2-IMGT nucleotide sequence (SEQ ID NO: 268)

[0948] ATCTTTTACAGTGGGAGCACC FR3-IMGT amino acid sequence (SEQ ID NO: 269)

[0949] Y YNPSLKSRVT ISVDTSKNQF SLKLNSVTAADTAVYYC FR3-IMGT nucleotide sequence (SEQ ID NO:270)

[0950] TACTACAACCCGTCCCTCAAGAGTCGAGTTACCATATCAGTTGACACGTCTAAGAA

[0951] CCAGTTCTCCCTGAAGCTGAACTCTGTGACTGCCGCGGACACGGCCGTGTATTACT

[0952] GT CDR3-IMGT amino acid sequence (SEQ ID NO: 271)

[0953] BELOW GGYYDIPDV CDR3-IMGT nucleotide sequence (SEQ ID NO: 272)

[0954] GCGAGCGAGGGAGGGTATTACGATTTCCGGACGTC FR4-IMGT amino acid sequence (SEQ ID NO: 273)

[0955] W GQGTTVTVSS FR4-IMGT nucleotide sequence (SEQ ID NO: 274)

[0956] TGGGGCCAAGGGACCACGGTCACCGTCCCTCCA FR1-KABAT amino acid sequence (SEQ ID NO: 275)

[0957] QVQLQESGPG LVKPSQTLSL TCTVSGGSIS FR1-KABAT nucleotide sequence (SEQ ID NO: 276)

[0958] CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGC CDR1-KABAT amino acid sequence (SEQ ID NO: 277)

[0959] SGGYYWS CDR1-KABAT nucleotide sequence (SEQ ID NO: 278)

[0960] AGTGGTGGTTACTACTGGAGC FR2-KABAT amino acid sequence (SEQ ID NO: 279)

[0961] WIR QHPGKGLEWI G FR2-KABAT nucleotide sequence (SEQ ID NO: 280)

[0962] TGGATCCGCCAGCCACCCAGGGAAGGGCCTGGAGTGGATTGGG CDR2-KABAT amino acid sequence (SEQ ID NO:281)

[0963] HIFYSGSTY YNPSLKS CDR2-KABAT nucleotide sequence (SEQ ID NO: 282)

[0964] CACATCTTTTACAGTGGGAGCACCTACTACAACCCGTCCCTCAAGAGT FR3-KABAT amino acid sequence (SEQ ID NO:283)

[0965] RVT ISVDTSKNQF SLKLNSVTAADTAVYYCAS FR3-KABAT nucleotide sequence (SEQ ID NO: 284)

[0966] CGAGTTACCATATCAGTTGACACGTCTAAAGAACCAGTTCTCCCTGAAGCTGAACTCTGTGACTGCCGCGGACACGGCCGTGTGTATTACTGTGCGAGC CDR3-KABAT amino acid sequence (SEQ ID NO: 285)

[0967] E GGYYDIPDV CDR3-KABAT nucleotide sequence (SEQ ID NO:286)

[0968] GAGGGAGGGTATTACGATATTCCGGACGTC FR4-KABAT amino acid sequence (SEQ ID NO: 287)

[0969] W GQGTTVTVSS FR4-KABAT nucleotide sequence (SEQ ID NO: 288)

[0970] TGGGGCCAAGGGACCACGGTCACCGTCTCCTCA CL-274711 Light Chain Kappa

[0971] Variable region amino acid sequence (SEQ ID NO: 289)

[0972]

[0973] Variable region nucleotide sequence (SEQ ID NO: 290)

[0974]

[0975] FR1-IMGT amino acid sequence (SEQ ID NO: 291)

[0976] EIVLTQSPAT LSLSPGERAT LSCRAS FR1-IMGT nucleotide sequence (SEQ ID NO: 292)

[0977] GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGT CDR1-IMGT amino acid sequence (SEQ ID NO: 293)

[0978] QSVS NY CDR1-IMGT nucleotide sequence (SEQ ID NO: 294)

[0979] CAGAGTGTTAGCAACTAC FR2-IMGT amino acid sequence (SEQ ID NO: 295)

[0980] LAWYQQKP GQAPRLLIS FR2-IMGT nucleotide sequence (SEQ ID NO: 236)

[0981] TTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTCT CDR2-IMGT amino acid sequence Column (SEQ ID NO:297)

[0982] D AS CDR2-IMGT nucleotide sequence (SEQ ID NO: 298)

[0983] GATGCATCC FR3-IMGT amino acid sequence (SEQ ID NO: 299)

[0984] NRATGIPARFSGSGSGTD FTLTISSLEP EDFAIYYC FR3-IMGT nucleotide sequence (SEQ ID NO: 300)

[0985] AACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAATTTATTACTGT CDR3-IMGT amino acid sequence (SEQ ID NO: 301)

[0986] QQ RSNWPLT CDR3-IMGT nucleotide sequence (SEQ ID NO: 302)

[0987] CAGCAGCGTAGCAACTGGCCGCTCACT FR4-IMGT amino acid sequence (SEQ ID NO: 303)

[0988] FGG GTKVEIK FR4-IMGT nucleotide sequence (SEQ ID NO: 304)

[0989] TTCGGCGGAGGGACCAAGGTGGAGATCAAA FR1-KABAT amino acid sequence (SEQ ID NO:305)

[0990] EIVLTQSPAT LSLSPGERAT LSC FR1-KABAT nucleotide sequence (SEQ ID NO:306)

[0991] GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGC CDR1-KABAT amino acid sequence (SEQ ID NO: 307)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0992] <h2 style=";text-align:left;direction:ltr"> RASQSVS NYLA<h2 style=";text-align:left;direction:ltr"> CDR1-KABAT nucleotide sequence (SEQ ID NO: 308) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0993] <h2 style=";text-align:left;direction:ltr"> AGGGCCAGTCAGAGTGTTAGCAACTACTTAGCC<h2 style=";text-align:left;direction:ltr"> FR2-KABAT amino acid sequence (SEQ ID NO:309) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0994] <h2 style=";text-align:left;direction:ltr"> WYQQKP GQAPRLLIS<h2 style=";text-align:left;direction:ltr"> FR2-KABAT nucleotide sequence (SEQ ID NO:310) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0995] <h2 style=";text-align:left;direction:ltr"> TGGTACCAACAGAAAACCTGGCCAGGCTCCCAGGCTCCTCATCTCT<h2 style=";text-align:left;direction:ltr"> CDR2-KABAT amino acid sequence (SEQ <h2 style=";text-align:left;direction:ltr"> ID NO:311) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0996] <h2 style=";text-align:left;direction:ltr"> D ASNRAT<h2 style=";text-align:left;direction:ltr"> CDR2-KABAT nucleotide sequence (SEQ ID NO: 312) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0997] <h2 style=";text-align:left;direction:ltr"> GATGCATCCAACAGGGCCACT<h2 style=";text-align:left;direction:ltr"> FR3-KABAT amino acid sequence (SEQ ID NO:313) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0998] <h2 style=";text-align:left;direction:ltr"> GIPA RFSGSGSGTD FTLT...

Claims

1. An antibody or fragment comprising a binding site that specifically binds to proprotein convertase subtilisin kexin type 9 (PCSK9), wherein the binding site comprises a VH domain encoded by a recombinant nucleotide sequence derived from a human VH gene segment, a DH gene segment, and a JH gene segment, wherein the VH gene segment is selected from IGHV4-31, IGHV4-59, IGHV4-4, and IGHV3-9.

2. The antibody or fragment according to claim 1, wherein (i) the VH gene segment is IGHV4-31 and the DH gene segment is the human gene segment IGHD3-9; or (ii) the VH gene segment is IGHV4-59 and the DH gene segment is the human gene segment IGHD3-10; or (iii) the VH gene segment is IGHV4-4 and the DH gene segment is the human gene segment IGHD2-15; or (iv) the VH gene segment is IGHV3-9 and the DH gene segment is the human gene segment IGHD3-9.

3. The antibody or fragment according to claim 1 or 2, wherein the JH gene segment is the human gene segment IGHJ6.

4. The antibody or fragment of any of the preceding claims, wherein the binding site comprises a CDRH3 sequence selected from SEQ ID NO: 271, 285, 15, 77, 29, 91, 211 and 225.

5. The antibody or fragment of any of the preceding claims, wherein the binding site comprises a VH domain comprising SEQ ID NO: 259, 1, 65 or 199.

6. The antibody or fragment of any of the preceding claims, wherein the binding site comprises a VH domain comprising SEQ ID NO: 259 paired with a VL domain comprising SEQ ID NO:

289.

7. The antibody or fragment of any one of claims 1 to 5, wherein the binding site comprises a VH domain comprising SEQ ID NO: 319 paired with a VL domain comprising SEQ ID NO:

349.

8. An antibody or fragment which specifically binds to PCSK9 and comprises the CDRH3 sequence of the anti-PCSK9 antibody according to any one of the preceding claims, or the CDRH3 sequence comprising 3, 2 or 1 amino acid substitutions.

9. An antibody or fragment (optionally according to any one of the preceding claims) that specifically binds to PCSK9 and comprises a VH domain comprising the CDRH3 sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said sequence comprising 3, 2 or 1 amino acid substitutions.

10. The antibody or fragment of claim 9, wherein the VH domain comprises: (i) a CDRH3 sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said CDRH3 sequence comprising 3, 2 or 1 amino acid substitutions; and (ii) a CDRH1 sequence of said selected antibody; or said CDRH1 sequence comprising 3, 2 or 1 amino acid substitutions.

11. The antibody or fragment according to claim 9 or 10, wherein the VH domain comprises: (iii) a CDRH3 sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said CDRH3 sequence comprising 3, 2 or 1 amino acid substitutions; and (iv) a CDRH2 sequence of said selected antibody; or said CDRH2 sequence comprising 3, 2 or 1 amino acid substitutions.

12. An antibody or fragment (optionally according to any of the preceding claims), comprising a binding site that specifically binds to PCSK9, wherein the binding site comprises a VH domain, the VH domain comprising the amino acid sequence of the VH domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid that is at least 70% identical thereto.

13. The antibody or fragment of claim 9, 10, 11 or 12, wherein the selected antibody is CL-274711 or CL-148219QLT.

14. The antibody or fragment of any one of the preceding claims, comprising a first copy and a second copy of the VH domain.

15. An antibody or fragment (optionally according to any one of the preceding claims), comprising a binding site that specifically binds to PCSK9, wherein the binding site comprises a VL domain, the VL domain is encoded by a nucleotide sequence derived from the recombination of a human VL gene segment and a JL gene segment, wherein the VL gene segment is selected from IGKV3-11, IGKV2-28 and IGKV2-29.

16. The antibody or fragment of claim 15, wherein the JL gene segment is a human gene segment selected from IGKJ4, IGJK3 and IGKJ1.

17. An antibody or fragment which specifically binds to PCSK9 and comprises the CDRL3 sequence of the anti-PCSK9 antibody according to any one of the preceding claims or the CDRL3 sequence comprising 3, 2 or 1 amino acid substitutions.

18. An antibody or fragment (optionally according to any of the preceding claims) that specifically binds to PCSK9 and comprises a VL domain comprising a CDRL3 sequence selected from SEQ ID NO: 301, 315, 47, 107, 61, 121, 241 and 255; or the selected CDRL3 sequence comprising 3, 2 or 1 amino acid substitutions.

19. An antibody or fragment (optionally according to any of the preceding claims) that specifically binds to PCSK9 and comprises a VL domain comprising the CDRL3 (and optionally CDRH3) sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or said sequences each comprising 3, 2 or 1 amino acid substitutions.

20. The antibody or fragment of claim 19, wherein the VL domain comprises: (i) a CDRL3 sequence (and optionally CDRH3) of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT), or said CDR3 sequence each comprising 3, 2 or 1 amino acid substitutions; and (ii) a CDRL1 (and optionally CDRH1) sequence of said selected antibody, or said CDR1 sequence each comprising 3, 2 or 1 amino acid substitutions.

21. The antibody or fragment of claim 19 or 20, wherein the VL domain comprises: (iii) a CDRL3 (and optionally CDRH3) sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT), or said CDR3 sequence each comprising 3, 2 or 1 amino acid substitutions; and (iv) a CDRL2 (and optionally CDRH2) sequence of said selected antibody, or said CDR2 sequence each comprising 3, 2 or 1 amino acid substitutions.

22. An antibody or fragment (optionally according to any of the preceding claims), comprising a binding site that specifically binds to PCSK9, wherein the binding site comprises a VL domain, the VL domain comprising the amino acid sequence of the VL domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid that is at least 70% identical thereto.

23. An antibody or fragment (optionally according to any of the preceding claims) that specifically binds to PCSK9 and comprises the heavy chain amino acid sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid that is at least 70% identical thereto.

24. An antibody or fragment (optionally according to any of the preceding claims) that specifically binds to PCSK9 and comprises the light chain amino acid sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (e.g., CL-274711 or CL-148219QLT); or an amino acid that is at least 70% identical thereto.

25. The antibody or fragment according to claim 23, comprising the light chain amino acid sequence of the selected antibody; or amino acids at least 70% identical thereto.

26. An antibody or fragment (optionally according to any one of the preceding claims) that specifically binds to an epitope of human PCSK9 that is identical to the epitope bound by the antibody according to any one of the preceding claims.

27. The antibody or fragment of claim 26, wherein the epitope is identified by unrelated amino acid scanning or by X-ray crystallography.

28. The antibody or fragment of claim 27, wherein the contact residues of the epitope are defined by at least a 10-fold decrease in affinity upon an irrelevant amino acid scan, such as an alanine scan as determined by SPR.

29. An antibody or fragment (optionally according to any one of the preceding claims) that competes with the antibody according to any one of the preceding claims for binding to human PCSK9.

30. The antibody or fragment of any of the preceding claims, which specifically binds to PCSK9 comprising an amino acid sequence selected from SEQ ID NOs: 189-194.

31. The antibody or fragment of any one of the preceding claims, wherein the antibody or fragment comprises a human constant region, optionally an IgG4 constant region or an IgGl constant region.

32. The antibody or fragment according to claim 31, wherein the constant region is an IgG4-PE constant region, optionally comprising the amino acid sequence of SEQ ID NO: 3 or 152.

33. The antibody or fragment according to any one of the preceding claims, further comprising an antigen binding site that specifically binds to another target antigen, optionally ANGPTL3.

34. An anti-PCSK9 antibody or fragment as defined in any one of the preceding claims for use in treating or preventing a PCSK9 mediated disease or condition (optionally hypercholesterolemia) in a subject.

35. The anti-PCSK9 antibody or fragment of claim 34, wherein the disease or condition is selected from hypercholesterolemia, hyperlipidemia, hypercholesterolemia, dyslipidemia, cholestatic liver disease, nephrotic syndrome, hypothyroidism, obesity, diabetes, atherosclerosis, or cardiovascular disease.

36. The antibody or fragment of claim 34 or 35, wherein the antibody or fragment is administered to the subject simultaneously or sequentially with a statin.

37. A combination of an amount of an anti-PCSK9 antibody or fragment and an amount of a statin (optionally comprising multiple doses of said antibody and / or statin), wherein said antibody or fragment is according to any one of claims 1 to 36.

38. The antibody, fragment or combination of any one of claims 1 to 37 for use in a method of treating or preventing hypercholesterolemia in a subject who has been previously treated with a statin regimen at a first dose, wherein the method comprises reducing the dose of a statin administered to the subject or not administering a statin to the subject, wherein the method comprises administering the antibody or fragment to the subject.

39. The combination according to claim 37 or 38, comprising a daily dose of 10 to 20 mg (e.g. 10 mg); or < 60 mg (e.g. 40 mg) of a statin.

40. An antibody, fragment or combination according to any one of the preceding claims, which is administered to a human or animal subject suffering from elevated cholesterol for reducing plasma low-density lipoprotein cholesterol (LDL-C) levels in the subject after the subject has received the anti-PCSK9 antibody or fragment.

41. Use of an antibody, fragment or combination as defined in any preceding claim in the manufacture of a medicament for administration to a subject for the treatment or prevention of a PCSK9 mediated disease or condition, optionally hypercholesterolemia.

42. A method for treating or preventing a PCSK9-mediated disease or condition (optionally hypercholesterolemia) in an individual, the method comprising administering to the individual a therapeutically effective amount of an antibody, fragment or combination as defined in any one of claims 1 to 40, wherein the PCSK9-mediated disease or condition is thereby treated or prevented.

43. The use according to claim 41 or the method according to claim 42, wherein the PCSK9-mediated disease or condition is hypercholesterolemia.

44. The antibody, fragment, combination, use or method according to any one of claims 34 to 43, further comprising administering to the individual an additional therapy, such as an additional therapeutic agent, optionally wherein the additional therapeutic agent is selected from the group consisting of: a. Statins; b. ANGPTL3 inhibitors (eg, anti-ANGPTL3 antibodies, such as evinacumab) c. Fibrate; d. Bile acid sequestrants; e. niacin; and f. Niacin.

45. A pharmaceutical composition comprising an antibody, fragment or combination as defined in any one of claims 1 to 40 and 44, and a pharmaceutically acceptable excipient, diluent or carrier, and optionally in combination with another therapeutic agent selected from the agents recited in claim 44.

46. ​​A pharmaceutical composition according to claim 45 for use in the treatment and / or prevention of a PCSK9-mediated condition or disease, optionally hypercholesterolemia.

47. A pharmaceutical composition according to claim 45 or 46, in combination with a label or instructions for use to treat and / or prevent said disease or condition in humans; optionally wherein said label or instructions comprises a marketing authorization number (optionally an FDA or EMA authorization number); optionally wherein said kit comprises an IV or injection device containing said antibody or fragment.

48. A nucleic acid encoding the VH domain and / or VL domain of an antibody or fragment as defined in any one of claims 1 to 33.

49. A nucleic acid encoding a VH domain comprising the amino acid sequence of the VH domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); or an amino acid at least 70% identical thereto.

50. A nucleic acid encoding a VL domain comprising the amino acid sequence of the VL domain of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); or an amino acid at least 70% identical thereto.

51. A nucleic acid comprising a nucleotide sequence that is at least 70% identical to the sequence of SEQ ID NO: 260 or 320.

52. A nucleic acid encoding the heavy and / or light chain of an antibody or fragment as defined in any one of claims 1 to 33.

53. A nucleic acid encoding a heavy chain comprising: A VH amino acid sequence that is at least 70% identical to SEQ ID NO: 259 or 319; and a C-region amino acid sequence that is at least 70% identical to the IGHG4 sequence, optionally at least 70% identical to SEQ ID NO: 3 or 152.

54. A nucleic acid encoding a light chain comprising: A VL amino acid sequence that is at least 70% identical to SEQ ID NO: 289 or 349; and a C region amino acid sequence that is at least 70% identical to an IGKC sequence, optionally at least 70% identical to SEQ ID NO:

156.

55. A nucleic acid (e.g., in a host cell, such as a CHO or HEK293 or Cos cell) comprising a. a nucleotide sequence that is at least 70% identical to the heavy chain sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT); and / or b. A nucleotide sequence that is at least 70% identical to the light chain sequence of an antibody selected from CL-274711, CL-148219QLT, CL-274698, CL-148219 and CL-148489 (eg, CL-274711 or CL-148219QLT), respectively.

56. A vector comprising a nucleic acid (eg, a nucleic acid according to any one of claims 48 to 55); optionally wherein the vector is a CHO or HEK293 vector.

57. A host cell comprising a nucleic acid (eg, a nucleic acid according to any one of claims 48 to 55) or a vector according to claim 56.

58. An antibody, fragment, combination, vector, host cell, use or method as herein described.